GLP-1R modulating compounds

By developing the compound of formula I-A-1, the shortcomings of existing GLP-1R agonists in therapeutic and metabolic properties have been solved, and GLP-1R agonists with long half-life and ideal metabolic properties have been achieved, which are suitable for the treatment of GLP-1R Mediated disease.

CN118984827APending Publication Date: 2024-11-19ASCLETIS BIOSCI CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380023894.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-11-18
Filing Date
2023-01-31
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

Existing GLP-1R agonists have insufficient ideal therapeutic and metabolic properties in the treatment of GLP-1R-mediated diseases, and the oral form has a short half-life that makes it difficult to meet clinical needs.

Method used

A compound of the general formula I-A-1 has been developed, which has specific structural characteristics, including combinations of various alkyl, cycloalkyl, aryl and heterocyclic groups, which can effectively activate or regulate GLP-1R , with a long half-life and ideal metabolic properties, suitable as an agonist or modulator of GLP-1R.

Benefits of technology

This compound can effectively activate GLP-1R, prolong the body half-life, and provide longer-lasting therapeutic effects. It is suitable for the treatment of GLP-1R-mediated diseases such as type 2 diabetes and obesity, with good metabolic properties and easy to take. Features.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005012413770000021
    Figure BDA0005012413770000021
  • Figure BDA0005012413770000171
    Figure BDA0005012413770000171
  • Figure BDA0005012413770000241
    Figure BDA0005012413770000241
Patent Text Reader

Abstract

The present application describes GLP-1R modulating compounds for use in the treatment of GLP-1R mediated diseases or conditions.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Related references

[0002] This application claims priority to U.S. Provisional Patent Application No. 63 / 268,622 filed on February 28, 2022, U.S. Provisional Patent Application No. 63 / 366,565 filed on June 17, 2022, and U.S. Patent Application No. 18 / 056,836 filed on November 18, 2022, all of which are hereby incorporated by reference in their entirety. Technical Field

[0003] The present application relates to compounds that bind to the glucagon-like peptide-1 receptor (GLP-1R) and act as agonists or modulators thereof, and such compounds are useful for treating and / or preventing diseases and conditions mediated by GLP-1R. Background Art

[0004] Glucagon-like peptide-1 (GLP-1) is a peptide hormone secreted by enteroendocrine cells in the intestine in response to a meal. GLP-1 is thought to play a role in the regulation of postprandial blood glucose, both by directly increasing meal-induced insulin secretion from pancreatic β cells and by promoting satiety by delaying the transit of food through the intestine. GLP-1 mediates intracellular signaling via the GLP-1 receptor (GLP-1R), which belongs to a family of G protein-coupled receptors present on cell membranes and can lead to the accumulation of the second messenger cyclic adenosine monophosphate (cAMP) upon activation. Nonalcoholic steatohepatitis (NASH) can be associated with features of the metabolic syndrome, including obesity, type 2 diabetes, insulin resistance, and cardiovascular disease.

[0005] GLP-1R agonists are currently being extensively studied for conditions associated with diabetes, obesity, and NASH. GLP-1R agonists include peptides such as exenatide, liraglutide, and dulaglutide, which have been approved for the treatment of type 2 diabetes. This class of peptide drugs is primarily administered by subcutaneous injection. Oral GLP-1 agonists are also being studied for the treatment of type 2 diabetes. Some GLP-1R agonists, such as liraglutide, dulaglutide, and exenatide, are resistant to rapid degradation by dipeptidyl peptidase 4, resulting in a longer half-life than endogenous GLP-1.

[0006] There remains a need for compounds, such as agonists of GLP-1R, that have desirable therapeutic properties, metabolic properties, and / or ease of administration for the treatment of GLP-1R mediated diseases and conditions.

[0007] summary

[0008] In one embodiment, the present disclosure provides a compound of formula IA-1:

[0009]

[0010] or a pharmaceutically acceptable salt thereof, wherein:

[0011] R 1 It is C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Cycloalkyl, heterocyclic, C 6-10 Aryl, 5-10 membered heteroaryl, -SR 1b , -S(O)R 1b , -S(O)(NH)R 1b , -S(O)2R 1b ,-S(O)2N(R 1b )(R 1c ), -S(O)(NR 1b )R 1c ,-C(O)N(R 1b )(R 1c ), -C(O)R 1b , or -C(O)OR 1c wherein the alkyl, haloalkyl, cycloalkyl, aryl, 5-10 membered heteroaryl or heterocyclyl is each optionally substituted by one to four Z 1 Replace, and any two Z 1 can combine with the atoms to which they are attached to form C 3-10 Cycloalkyl or heterocyclic or C 6-10 Aryl or 5-10 membered heteroaryl;

[0012] Ring A is C 3-10 Cycloalkyl, heterocyclic, C 6-10 Aryl or 5-10 membered heteroaryl, the C 3-10 Cycloalkyl, heterocyclic, C 6-10 The aryl or 5-10 membered heteroaryl groups are each substituted with 1 to 4 Z 1a Optional substitution;

[0013] Ring B is C 3-10 Cycloalkyl, heterocyclic, C 6-10 Aryl or 5-10 membered heteroaryl, the C 3-10 Cycloalkyl, heterocyclic, C 6-10 The aryl or 5-10 membered heteroaryl groups are each supported by 1 to 4 R 4 Optional substitution;

[0014] Ring A and Ring B each contain 0-3 double bonds;

[0015] R 2 Yes H, C1-6 Alkyl, -C 1-6 Alkyl-alkoxy, -C 1-6 Alkyl-cycloalkoxy, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Cycloalkyl, heterocyclic, C 6-10 Aryl, 5-10 membered heteroaryl, -CN, -OR 2a , -SR 2a , -S(O)R 2a , -S(O)(NH)R 2a , -S(O)2R 2a ,-S(O)2N(R 2a )(R 2b ), or -S(O)(NR 2a )R 2b , wherein the alkyl, alkoxy, cycloalkyloxy, haloalkyl, cycloalkyl, heterocyclyl, aryl or 5-10 membered heteroaryl groups can be each substituted by 1 to 4 Z 1 Replace, and any two Z 1 can combine with the atoms to which they are attached to form C 3-10 Cycloalkyl or heterocyclic or C 6-10 Aryl or 5-10 membered heteroaryl.

[0016] X is independently -N=, -C(H)=, or -C(R 8 )=;

[0017] R 3 and R 3’ Each independently is H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen, C3- 10 Cycloalkyl, heterocyclic, C 6-10 Aryl, 5-10 membered heteroaryl, -CN, -NO2, -OR 3a , -C(O)R 3a ,-CH2C(O)OR 3a , -C(O)OR 3a ,-C(O)N(R 3a )(R 3b ), -N(R 3a )C(O)R 3b , -N(R 3a )C(O)OR 3b , -N(R 3a )C(O)N(R 3b)2,-C(O)NHS(O)2R 3a , -C(O)NR 3a S(O)2R 3b , -C(O)NR 3a S(O)2NR3 b R 3c , -C(O)NR 3a -S(O)(=NR 3b )R 3c , -S(O)2R 3a , -S(O)2OR 3a ,-S(O)2N(R 3a )(R 3b ), -N(R 3a )S(O)2R 3b ,-S(O)2NHC(O)R 3a , -S(O)(=NR 3a )R 3b , -S(O)(=NR 3 a)NR 3b ,-S(=NR 3a )(=NR 3b )R 3c , -P(O)(OR 3a )(R 3b ), -P(O)(OR 3a )(OR 3b ), -B(OR 3a )(OR 3b ), or -OC 1-6 Alkyl-C(O)OR 3a wherein the alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or 5-10 membered heteroaryl groups are each substituted by 1 to 4 R 3d replace;

[0018] Each R 3a , R 3b , and R 3c Independently H, C 1-6 Alkyl, C 6-10 Aryl, 5-10 membered heteroaryl, C 1-6 Haloalkyl, C 2-8 Alkoxyalkyl, -C 1-4 Alkyl-N(R 9a )(R 9b ), -C 1-4 Alkyl-N(R 9a )C(O)-OC 1-4 Alkyl-OP(O)(OR 9c )2, -C 1-4Alkyl-C(O)N(R 9a )(R 9b ), -C 1-4 Alkyl-OC(O)-OC 1-4 Alkyl, -C 1-4 Alkyl-OC(O)-C 1-4 Alkyl-N(R 9a )(R 9b ), -C 1-4 Alkyl-OC(O)-C 1-4 Alkyl-OP(O)(OR 9c )2, -C 1-4 Alkyl-C 3-8 Cycloalkyl, -C 1-4 Alkyl-heterocyclyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Cycloalkyl, heterocyclyl, -CH2CH(N(R 9a )2)C(O)OR 9b , -P(O)(OR 9c )2, -OP(O)(OR 9c )2,-CH2P(O)(OR 9c )2,-CH2OP(O)(OR 9c )2,-OCH2P(O)(OR 9c )2,-C(O)OCH2P(O)(OR 9c )2,-P(O)(R 9c )(OR 9d ), -OP(O)(R 9c )(OR 9d ), -CH2P(O)(R 9c )(OR 9d ), -OCH2P(O)(R 9c )(OR 9d ), -C(O)OCH2P(O)(R 9c )(OR 9d ), -P(O)(N(R 9c )2)2,-OP(O)(N(R 9c )2)2,-CH2P(O)(N(R 9c )2)2,-OCH2P(O)(N(R 9c )2)2,-C(O)OCH2P(O)(N(R 9c )2)2,-P(O)(N(R 9c )2)(OR 9d ), -OP(O)(N(R 9c )2)(OR 9d), -CH2P(O)(N(R 9c )2)(OR 9 d), -OCH2P(O)(N(R 9c )2)(OR 9d ), -C(O)OCH2P(O)(N(R 9c )2)(OR 9d ), -P(O)(R 9c )(N(R 9d )2),-OP(O)(R 9c )(N(R 9d )2), -CH2P(O)(R 9c )(N(R 9d )2), -OCH2P(O)(R 9c )(N(R 9d )2), -C(O)OCH2P(O)(R 9c )(N(R 9d )2), C 1-6 Alkyl-heterocyclyl, C 1-6 Alkyl-aryl or C 1-6 Alkyl-(5-10 membered) heteroaryl, wherein the alkyl, alkenyl, cycloalkyl, heterocyclyl, aryl or 5-10 membered heteroaryl can be substituted by 1 to 4 Z 1b replace;

[0019] Each R 4 are independently H, -OH, CH2OH, C 1-9 Alkyl, C 1-8 Haloalkyl, C 1-6 Haloalkoxy, C 2-6 Alkoxyalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen, C 3-15 Cycloalkyl, heterocyclic, C 6-10 Aryl, 5-10 membered heteroaryl, oxo, -NO2, -CN, -N3, -OR 4a , -C(O)R 4a , -C(O)OR 4a ,-C(O)N(R 4a )(R 4b ), -N(R 4a )(R 4b ), -N(R 4a )2(R 4b ) + , -N(R 4a )-C(O)R 4b , -N(R 4a )C(O)O(R 4b ), -N(R4a )C(O)N(R 4b )(R 4c ), -N(R 4a )S(O)2(R 4b ), -N(R 4a )S(O)2-N(R 4b )(R 4c ), -N(R 4a )S(O)2O(R 4b ), -OC(O)R 4a , -OC(O)OR 4a ,-OC(O)-N(R 4a )(R 4b ), -SR 4a , -S(O)R 4a , -S(O)(NH)R 4a , -S(O)2R 4a ,-S(O)2N(R 4a )(R 4b ), -S(O)(NR 4a )R 4b , or -Si(R 4a )3; wherein the alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or 5-10 membered heteroaryl are each optionally substituted by 1 to 4 Z 1b or, two R attached to adjacent ring atoms 4 The groups combine with the atoms to which they are attached to form C 5-10 Cycloalkyl or heterocyclic group, each of which may be replaced by 1 to 4 Z 1b replace;

[0020] Each R 5a and R 5b Independently H, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 2-6 Alkoxyalkyl, halogen, C 3-10 Cycloalkyl, heterocyclyl, -C 1-6 Alkyl-N(R 9a )(R 9b ), -CN, -OR 5a1 , or -N(R 5a1 )(R5 a2 ); or, R 5a and R 5b Combine with the atoms to which they are attached to form C 3-10 Cycloalkyl or heterocyclic group, each of which may be replaced by 1 to 4 R5 a3 Replace; or, R 5a or R5b Can combine with any substituent on ring A to form C 5-10 Cycloalkyl or heterocyclic group, each of which may be replaced by 1 to 4 R 5 a 3 replace;

[0021] Each R 5a1 and R5 a2 Independently H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Cycloalkyl, heterocyclic, C 6-10 aryl or 5-10 membered heteroaryl, wherein the cycloalkyl, heterocyclyl, aryl or 5-10 membered heteroaryl can be each substituted by 1 to 4 R5 a4 replace;

[0022] V is -C(O)-, -O-, -N(R 6a )-, or -C(R 6b )(R 6c )-;

[0023] R 6a Yes H, C 1-6 Alkyl, C 3-10 Cycloalkyl, heterocyclyl, -S(O)2R 6a1 , or -S(O)2N(R 6a1 )(R 6a2 ), wherein the cycloalkyl or heterocyclic group may be C 1-6 Alkyl, F or -CN substitution;

[0024] Each R 6b and R 6c Independently H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkoxyalkyl, halogen, C 3-10 Cycloalkyl, heterocyclyl, -C 1-6 Alkyl-N(R 9a )(R 9b ), -CN, -OR 6c1 , or -N(R 6c2 )(R 6c3 ), wherein the alkyl, cycloalkyl or heterocyclic group may be each substituted by 1 to 4 R 6b1 Replace; or R 6b and R 6 c combines with the atoms to which they are attached to form C 3-10 Cycloalkyl or heterocyclic group, each of which may be replaced by 1 to 4 R 6b1 Replace; or R 6a or R 6cWith an R 4 The groups and the atoms to which they are attached combine to form C 5-10 Cycloalkyl or heterocyclic group, each of which may be replaced by 1 to 4 R 10 replace;

[0025] Y is -N(R 7 )-, -O-, -S-, -S(O)-, -S(O)2-, -S(O)(=NH)-, or -S(O)(=NR 7 )-;

[0026] Each R 3d , R5 a3 , R 5a4 , R 6b1 , and R 10 Independently H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkoxyalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen, C 3-10 Cycloalkyl, heterocyclic, C 6-10 Aryl, 5-10 membered heteroaryl, oxo, -OH, -CN, -CO2R 3e , -NO2, or -C(O)N(R 2a )(R 2b ), wherein the heterocyclic group or the 5-10 membered heteroaryl group can be C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 Haloalkoxy substitution;

[0027] Each R 6a1 , R 6a2 , R 6c1 , R 6c2 , R 6c3 and R 7 Independently H, C 1-6 Alkyl or C 3-10 Cycloalkyl;

[0028] Each R 8 Independently for C 1-9 Alkyl, C 1-8 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen, oxo, -OH, -CN, CO2R 3e ,-NO2,-NH2,-N3,-SH,-O(C 1-9 alkyl), -O(C 1-8haloalkyl), -NH(C 1-9 Alkyl), -NH(C 1-8 haloalkyl), -N(C 1-9 Alkyl)2,-N(C 1-8 Haloalkyl)2;

[0029] Each R 9a and R 9b Independently H, C 1-9 Alkyl, C 1-8 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkoxyalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen, C 3-15 Cycloalkyl, heterocyclic, C 6-10 Aryl, 5-10 membered heteroaryl, oxo, -NO2, -CN, -N3, -OR 12a , -C(O)R 12a , -C(O)OR 12a ,-C(O)N(R 12a )(R 12b ), -N(R 12a )(R 12b ), -N(R 12a )2(R 12b ) + , -N(R 12a )-C(O)R 12b , -N(R 12a )C(O)O(R 12b ), -N(R 12a )C(O)N(R 12b )(R 12c ), -N(R 12a )S(O)2(R 12b ), -N(R 12a )S(O)2-N(R 12b )(R 12c ), -N(R 12a )S(O)2O(R 12b ), -OC(O)R 12a , -OC(O)OR 12a ,-OC(O)-N(R 12a )(R 12b ), -SR 12a , -S(O)R 12a , -S(O)(NH)R 12a , -S(O)2R 12a ,-S(O)2N(R 12a)(R 12b ), -S(O)(NR 12a )R 12b , or -Si(R 12a )3; or R 9a and R 9b Fusion forms a 3-10 membered heterocyclic group which may be substituted by: C 1-9 Alkyl, C 1-8 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkoxyalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen, C 3-15 Cycloalkyl, heterocyclic, C 6-10 Aryl, heteroaryl, oxo, -NO2, -CN, -N3, -OR 12a , -C(O)R 12a , -C(O)OR 12a ,-C(O)N(R 12a )(R 12b ), -N(R 12a )(R 12b ), -N(R 12a )2(R 12b ) + , -N(R 12a )-C(O)R 12b , -N(R 12a )C(O)O(R 12b ), -N(R 12a )C(O)N(R 12b )(R 12c ), -N(R 12a )S(O)2(R 12b ), -N(R 12a )S(O)2-N(R 12b )(R 12c ), -N(R 12a )S(O)2O(R 12b ), -OC(O)R 12a , -OC(O)OR 12a ,-OC(O)-N(R 12 a)(R 12b ), -SR 12a , -S(O)R 12a , -S(O)(NH)R 12a , -S(O)2R 12a ,-S(O)2N(R 12a )(R 12b ), -S(O)(NR12a )R 12b , or -Si(R 12a )3;

[0030] Each Z1 is independently C 1-9 Alkyl, C 1-8 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkoxyalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen, C 3-15 Cycloalkyl, heterocyclic, C 6-10 Aryl, 5-10 membered heteroaryl, oxo, -NO2, -N3, -CN, -OR 12a , -C(O)-R 12a , -C(O)OR 12a ,-C(O)-N(R 12a )(R 12b ), -N(R 12a )(R 12b ), -N(R 12a )2(R 12b ) + , -N(R 12a )C(O)R 12b , -N(R 12a )C(O)OR 12b , -N(R 12a )C(O)N(R 12b )(R 12c ), -N(R 12a )S(O)2(R 12b ), -N(R 12a )S(O)2N(R 12b )(R 12c ), -NR 12a S(O)2O(R 12b ), -OC(O)R 12a , -OC(O)OR 12a ,-OC(O)-N(R 12a )(R 12b ), -SR 12a , -S(O)R 12a , -S(O)(NH)R 12a , -S(O)2R 12a ,-S(O)2N(R 12a )(R 12b ), -S(O)(NR 12a )R 12b , or -Si(R 12a)3, wherein the alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or 5-10 membered heteroaryl groups can each be substituted by 1 to 4 Z 1a replace;

[0031] Each Z 1a Independently H, C 1-9 Alkyl, C 1-8 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkoxyalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen, C 3-15 Cycloalkyl, heterocyclic, C 6-10 Aryl, 5-10 membered heteroaryl, oxo, -NO2, -CN, -N3, -OR 12a , -C(O)R 12a , -C(O)OR 12a ,-C(O)N(R 12a )(R 12b ), -N(R 12a )(R 12b ), -N(R 12a )2(R 12b ) + , -N(R 12a )-C(O)R 12b , -N(R 12a )C(O)O(R 12b ), -N(R 12a )C(O)N(R 12b )(R 12c ), -N(R 12a )S(O)2(R 12b ), -N(R 12a )S(O)2-N(R 12b )(R 12c ), -N(R 12a )S(O)2O(R 12b ), -OC(O)R 12a , -OC(O)OR 12a ,-OC(O)-N(R 12a )(R 12b ), -SR 12a , -S(O)R 12a , -S(O)(NH)R 12a , -S(O)2R 12a ,-S(O)2N(R 12a )(R 12b ), -S(O)(NR 12a )R12b , or -Si(R 12a )3, wherein the alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or 5-10 membered heteroaryl groups can each be substituted by 1 to 4 Z 1b replace;

[0032] Each Z 1b Independently H, C 1-9 Alkyl, C 1-8 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen, C 3-15 Cycloalkyl, heterocyclic, C 6-10 Aryl, 5-10 membered heteroaryl, oxo, -OH, -CN, CO2R 3 e, -NO2, -NH2, -N3, -SH, -O(C 1-9 alkyl), -O(C 1-8 haloalkyl), -O(C 2-6 alkenyl), -O(C 2-6 Alkynyl), -O(C 3-15 Cycloalkyl), -O(heterocyclyl), -O(C 6-10 aryl), -O(5-10 membered heteroaryl), -NH(C 1-9 Alkyl), -NH(C 1-8 haloalkyl), -NH(C 2-6 alkenyl), -NH(C 2-6 Alkynyl), -NH(C 3-15 Cycloalkyl), -NH(heterocyclyl), -NH(C 6-10 aryl), -NH(5-10 membered heteroaryl), -N(cyclo-alkyl), -N(C 1-9 Alkyl)2,-N(C 1-8 Haloalkyl)2,-N(C 2-6 Alkenyl)2,-N(C 2-6 Alkynyl)2,-N(C 3-15 Cycloalkyl)2,-N(heterocyclyl)2,-N(C 6-10 Aryl)2,-N(5-10 membered heteroaryl)2,-N(C 1-9 Alkyl)(C 1-8 haloalkyl), -N(C 1-9 Alkyl)(C 2-6 alkenyl), -N(C 1-9 Alkyl)(C 2-6 Alkynyl), -N(C 1-9 Alkyl)(C 3-15 Cycloalkyl), -N(C 1-9 alkyl)(heterocyclyl),-N(C 1-9 Alkyl)(C6-10 Aryl), -N(C 1-9 alkyl)(5-10 membered heteroaryl), -C(O)(C 1-9 alkyl), -C(O)(C 1-8 haloalkyl), -C(O)(C 2-6 alkenyl), -C(O)(C 2-6 Alkynyl), -C(O)(C 3-15 Cycloalkyl), -C(O)(heterocyclyl), -C(O)(C 6-10 aryl), -C(O)(5-10 membered heteroaryl), -C(O)O(C 1-9 alkyl), -C(O)O(C 1-8 haloalkyl), -C(O)O(C 2-6 alkenyl), -C(O)O(C 2-6 Alkynyl), -C(O)O(C 3-15 Cycloalkyl), -C(O)O(heterocyclyl), -C(O)O(C 6-10 aryl), -C(O)O(5-10 membered heteroaryl), -C(O)NH2, -C(O)NH(C 1-9 alkyl), -C(O)NH(C 1-8 haloalkyl), -C(O)NH(C 2-6 alkenyl), -C(O)NH(C 2-6 Alkynyl), -C(O)NH(C 3-1 5 cycloalkyl), -C(O)NH(heterocyclyl), -C(O)NH(C 6-10 aryl), -C(O)NH(5-10 membered heteroaryl), -C(O)N(C 1-9 Alkyl)2,-C(O)N(C 1-8 Haloalkyl)2,-C(O)N(C 2-6 alkenyl)2,-C(O)N(C 2-6 Alkynyl)2,-C(O)N(C 3-15 Cycloalkyl)2,-C(O)N(heterocyclyl)2,-C(O)N(C 6-10 Aryl)2,-C(O)N(5-10 membered heteroaryl)2,-NHC(O)(C 1-9 alkyl), -NHC(O)(C 1-8 haloalkyl), -NHC(O)(C 2-6 alkenyl), -NHC(O)(C 2-6 Alkynyl), -NHC(O)(C 3-15 Cycloalkyl), -NHC(O)(heterocyclyl), -NHC(O)(C 6-10 aryl), -NHC(O)(5-10 membered heteroaryl), -NHC(O)O(C1-9 alkyl), -NHC(O)O(C 1-8 haloalkyl), -NHC(O)O(C 2-6 alkenyl), -NHC(O)O(C 2-6 Alkynyl), -NHC(O)O(C 3-15 Cycloalkyl), -NHC(O)O(heterocyclyl), -NHC(O)O(C 6-10 aryl), -NHC(O)O(5-10 membered heteroaryl), -NHC(O)NH(C 1-9 alkyl), -NHC(O)NH(C 1-8 haloalkyl), -NHC(O)NH(C 2-6 alkenyl), -NHC(O)NH(C 2-6 Alkynyl), -NHC(O)NH(C 3-15 Cycloalkyl), -NHC(O)NH(heterocyclyl), -NHC(O)NH(C 6-10 aryl), -NHC(O)NH(5-10 membered heteroaryl), -NHS(O)(C 1-9 Alkyl), -N(C 1-9 Alkyl)(S(O)(C 1-9 Alkyl), -S(C 1-9 Alkyl), -S(C 1-8 haloalkyl), -S(C 2-6 alkenyl), -S(C 2-6 Alkynyl), -S(C 3-15 Cycloalkyl), -S(heterocyclyl), -S(C 6-10 aryl), -S(5-10 membered heteroaryl), -S(O)N(C 1-9 Alkyl)2,-S(O)(C 1-9 alkyl), -S(O)(C 1-8 haloalkyl), -S(O)(C 2-6 alkenyl), -S(O)(C 2-6 Alkynyl), -S(O)(C 3-15 Cycloalkyl), -S(O)(heterocyclyl), -S(O)(C 6-10 aryl), -S(O)(5-10 membered heteroaryl), -S(O)2(C 1-9 Alkyl), -S(O)2(C 1-8 haloalkyl), -S(O)2(C 2-6 alkenyl), -S(O)2(C 2-6 Alkynyl), -S(O)2(C 3-15 Cycloalkyl), -S(O)2(heterocyclyl), -S(O)2(C 6-10Aryl), -S(O)2(5-10 membered heteroaryl), -S(O)(NH)(C 1-9 alkyl), -S(O)2NH(C 1-9 alkyl), or -S(O)2N(C 1-9 wherein the alkyl, cycloalkyl, heterocyclyl, aryl or 5-10 membered heteroaryl may be substituted by 1 to 3 of the following in each case: 1-9 Alkyl, C 1-8 Haloalkyl, halogen, -OH, -NH2, CO2H-O(C 1-9 alkyl), -O(C 1-8 haloalkyl), -O(C 3-15 cycloalkyl), -O(heterocyclyl), -O(aryl), -O(5-10 membered heteroaryl), -NH(C 1-9 Alkyl), -NH(C 1-8 haloalkyl), -NH(C 3-15 cycloalkyl), -NH(heterocyclyl), -NH(aryl), -NH(5-10 membered heteroaryl), -N(C 1-9 Alkyl)2,-N(C3- 15 Cycloalkyl)2,-NHC(O)(C 1-8 haloalkyl), -NHC(O)(C 3-15 cycloalkyl), -NHC(O)(heterocyclyl), -NHC(O)(aryl), -NHC(O)(5-10 membered heteroaryl), -NHC(O)O(C 1-9 alkyl), -NHC(O)O(C 1-8 haloalkyl), -NHC(O)O(C 2-6 Alkynyl), -NHC(O)O(C 3-15 Cycloalkyl), -NHC(O)O(heterocyclyl), -NHC(O)O(aryl), -NHC(O)O(5-10 membered heteroaryl), -NHC(O)NH(C 1-9 Alkyl), S(O)2(C 1-9 Alkyl), -S(O)2(C 1-8 haloalkyl), -S(O)2(C 3-15 Cycloalkyl), -S(O)2(heterocyclyl), -S(O)2(aryl), -S(O)2(5-10 membered heteroaryl), -S(O)(NH)(C 1-9 alkyl), -S(O)2NH(C 1-9 alkyl), or -S(O)2N(C 1-9 Alkyl)2;

[0033] Each R 1b , R 1c , R 2a, R 2b , R 4a , R 4b , R 4c , R 9 c, R 9d , R 12a , R 12b , and R 12c are independently H, -OH, C 1-9 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-15 Cycloalkyl, heterocyclic, C 6-10 aryl, or 5-10 membered heteroaryl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or 5-10 membered heteroaryl can be substituted by 1 to 4 Z 1b Replacement; and

[0034] Each R3e is independently H, C 1-6 Alkyl, C 1-6 Haloalkyl, -C 14 Alkyl-N(R 9a )(R 9b ), -C 1-4 Alkyl-C(O)N(R 9a )(R 9b ), -C 1-4 Alkyl-OC(O)-OC 1-4 Alkyl, -C 14 Alkyl-OC(O)-C 1-4 Alkyl-N(R 9a )(R 9b ), -C 1-4 Alkyl-C 3-8 Cycloalkyl, -C 1-4 Alkyl-heterocyclyl, C 3-10 Cycloalkyl, heterocyclic, C 6-10 Aryl, 5-10 membered heteroaryl, -P(O)(OR 9c )2,-CH2P(O)(OR 9c )2,-OCH2P(O)(OR 9c )2,-C(O)OCH2P(O)(OR 9c )2,-P(O)(R 9c )(OR 9d ), -OP(O)(R 9c )(OR 9d ), -CH2P(O)(R 9c )(OR 9d ), -C(O)OCH2P(O)(R 9c )(OR 9d ), -P(O)(N(R9c )2)2,-CH2P(O)(N(R 9c )2)2,-C(O)OCH2P(O)(N(R 9c )2)2,-P(O)(N(R 9c )2)(OR 9d ), -CH2P(O)(N(R 9c )2)(OR 9d ), -C(O)OCH2P(O)(N(R 9c )2)(OR 9d ), -P(O)(R 9c )(N(R 9d )2), -CH2P(O)(R 9c )(N(R 9d )2), or -C(O)OCH2P(O)(R 9c )(N(R 9d )2), wherein the alkyl, alkenyl, cycloalkyl, heterocyclyl, aryl or 5-10 membered heteroaryl are each optionally substituted by 1 to 4 Z 1b substituted; wherein each 5-10 membered heteroaryl has a 5- to 12-membered structure and has 1 to 4 heteroatoms that are each independently N, O or S; and wherein each heterocyclyl has a 3- to 12-membered structure and has 1 to 4 heteroatoms that are each independently N, O or S.

[0035] Another aspect of the present application relates to methods of treating a GLP-1R mediated disease or condition using the compounds of the present application.

[0036] Another aspect of the present application relates to a method for preparing the compounds of the present application

[0037] I. Definitions

[0038] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. A dash at the beginning or end of a chemical group is used for convenience to indicate the point of attachment to the parent moiety; a chemical group may be described with or without one or more dashes without losing its ordinary meaning. A prefix such as "C u-v " or "C u- C v " means that the following group has u to v carbon atoms, where u and v are integers. For example, "C 1-6 Alkyl" or "C 1- "C6 alkyl" means that the alkyl group has 1 to 6 carbon atoms.

[0039] "Alkyl" is a monovalent or divalent linear or branched saturated hydrocarbon group. For example, an alkyl group can have 1 to 10 carbon atoms (i.e., C 1-10Alkyl) or 1 to 8 carbon atoms (i.e. C 1-8 Alkyl) or 1 to 6 carbon atoms (i.e. C 1-6 Alkyl) or 1 to 4 carbon atoms (i.e. C 1-4 Examples of alkyl groups include, but are not limited to, methyl (Me, -CH3), ethyl (Et, -CH2CH3), 1-propyl (n-Pr, n-propyl, -CH2CH3), 2-propyl (i-Pr, isopropyl, -CH(CH3)2), 1-butyl (n-Bu, n-butyl, -CH2CH2CH2CH3), 2-methyl-1-propyl (i-Bu, isobutyl, -CH2CH(CH3)2), 2-butyl (s-Bu, sec-butyl, -CH(CH3)CH2CH3) , 2-methyl-2-propyl (t-Bu, tert-butyl, -C(CH3)3); 1-pentyl (n-pentyl, -CH2CH2CH2CH2CH3), 2-pentyl (-CH(CH3)CH2CH2CH3), 3-pentyl (-CH(CH2CH3)2), 2-methyl-2-butyl (-C(CH3)2CH2CH3), 3-methyl-2-butyl (-CH(CH3)CH(CH3)2), 3-methyl-1-butyl (-CH2CH2CH(CH3)2 ), 2-methyl-1-butyl (-CH2CH(CH3)CH2CH3); 1-hexyl (-CH2CH2CH2CH2CH2CH3), 2-hexyl (-CH(CH3)CH2CH2CH2CH3), 3-hexyl (-CH(CH2CH3)(CH2CH2CH3)), 2-methyl-2-pentyl (-C(CH3)2CH2CH2CH3); 3-methyl-2-pentyl (-CH(CH3)CH(CH3)CH2CH3), 4-methyl Alkyl groups may be unsubstituted or substituted.

[0040] "Alkoxy" refers to the group -O-alkyl, where alkyl is as defined above. 1-4 Alkoxy refers to an -O-alkyl group having 1 to 4 carbon atoms. Alkoxy may be unsubstituted or substituted.

[0041] "Alkoxyalkyl" is an alkoxy group attached to an alkyl group as defined above, thereby making the alkyl group divalent. 2-6Alkoxyalkyl includes -CH2-OMe, -CH2-O-iPr, -CH2-CH2-OMe, -CH2-CH2-O-CH2-CH3, and -CH2-CH2-O-tBu. Alkoxyalkyl may be unsubstituted or substituted.

[0042] "Alkenyl" is a monovalent or divalent linear or branched hydrocarbon radical having at least one carbon-carbon double bond. For example, an alkenyl group can have 2 to 8 carbon atoms (i.e., C2-8 alkenyl) or 2 to 6 carbon atoms (i.e., C2-6 alkenyl) or 2 to 4 carbon atoms (i.e., C 2-4 Examples of alkenyl groups include, but are not limited to, vinyl (-CH=CH2), allyl (-CH2CH=CH2), and -CH2-CH=CH-CH3. Alkenyl groups may be unsubstituted or substituted.

[0043] "Alkynyl" is a monovalent or divalent linear or branched hydrocarbon radical having at least one carbon-carbon triple bond. For example, an alkynyl group can have 2 to 8 carbon atoms (i.e., C 2-8 Alkynyl) or 2 to 6 carbon atoms (i.e. C 2-6 Alkynyl) or 2 to 4 carbon atoms (i.e. C 2-4 Examples of alkynyl groups include, but are not limited to, ethynyl (-C≡CH), propynyl (-CH2C≡CH), and -CH2-C≡C-CH3. Alkynyl groups may be unsubstituted or substituted.

[0044] "Halogen" refers to fluorine (-F), chlorine (-Cl), bromine (-Br) and iodine (-I).

[0045] "Haloalkyl" is an alkyl group as defined herein, wherein one or more hydrogen atoms of the alkyl group are independently replaced by a halogen, which may be the same or different, such that the alkyl group is divalent. The alkyl group and the halogen may be any of those described above. In some embodiments, the haloalkyl group specifies the number of carbon atoms in the alkyl portion, e.g., C 1-4 Haloalkyl groups include CF3, CH2F, CHF2, CH2CF3, CH2CH2CF3, CCl2CH2CH2CH3 and C(CH3)2(CF2H). The haloalkyl group may be unsubstituted or substituted.

[0046] "Haloalkoxy" is an alkoxy group as defined herein, wherein one or more hydrogen atoms in the alkoxy group are independently replaced by halogen, which may be the same or different, so that the alkyl group is divalent. Alkoxy and halogen may be any of those described above. In some embodiments, haloalkoxy defines the number of carbon atoms in the alkyl group, for example, C1-4 haloalkoxy includes OCF3, OCH2F, OCH2CF3, OCH2CH2CF3, OCCl2CH2CH2CH3 and OC(CH3)2(CF2H). Haloalkoxy may be unsubstituted or substituted.

[0047] "Cycloalkyl" is a monovalent or divalent single all-carbon ring or multiple condensed all-carbon ring system, wherein the ring in each example is a non-aromatic saturated or unsaturated ring. For example, in some embodiments, cycloalkyl has 3 to 12 carbon atoms, 3 to 10 carbon atoms, 3 to 8 carbon atoms, 3 to 6 carbon atoms, 3 to 5 carbon atoms, or 3 to 4 carbon atoms. Exemplary monocyclic cycloalkyls include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloalkenyl, cycloheptyl, cycloheptenyl and cyclooctyl. Cycloalkyl also includes multiple condensed ring systems (for example, including 2 ring systems) with about 7 to 12 carbon atoms. When valence requirements allow, the rings of multiple condensed ring systems can be interconnected by fusion bonds, spiral bonds or bridging bonds. Exemplary multicyclic cycloalkyls include octahydropentene, bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane, bicyclo[2.2]oct-2ene, and spiro[2.5]octane. Cycloalkyl groups can be unsubstituted or substituted.

[0048] "Alkylcycloalkyl" refers to an alkyl group as defined herein, wherein one or more hydrogen atoms of the alkyl group are independently replaced by a cycloalkyl group, which may be the same or different. The alkyl group and the cycloalkyl group may be any of the above. In some embodiments, the number of carbon atoms in the alkyl and cycloalkyl groups may be specified separately, for example, C 1-6 Alkyl-C 3-12 Cycloalkyl. Alkylcycloalkyl groups can be unsubstituted or substituted.

[0049] As used herein, "aryl" refers to a monovalent or divalent single all-carbon aromatic ring or a polycondensed all-carbon ring system, wherein the ring is aromatic. For example, in some embodiments, an aryl has 6 to 20 carbon atoms, 6 to 14 carbon atoms, 6 to 12 carbon atoms, or 6 to 10 carbon atoms. Aryl includes a phenyl group. Aryl also includes multiple condensed ring systems (e.g., ring systems consisting of 2, 3, or 4 rings) having about 9 to 20 carbon atoms, wherein multiple rings are aromatic. Where valence requirements permit, the rings of multiple condensed ring systems can be interconnected by fusion bonds. It is also understood that when referring to a member aryl of a certain atomic range (e.g., an aryl of 6-10 members), the atomic range refers to the total ring atoms of the aryl. For example, an aryl of 6 members includes phenyl, and an aryl of 10 members includes naphthyl. Non-limiting examples of aryl include, but are not limited to, phenyl, naphthyl, anthracenyl, etc. Aryl can be unsubstituted or substituted.

[0050] "Alkylaryl" refers to an alkyl group as defined herein, wherein one or more hydrogen atoms of the alkyl group are independently replaced by an aryl group, which may be the same or different. The alkyl and aryl groups may be any of those described above, and such alkyl groups are divalent. In some embodiments, an alkylaryl group has 7 to 24 carbon atoms, 7 to 16 carbon atoms, 7 to 13 carbon atoms, or 7 to 11 carbon atoms. An alkylaryl group defined by the number of carbon atoms refers to the total number of carbon atoms present in the alkyl and aryl groups. For example, C7 alkylaryl refers to benzyl, while C 11 Alkylaryl includes 1-methylnaphthalene and n-pentylphenyl. In some embodiments, the number of carbon atoms in the alkyl and aryl portions can be specified separately, for example, C 1-6 Alkyl-C 6-10 Aryl. Non-limiting examples of alkylaryl groups include, but are not limited to, benzyl, 2,2-dimethylphenyl, n-pentylphenyl, 1-methylnaphthyl, 2-ethylnaphthyl, etc. Alkylaryl groups can be unsubstituted or substituted.

[0051] As used herein, "heterocycle" or "heterocyclic ring" or "heterocyclyl" refers to a single saturated or partially unsaturated non-aromatic ring or non-aromatic polycyclic ring system having at least one heteroatom in the ring (i.e., at least one cyclic (i.e., annular) heteroatom selected from oxygen, nitrogen, and sulfur). Unless otherwise specified, a heterocyclic group has 3 to about 20 ring atoms, such as 3 to 12 ring atoms, such as 4 to 12 ring atoms, 4 to 10 ring atoms, or 3 to 8 ring atoms, or 3 to 6 ring atoms, or 3 to 5 ring atoms, or 4 to 6 ring atoms, or 4 to 5 ring atoms. Thus, the term includes single saturated or partially unsaturated rings (e.g., 3-, 4-, 5-, 6-, or 7-membered rings) having about 1 to 6 ring carbon atoms and about 1 to 3 ring heteroatoms, wherein the heteroatoms in these rings are selected from the group consisting of oxygen, nitrogen, and sulfur. Where valence requirements permit, the rings of multiple condensed ring systems (e.g., bicyclic heterocycles) may be interconnected by fusion bonds, spiral bonds, and bridge bonds. Heterocycles include, but are not limited to, azetidine, azapyridine, imidazolidine, morpholine, oxirane (epoxide), oxygen heterocycle, sulfur heterocycle, piperazine, piperidine, pyrazolidine, piperidine, pyrrolidine, pyrrolidone, tetrahydrofuran, tetrahydrothiophene, dihydropyridine, tetrahydropyridine, quinuclidine, 2-oxo-6-azaspiro[3.3]heptane-6-yl, 6-oxa-1-azaspiro[3.3]heptane-1-yl, 2-thia- 6-azaspiro[3.3]heptane-6-yl, 2,6-diazaspiro[3.3]heptane-2-yl, 2-azabicyclo[3.1.0]hexane-2-yl, 3-azabicyclo[3.1.0]hexane, 2-azabicyclo[2.1.1]hexane, 2-azabicyclo[2.2.1]heptane-2-yl, 4-azaspiro[2.4]heptane, 5-azaspiro[2.4]heptane, and the like. The heterocyclyl group can be unsubstituted or substituted.

[0052] "Alkylheterocyclyl" refers to an alkyl group as defined herein, wherein one or more hydrogen atoms of the alkyl group are independently replaced by a heterocyclyl group, which may be the same or different. The alkyl group and the heterocyclyl group may be any of the above, and such an alkyl group is divalent. In some embodiments, the number of atoms in the alkyl and heterocyclyl portions may be specified separately, for example, C 1-6 Alkyl-3 to 12 member heterocyclyl has 1 to 3 heteroatoms, each heteroatom independently being N, O or S. Alkylheterocyclyl may be unsubstituted or substituted.

[0053] "5-10 membered heteroaryl" refers to a single aromatic ring having at least one atom other than carbon in the ring, wherein the atom is selected from the group consisting of oxygen, nitrogen and sulfur; "5-10 membered heteroaryl" also includes multiple condensed ring systems having at least one such aromatic ring, which multiple condensed ring systems are further described below. Therefore, "5-10 membered heteroaryl" includes a single aromatic ring of about 1-6 carbon atoms and about 1-4 heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur. The sulfur and nitrogen atoms may also be present in oxidized form, as long as the ring is aromatic. Exemplary 5-10 membered heteroaryl ring systems include, but are not limited to, pyridyl, pyrimidinyl, oxazolyl or furanyl. "5-10 membered heteroaryl" also includes multiple condensed ring systems (e.g., ring systems consisting of 2, 3, or 4 rings), wherein the 5-10 membered heteroaryl as defined above is condensed with one or more rings selected from 5-10 membered heteroaryl (forming, for example, 1,8-naphthyridinyl) and aryl (forming, for example, benzimidazolyl or indazolyl) to form multiple condensed ring systems. Thus, the 5-10 membered heteroaryl (single aromatic ring or multiple condensed ring systems) can have about 1-20 carbon atoms and about 1-6 heteroatoms within the 5-10 membered heteroaryl ring. For example, tetrazolyl has 1 carbon atom and 4 nitrogen heteroatoms within the ring. Where valence requirements permit, the rings of multiple condensed ring systems can be interconnected by fusion bonds. It should be understood that the individual rings of the multiple condensed ring systems can be interconnected in any order. It should be understood that the connection point of the 5-10 heteroaryl or 5-10 heteroaryl multiple condensed ring system can be any suitable atom of the 5-10 heteroaryl or 5-10 heteroaryl multiple condensed ring system, including carbon atoms and heteroatoms (e.g., nitrogen). It should also be understood that when referring to a member heteroaryl of a certain atomic range (e.g., a heteroaryl of 5 to 10 members), the atomic range is for the total ring atoms of the heteroaryl, including carbon atoms and heteroatoms. It should also be understood that the ring of the multiple condensed ring system can include an aryl ring fused to a heterocycle (e.g., 3, 4, 5, 6 or 7 rings) with a saturated or partially unsaturated bond, the ring having about 1 to 6 annular carbon atoms and about 1 to 3 annular heteroatoms selected from oxygen, nitrogen and sulfur in the ring. For example, a 5-10 heteroaryl includes a thiazolyl group, and a 5-10 heteroaryl includes a quinolyl group. Exemplary 5-10 membered heteroaryl groups include, but are not limited to, pyridinyl, pyrrolyl, pyrazinyl, pyrimidinyl, pyridazinyl, pyrazolyl, thienyl, indolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, furanyl, oxadiazolyl, thiadiazolyl, quinolyl, isoquinolyl, benzothiazolyl, benzoxazolyl, indazolyl, quinoxazolyl, quinazolyl, benzofuranyl, benzimidazolyl, thiophenyl, pyrrolo[2,3-b]pyridinyl, quinazolinyl-4(3H)-one, triazolyl, and tetrazolyl. The 5-10 membered heteroaryl group may be unsubstituted or substituted.

[0054] "Alkyl-heteroaryl" refers to an alkyl group as defined herein, wherein one or more hydrogen atoms of the alkyl group are independently replaced by heteroaryl groups, which may be the same or different, thereby making the alkyl group divalent. The alkyl and heteroaryl groups may be any of the above. In some embodiments, the number of atoms in the alkyl and heteroaryl portions is specified separately, for example, C 1-6 Alkyl-5 to 10 member heteroaryl having 1 to 4 heteroatoms, each heteroatom independently being N, O or S. Alkylheteroaryl can be unsubstituted or substituted.

[0055] As used herein, "Oxo" means =O.

[0056] As used herein, "substituted" refers to groups wherein one or more hydrogen atoms of the group are independently replaced with one or more substituents (eg, 1, 2, 3, or 4 or more), as indicated.

[0057] "Compounds of the present disclosure" include compounds disclosed herein, for example, compounds of the present disclosure include compounds of Formula IA-1, including compounds of the Examples. In some embodiments, "compounds of the present disclosure" include compounds of Formula IA-1.

[0058] "Pharmaceutically acceptable excipients" include, but are not limited to, any adjuvant, carrier, vehicle, lubricant, sweetener, diluent, preservative, dye / colorant, flavor enhancer, surfactant, wetting agent, dispersant, suspending agent, stabilizer, isotonic agent, solvent or emulsifier that has been approved by the U.S. Food and Drug Administration for use in humans or livestock.

[0059] As used herein, "therapeutically effective amount" or "effective amount" refers to an amount that is effective to cause a desired biological or medical response, including an amount of a compound that is sufficient to affect the treatment of a disease when administered to a subject being treated for the disease. The effective amount will vary depending on factors such as the compound, the disease and its severity, and the age, weight, and other factors of the subject to be treated. The effective amount may include a range of amounts. As is understood in the art, an effective amount may be one or more doses, i.e., one dose or multiple doses may be required to achieve the desired therapeutic endpoint. An effective amount may be considered in the context of administering one or more therapeutic agents, and if used in conjunction with one or more other agents, a desired or beneficial result may or has been achieved, then a single agent may be considered to be administered in an effective amount. Due to the combined action of the compounds (e.g., additive or synergistic), the appropriate dose of any co-administered compound may be selectively reduced.

[0060] As used herein, "co-administration" refers to administration of a unit dose of a compound of the present disclosure before or after administration of a unit dose of one or more additional therapeutic agents, for example, administration of a compound of the present disclosure within a few seconds, minutes, or hours of administration of one or more additional therapeutic agents. For example, in some embodiments, a unit dose of a compound of the present disclosure is administered first, followed by administration of a unit dose of one or more additional therapeutic agents within a few seconds or minutes. Alternatively, in other embodiments, a unit dose of one or more additional therapeutic agents is administered first, followed by administration of a unit dose of a compound of the present disclosure within a few seconds or minutes. In some embodiments, a unit dose of a compound of the present disclosure is administered first, followed by administration of a unit dose of one or more additional therapeutic agents a few hours later (e.g., 1-12 hours). In other embodiments, a unit dose of one or more additional therapeutic agents is administered first, followed by administration of a unit dose of a compound of the present disclosure a few hours later (e.g., 1-12 hours). Co-administration of a compound disclosed herein with one or more additional therapeutic agents generally refers to administration of a compound disclosed herein and one or more additional therapeutic agents simultaneously or sequentially, such that a therapeutically effective amount of each agent is present in the subject's body.

[0061] Also provided are pharmaceutically acceptable salts, hydrates, solubilized forms, isomeric forms, polymorphs, and prodrugs of the compounds described herein.

[0062] "Pharmaceutically acceptable" or "physiologically acceptable" refers to compounds, salts, compositions, dosage forms, and other materials that are useful in preparing pharmaceutical compositions suitable for veterinary or human pharmaceutical use.

[0063] The compounds described herein can be prepared and / or formulated as pharmaceutically acceptable salts or as free bases where appropriate. Pharmaceutically acceptable salts are non-toxic salts of the free base form of the compound that have the pharmacological activity required of the free base. These salts can be extracted from inorganic or organic acids or bases. For example, compounds containing basic nitrogen can be prepared into pharmaceutically acceptable salts by contacting the compound with an inorganic or organic acid. Non-limiting examples of pharmaceutically acceptable salts include sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, phosphates, monohydrogen phosphates, dihydrogen phosphates, metaphosphates, pyrophosphates, chlorides, bromides, iodides, acetates, propionates, decanoates, octanoates, acrylates, formates, isobutyrates, caproates, enanthates, propanolates, oxalates, malonates, succinates, suberates, sebacates, fumarates, maleates, butyrates. The pharmaceutically acceptable salts of the present invention are hydroxybenzoate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, phthalate, sulfonate, methanesulfonate, propanesulfonate, benzenesulfonate, xylenesulfonate, naphthalene-1-sulfonate, naphthalene-2-sulfonate, phenylacetate, phenylpropionate, phenylbutyrate, citrate, lactate, gamma-hydroxybutyrate, glycolate, tartrate and mandelate. A list of other suitable pharmaceutically acceptable salts can be found in Remington: The Science and Practice of Pharmacy, 21st ed., Lippincott Williams & Wilkins, Philadelphia, Pennsylvania, 2006.

[0064] Examples of "pharmaceutically acceptable salts" of the compounds disclosed herein also include salts from appropriate bases, such as alkali metals (e.g., sodium, potassium), alkaline earth metals (e.g., magnesium), ammonium, and N (C1-C4 alkyl) 4+. Also included are base addition salts, such as sodium or potassium salts.

[0065] Also provided are compounds described herein or pharmaceutically acceptable salts, isomers or mixtures thereof, wherein 1 to n hydrogen atoms attached to a carbon atom may be replaced by deuterium atoms or D, wherein n is the number of hydrogen atoms in the molecule. As is known in the art, a deuterium atom is a non-radioactive isotope of a hydrogen atom. Such compounds may increase resistance to metabolism and thus may be used to increase the half-life of a compound described herein or a pharmaceutically acceptable salt, isomer or mixture thereof when administered to a mammal. See Foster, "Deuterium Isotope Effects in Drug Metabolism Studies," Trends Pharmacol, Science 5(12): 524-527 (1984). Such compounds are synthesized by methods well known in the art, such as using starting materials in which one or more hydrogen atoms are replaced by deuterium.

[0066] Examples of isotopes that may be incorporated into the disclosed compounds also include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine, chlorine, and iodine, such as 2H, 3 H,11 C, 13 C, 14 C, 13 N, 15 N, 15 Oh, 17 Oh, 18 Oh, 31 P, 32 P, 35 S, 18 F, 36 Cl, 123 I and 125 I. Using positron emitting isotopes, such as 11 C. 18 F. 15 O and 13 N substitution can be used for positron emission topograph (PET) studies to examine substrate receptor occupancy. Isotopically labeled compounds of formula (IA-1) can generally be prepared by conventional techniques known to those skilled in the art, or by processes similar to those described in the following examples, using an appropriate isotopically labeled reagent instead of the non-labeled reagent previously used.

[0067] The compounds of the embodiments disclosed herein, or pharmaceutically acceptable salts thereof, may contain one or more asymmetric centers and may therefore give rise to enantiomers, tautomers, diastereomers and other stereoisomeric forms which may be defined in terms of absolute stereochemistry as (R)- or (S)-, or, for amino acids, as (D)- or (L)-, and their deuterated analogs. It is intended that all such possible isomers be included, as well as their racemates and optically pure forms. Optically active (+) and (-), (R) and (S), or (D) and (L)-isomers may be prepared using chiral syntheses or chiral reagents, or resolved using conventional techniques, such as chromatography and fractional crystallization. Conventional techniques for preparing / isolating individual enantiomers include chiral synthesis from suitable optically pure precursors, or resolving racemates (or racemates of salts or derivatives) using, for example, chiral high pressure liquid chromatography (HPLC). When the compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, unless specified otherwise, these compounds are intended to include both E and Z geometric isomers. Likewise, all isomeric forms are included. When a compound is represented in its chiral form, it is understood that the embodiment includes, but is not limited to, the specific diastereomer or enantiomerically enriched form. If chirality is not specified but exists, it is understood that the embodiment is directed to the specific diastereomer or enantiomerically enriched form; or a racemic or scalar mixture of such a compound. As used herein, "scalar mixture" refers to a mixture of stereoisomers in a ratio other than 1:1.

[0068] As used herein, "stereoisomers" refer to compounds that are bound by the same atoms but have different three-dimensional structures and are not interchangeable. The present disclosure contemplates various stereoisomers and mixtures thereof, and includes "enantiomers," which refer to two stereoisomers whose molecules are non-superimposable mirror images of each other.

[0069] As used herein, "tautomer" refers to a proton transfer from one atom of one molecule to another atom of the same molecule. In some embodiments, the present disclosure includes tautomers of the compounds.

[0070] As used herein, "solvate" refers to the result of the interaction of a solvent and a compound. Also provided are solvates of the salts of the compounds described herein. Also provided are hydrates of the compounds described herein.

[0071] As used herein, "hydrate" refers to a compound of the present invention chemically bound to one or more water molecules.

[0072] "Prevention" or "prevention" refers to any treatment for a disease or condition that results in clinical symptoms of the disease or condition not developing. In some embodiments, the compound can be administered to a subject (including a human) at risk for or with a family history of the disease or condition.

[0073] As used herein, "prodrug" refers to a derivative of a drug that is converted into a parent drug according to a certain chemical or enzymatic pathway after administration to the human body. In some embodiments, a prodrug is a biologically active derivative of a drug that is converted into a biologically active parent drug according to some chemical or enzymatic pathway after administration to the human body.

[0074] As used herein, "treatment" or "treating" refers to an approach to obtaining beneficial or desired results. For purposes of this disclosure, beneficial or desired results include, but are not limited to, alleviating symptoms and / or reducing the severity of symptoms and / or preventing worsening of symptoms associated with a disease or condition. In one embodiment, " "Treatment" or "treating" includes one or more of the following: a) inhibiting the disease or condition (e.g., reducing one or more symptoms caused by the disease or condition, and / or reducing the extent of the disease or condition); b) slowing or arresting the development of one or more symptoms associated with the disease or condition (e.g., stabilizing the disease or condition, delaying the deterioration or progression of the disease or condition); and c) alleviating the disease or condition, for example, causing regression of clinical symptoms, improving the disease state, delaying disease progression, improving quality of life and / or prolonging survival. As used herein, "at-risk individual" refers to an individual who is at risk of developing a disease in need of treatment.

[0075] An individual who is "at risk" may or may not have a detectable disease or condition, and may or may not have manifested a detectable disease prior to the treatment methods described herein. "At risk" means that the individual has one or more so-called risk factors, which are measurable parameters that correlate with the development of a disease or condition, and are known in the art to increase the probability of an individual having one or more of these risk factors developing a disease or condition compared to an individual without these risk factors.

[0076] II.Compounds

[0077] One aspect of the present application relates to compounds that bind to GLP-1R and act as GLP-1R agonists or modulators. In some embodiments, the compounds disclosed herein are compounds of formula IA-1:

[0078]

[0079] or a pharmaceutically acceptable salt thereof, wherein:

[0080] R 1 It is C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Cycloalkyl, heterocyclic, C 6-10 Aryl, 5-10 membered heteroaryl, -SR 1b , -S(O)R 1b , -S(O)(NH)R 1b , -S(O)2R 1b ,-S(O)2N(R 1b )(R 1c ), -S(O)(NR 1b )R 1c ,-C(O)N(R 1b )(R 1c ), -C(O)R 1b , or -C(O)OR 1c wherein the alkyl, haloalkyl, cycloalkyl, aryl, 5-10 membered heteroaryl or heterocyclyl is each optionally substituted by one to four Z 1 Replace, and any two Z 1 can combine with the atoms to which they are attached to form C 3-10 Cycloalkyl or heterocyclic or C 6-10 Aryl or 5-10 membered heteroaryl;

[0081] Ring A is C 3-10 Cycloalkyl, heterocyclic, C 6-10 Aryl or 5-10 membered heteroaryl, the C3-10 Cycloalkyl, heterocyclic, C 6-10 The aryl or 5-10 membered heteroaryl groups are each substituted with 1 to 4 Z 1a Optional substitution;

[0082] Ring B is C 3-10 Cycloalkyl, heterocyclic, C 6-10 Aryl or 5-10 membered heteroaryl, the C 3-10 Cycloalkyl, heterocyclic, C 6-10 Aryl or 5-10 membered heteroaryl is each optionally substituted by 1 to 4 R4;

[0083] Ring A and Ring B each contain 0-3 double bonds;

[0084] R2 is H, C 1-6 Alkyl, C 1-6 Alkyl-alkoxy, C 1-6 Alkyl-cycloalkoxy, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Cycloalkyl, heterocyclic, C 6-10 Aryl, 5-10 membered heteroaryl, -CN, -OR 2a , -SR 2a , -S(O)R 2a , -S(O)(NH)R 2a , -S(O)2R 2a ,-S(O)2N(R 2a )(R 2b ), or -S(O)(NR 2a )R 2b , wherein the alkyl, alkoxy, cycloalkyloxy, haloalkyl, cycloalkyl, heterocyclyl, aryl or 5-10 membered heteroaryl groups can each be substituted by 1 to 4 Z 1 Replace, and any two Z 1 can combine with the atoms to which they are attached to form C 3-10 Cycloalkyl or heterocyclic or C 6-10 Aryl or 5-10 membered heteroaryl;

[0085] X is independently -N=, -C(H)=, or -C(R 8 )=;

[0086] Each R3 and R3' is independently H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen, C 3-10 Cycloalkyl, heterocyclic, C 6-10Aryl, 5-10 membered heteroaryl, -CN, -NO2, -OR 3a , -C(O)R 3a ,-CH2C(O)OR 3a , -C(O)OR 3a ,-C(O)N(R 3a )(R 3b ), -N(R 3a )C(O)R 3b , -N(R 3a )C(O)OR 3b , -N(R 3a )C(O)N(R 3b )2,-C(O)NHS(O)2R 3a , -C(O)NR 3a S(O)2R 3b , -C(O)NR 3a S(O)2NR 3b R 3c , -C(O)NR 3a -S(O)(=NR 3b ) R3c , -S(O)2R 3a , -S(O)2OR 3a ,-S(O)2N(R 3a )(R 3b ), -N(R 3a )S(O)2R 3b ,-S(O)2NHC(O)R 3a , -S(O)(=NR 3a )R 3b , -S(O)(=NR 3a )NR 3b ,-S(=NR 3a )(=NR 3b )R 3c , -P(O)(OR 3a )(R 3b ), -P(O)(OR 3a )(OR 3b ), -B(OR 3a )(OR3 b ), or -OC 1-6 Alkyl-C(O)OR 3a , wherein the alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or 5-10 membered heteroaryl groups can each be substituted by 1 to 4 R3 d replace;

[0087] Each R 3a , R 3b , and R3c Independently H, C 1-6 Alkyl, C 6-10 Aryl, 5-10 membered heteroaryl, C 1-6 Haloalkyl, C 2-8 Alkoxyalkyl, -C 1-4 Alkyl-N(R 9a )(R 9b ), -C 1-4 Alkyl-N(R 9a )C(O)-OC 1-4 Alkyl-OP(O)(OR 9c )2, -C 1-4 Alkyl-C(O)N(R 9a )(R 9b ), -C 1-4 Alkyl-OC(O)-OC 1-4 Alkyl, -C 1-4 Alkyl-OC(O)-C 1-4 Alkyl-N(R 9a )(R 9b ), -C 1-4 Alkyl-OC(O)-C 1-4 Alkyl-OP(O)(OR 9c )2, -C 1-4 Alkyl-C 3-8 Cycloalkyl, -C 1-4 Alkyl-heterocyclyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Cycloalkyl, heterocyclyl, -CH2CH(N(R 9a )2)C(O)OR 9b , -P(O)(OR 9c )2, -OP(O)(OR 9c )2,-CH2P(O)(OR 9c )2,-CH2OP(O)(OR 9c )2,-OCH2P(O)(OR 9c )2,-C(O)OCH2P(O)(OR 9c )2,-P(O)(R 9c )(OR 9d ), -OP(O)(R 9c )(OR 9d ), -CH2P(O)(R 9c )(OR 9d ), -OCH2P(O)(R 9c )(OR 9d ), -C(O)OCH2P(O)(R 9c )(OR9d ), -P(O)(N(R 9c )2)2,-OP(O)(N(R 9c )2)2,-CH2P(O)(N(R 9c )2)2,-OCH2P(O)(N(R 9c )2)2,-C(O)OCH2P(O)(N(R 9c )2)2,-P(O)(N(R 9c )2)(OR 9d ), -OP(O)(N(R 9c )2)(OR 9d ), -CH2P(O)(N(R 9c )2)(OR 9d ), -OCH2P(O)(N(R 9c )2)(OR 9d ), -C(O)OCH2P(O)(N(R 9c )2)(OR 9d ), -P(O)(R 9c )(N(R 9d )2),-OP(O)(R 9c )(N(R 9d )2), -CH2P(O)(R 9c )(N(R 9d )2), -OCH2P(O)(R 9c )(N(R 9d )2), -C(O)OCH2P(O)(R 9c )(N(R 9d )2), C 1-6 Alkyl-heterocyclyl, C 1-6 Alkyl-aryl or C 1-6 Alkyl-(5-10 membered) heteroaryl, wherein the alkyl, alkenyl, cycloalkyl, heterocyclyl, aryl or 5-10 membered heteroaryl can be substituted by 1 to 4 Z 1b replace;

[0088] Each R 4 are independently H, -OH, CH2OH, C 1-9 Alkyl, C 1-8 Haloalkyl, C 1-6 Haloalkoxy, C 2-6 Alkoxyalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen, C 3-15 Cycloalkyl, heterocyclic, C 6-10 Aryl, 5-10 membered heteroaryl, oxo, -NO2, -CN, -N3, -OR 4a, -C(O)R 4a , -C(O)OR 4a ,-C(O)N(R 4a )(R 4b ), -N(R 4a )(R 4b ), -N(R 4a )2(R 4b ) + , -N(R 4a )-C(O)R 4b , -N(R 4a )C(O)O(R 4b ), -N(R 4a )C(O)N(R 4b )(R 4c ), -N(R 4a )S(O)2(R 4b ), -N(R 4a )S(O)2-N(R 4b )(R 4c ), -N(R 4a )S(O)2O(R 4b ), -OC(O)R 4a , -OC(O)OR 4a ,-0C(O)-N(R 4a )(R 4b ), -SR 4a , -S(O)R 4a , -S(O)(NH)R 4a , -S(O)2R 4a ,-S(O)2N(R 4a )(R 4b ), -S(O)(NR 4a )R 4b , or -Si(R 4a )3; wherein the alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or 5-10 membered heteroaryl are each optionally substituted by 1 to 4 Z 1b or, two R attached to adjacent ring atoms 4 The groups combine with the atoms to which they are attached to form C 5-10 Cycloalkyl or heterocyclic group, each of which may be replaced by 1 to 4 Z 1b replace;

[0089] Each R 5a and R 5b Independently H, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 2-6Alkoxyalkyl, halogen, C 3-10 Cycloalkyl, heterocyclyl, -C 1-6 Alkyl-N(R 9a )(R 9b ), -CN, -OR 5a1 , or -N(R 5a1 )(R 5a2 ); or, R 5a and R 5b Combine with the atoms to which they are attached to form C 3-10 Cycloalkyl or heterocyclic group, each of which may be replaced by 1 to 4 R 5 a 3 Substituted; or, R5a or R 5b Can combine with any substituent on ring A to form C 5-10 Cycloalkyl or heterocyclic group, each of which may be replaced by 1 to 4 R 5a3 replace;

[0090] Each R 5 a 1 and R 5 a 2 Independently H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Cycloalkyl, heterocyclic, C 6-10 aryl or 5-10 membered heteroaryl, wherein the cycloalkyl, heterocyclyl, aryl or 5-10 membered heteroaryl can be each substituted by 1 to 4 R 5 a 4 replace;

[0091] V is -C(O)-, -O-, -N(R 6a )-, or -C(R 6b )(R 6c )-;

[0092] R6 a is H, C 1-6 Alkyl, C 3-10 Cycloalkyl, heterocyclyl, -S(O)2R 6a1 , or -S(O)2N(R 6a1 )(R 6a2 ), wherein the cycloalkyl or heterocyclic group may be C 1-6 Alkyl, F or -CN substitution;

[0093] Each R 6b and R 6c Independently H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkoxyalkyl, halogen, C3-10 Cycloalkyl, heterocyclyl, -C 1-6 Alkyl-N(R 9a )(R 9b ), -CN, -OR 6c1 , or -N(R 6c2 )(R 6c3 ); wherein the alkyl, cycloalkyl or heterocyclic group can be each be 1 to 4 R 6b1 Replacement; or R 6b and R 6c Combine with the atoms to which they are attached to form C 3-10 Cycloalkyl or heterocyclic group, each of which may be replaced by 1 to 4 R 6b1 Replacement; or R 6a or R 6c With an R 4 The groups and the atoms to which they are attached combine to form C 5-10 Cycloalkyl or heterocyclic group, each of which may be replaced by 1 to 4 R 10 replace;

[0094] Y is -N(R 7 )-, -O-, -S-, -S(O)-, -S(O)2-, -S(O)(=NH)-, or -S(O)(=NR 7 )-;

[0095] Each R 3d , R5 a3 , R 5a4 , R 6b1 , and R 10 Independently H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkoxyalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen, C 3-10 Cycloalkyl, heterocyclic, C 6-10 Aryl, 5-10 membered heteroaryl, oxo, -OH, -CN, -CO2R 3c , -NO2, or -C(O)N(R 2a )(R 2b ), wherein the heterocyclic group or the 5-10 membered heteroaryl group can be C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 Haloalkoxy substitution;

[0096] Each R 6a1 , R 6a2 , R 6c1 , R6c2 , R 6c3 and R 7 Independently H, C 1-6 Alkyl or C 3-10 Cycloalkyl;

[0097] Each R 8 Independently for C 1-9 Alkyl, C 1-8 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen, oxo, -OH, -CN, CO2R 3e ,-NO2,-NH2,-N3,-SH,-O(C 1-9 alkyl), -O(C 1-8 haloalkyl), -NH(C 1-9 Alkyl), -NH(C 1-8 haloalkyl), -N(C 1-9 Alkyl)2,-N(C 1-8 Haloalkyl)2;

[0098] Each R 9a and R 9b Independently H, C 1-9 Alkyl, C 1-8 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkoxyalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen, C 3-15 Cycloalkyl, heterocyclic, C 6-10 Aryl, 5-10 membered heteroaryl, oxo, -NO2, -CN, -N3, -OR 12a , -C(O)R 12a , -C(O)OR 12a ,-C(O)N(R 12a )(R 12b ), -N(R 12a )(R 12b ), -N(R 12a )2(R 12b ) + , -N(R 12a )-C(O)R 12b , -N(R 12a )C(O)O(R 12b ), -N(R 12a )C(O)N(R 12b )(R 12c ), -N(R 12a )S(O)2(R 12b), -N(R 12a )S(O)2-N(R 12b )(R 12c ), -N(R 12a )S(O)2O(R 12b ), -OC(O)R 12a , -OC(O)OR 12a ,-OC(O)-N(R 12a )(R 12b ), -SR 12a , -S(O)R 12a , -S(O)(NH)R 12a , -S(O)2R 12a ,-S(O)2N(R 12a )(R 12b ), -S(O)(NR 1 2a) R 12b , or -Si(R 12a )3; or R 9a and R 9b Fusion forms a 3-10 membered heterocyclic group which may be substituted by: C 1-9 Alkyl, C 1-8 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkoxyalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen, C 3-15 Cycloalkyl, heterocyclic, C 6-10 Aryl, 5-10 membered heteroaryl, oxo, -NO2, -CN, -N3, -OR 12a , -C(O)R 12a , -C(O)OR 12a ,-C(O)N(R 12a )(R 12b ), -N(R 12a )(R 12b ), -N(R 12a )2(R 12b ) + , -N(R 12a )-C(O)R 12b , -N(R 12a )C(O)O(R 12b ), -N(R 12a )C(O)N(R 12b )(R 12c ), -N(R 12a )S(O)2(R 12b ), -N(R 12a)S(O)2-N(R 12b )(R 12c ), -N(R 12a )S(O)2O(R 12b ), -OC(O)R 12a , -OC(O)OR 12a ,-OC(O)-N(R 12a )(R 12b ), -SR 12a , -S(O)R 12a , -S(O)(NH)R 12a , -S(O)2R 12a ,-S(O)2N(R 12a )(R 12b ), -S(O)(NR 12a )R 12b , or -Si(R 12a )3;

[0099] Each Z 1 Independently C 1-9 Alkyl, C 1-8 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkoxyalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen, C 3-i5 Cycloalkyl, heterocyclic, C 6-10 Aryl, 5-10 membered heteroaryl, oxo, -NO2, -N3, -CN, -OR 12a , -C(O)-R 12a , -C(O)OR 12a ,-C(O)N(R 12a )(R 12b ), -N(R 12a )(R 12b ), -N(R 12a )2(R 12b ) + , -N(R 12a )C(O)-R 12b , -N(R 1 2a) C(O)OR 12b , -N(R 12a )C(O)N(R 12b )(R 12c ), -N(R 12a )S(O)2(R 12b ), -NR 12a S(O)2N(R 12b )(R 12c), -NR 12a S(O)2O(R 12b ), -OC(O)R 12a , -OC(O)OR 12a ,-OC(O)-N(R 12a )(R 12b ), -SR 12a , -S(O)R 12a , -S(O)(NH)R 12a , -S(O)2R 12a ,-S(O)2N(R 12 a)(R 12b ), -S(O)(NR 12a )R 12b , or -Si(R 12a )3; wherein the alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or 5-10 membered heteroaryl can be each substituted by 1 to 4 Z 1a replace;

[0100] Each Z 1a Independently H, C 1-9 Alkyl, C 1-8 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkoxyalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen, C 3-15 Cycloalkyl, heterocyclic, C 6-10 Aryl, 5-10 membered heteroaryl, oxo, -NO2, -CN, -N3, -OR 12a , -C(O)R 12a , -C(O)OR 12a ,-C(O)N(R 12a )(R 12b ), -N(R 12a )(R 12b ), -N(R 12a )2(R 12b ) + , -N(R 12a )-C(O)R 12b , -N(R 12a )C(O)O(R 12b ), -N(R 12a )C(O)N(R 12b )(R 12c ), -N(R 12a )S(O)2(R 12b ), -N(R 12a )S(O)2-N(R12b )(R 12c ), -N(R 12a )S(O)2O(R 12b ), -OC(O)R 12a , -OC(O)OR 12a ,-OC(O)-N(R 12a )(R 12b ), -SR 12a , -S(O)R 12a , -S(O)(NH)R 12a , -S(O)2R 12a ,-S(O)2N(R 12a )(R 12b ), -S(O)(NR 12a )R 12b , or -Si(R 12a )3, wherein the alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or 5-10 membered heteroaryl groups can each be substituted by 1 to 4 Z 1b replace;

[0101] Each Z 1b Independently H, C 1-9 Alkyl, C 1-8 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen, C 3-15 Cycloalkyl, heterocyclic, C 6-10 Aryl, 5-10 membered heteroaryl, oxo, -OH, -CN, CO2R 3 e, -NO2, -NH2, -N3, -SH, -O(C 1-9 alkyl), -O(C 1-8 haloalkyl), -O(C 2-6 alkenyl), -O(C 2-6 Alkynyl), -O(C 3-15 Cycloalkyl), -O(heterocyclyl), -O(C 6-10 aryl), -O(5-10 membered heteroaryl), -NH(C 1-9 Alkyl), -NH(C 1-8 haloalkyl), -NH(C 2-6 alkenyl), -NH(C 2-6 Alkynyl), -NH(C 3-15 Cycloalkyl), -NH(heterocyclyl), -NH(C 6-10 aryl), -NH(5-10 membered heteroaryl), -N(cyclo-alkyl), -N(C 1-9 Alkyl)2,-N(C 1-8 Haloalkyl)2,-N(C 2-6Alkenyl)2,-N(C 2-6 Alkynyl)2,-N(C 3-15 Cycloalkyl)2,-N(heterocyclyl)2,-N(C 6-10 Aryl)2,-N(5-10 membered heteroaryl)2,-N(C 1-9 Alkyl)(C 1-8 haloalkyl), -N(C 1-9 Alkyl)(C 2-6 alkenyl), -N(C 1-9 Alkyl)(C 2-6 Alkynyl), -N(C 1-9 Alkyl)(C 3-15 Cycloalkyl), -N(C 1-9 alkyl)(heterocyclyl),-N(C 1-9 Alkyl)(C 6-10 Aryl), -N(C 1-9 alkyl)(5-10 membered heteroaryl), -C(O)(C 1-9 alkyl), -C(O)(C 1-8 haloalkyl), -C(O)(C 2-6 alkenyl), -C(O)(C 2-6 Alkynyl), -C(O)(C 3-15 Cycloalkyl), -C(O)(heterocyclyl), -C(O)(C 6-10 aryl), -C(O)(5-10 membered heteroaryl), -C(O)O(C 1-9 alkyl), -C(O)O(C 1-8 haloalkyl), -C(O)O(C 2-6 alkenyl), -C(O)O(C 2-6 Alkynyl), -C(O)O(C 3-15 Cycloalkyl), -C(O)O(heterocyclyl), -C(O)O(C 6-10 aryl), -C(O)O(5-10 membered heteroaryl), -C(O)NH2, -C(O)NH(C 1-9 alkyl), -C(O)NH(C 1-8 haloalkyl), -C(O)NH(C 2-6 alkenyl), -C(O)NH(C 2-6 Alkynyl), -C(O)NH(C 3-15 Cycloalkyl), -C(O)NH(heterocyclyl), -C(O)NH(C 6-10 aryl), -C(O)NH(5-10 membered heteroaryl), -C(o)N(C 1-9 Alkyl)2,-C(O)N(C 1-8 Haloalkyl)2,-C(O)N(C 2-6 alkenyl)2,-C(O)N(C2-6 Alkynyl)2,-C(O)N(C 3-15 Cycloalkyl)2,-C(O)N(heterocyclyl)2,-C(O)N(C 6-10 Aryl)2,-C(O)N(5-10 membered heteroaryl)2,-NHC(O)(C 1-9 alkyl), -NHC(O)(C 1-8 haloalkyl), -NHC(O)(C 2-6 alkenyl), -NHC(O)(C 2-6 Alkynyl), -NHC(O)(C 3-15 Cycloalkyl), -NHC(O)(heterocyclyl), -NHC(O)(C 6-10 aryl), -NHC(O)(5-10 membered heteroaryl), -NHC(O)O(C 1-9 alkyl), -NHC(O)O(C 1-8 haloalkyl), -NHC(O)O(C 2-6 alkenyl), -NHC(O)O(C 2-6 Alkynyl), -NHC(O)O(C 3-15 Cycloalkyl), -NHC(O)O(heterocyclyl), -NHC(O)O(C 6-10 aryl), -NHC(O)O(5-10 membered heteroaryl), -NHC(O)NH(C 1-9 alkyl), -NHC(O)NH(C 1-8 haloalkyl), -NHC(O)NH(C 2-6 alkenyl), -NHC(O)NH(C 2-6 Alkynyl), -NHC(O)NH(C 3-15 Cycloalkyl), -NHC(O)NH(heterocyclyl), -NHC(O)NH(C 6-10 aryl), -NHC(O)NH(5-10 membered heteroaryl), -NHS(O)(C 1-9 Alkyl), -N(C 1-9 Alkyl)(S(O)(C 1-9 Alkyl), -S(C 1-9 Alkyl), -S(C 1-8 haloalkyl), -S(C 2-6 alkenyl), -S(C 2-6 Alkynyl), -S(C 3-15 Cycloalkyl), -S(heterocyclyl), -S(C 6-10 aryl), -S(5-10 membered heteroaryl), -S(O)N(C 1-9 Alkyl)2,-S(O)(C 1-9 alkyl), -S(O)(C 1-8 haloalkyl), -S(O)(C2-6 alkenyl), -S(O)(C 2-6 Alkynyl), -S(O)(C 3-15 Cycloalkyl), -S(O)(heterocyclyl), -S(O)(C 6-10 aryl), -S(O)(5-10 membered heteroaryl), -S(O)2(C 1-9 Alkyl), -S(O)2(C 1-8 haloalkyl), -S(O)2(C 2-6 alkenyl), -S(O)2(C 2-6 Alkynyl), -S(O)2(C 3-15 Cycloalkyl), -S(O)2(heterocyclyl), -S(O)2(C 6-10 Aryl), -S(O)2(5-10 membered heteroaryl), -S(O)(NH)(C 1-9 alkyl), -S(O)2NH(C 1-9 alkyl), or -S(O)2N(C 1-9 wherein the alkyl, cycloalkyl, heterocyclyl, aryl or 5-10 membered heteroaryl may be substituted in each case by 1 to 3 of the following: 1-9 Alkyl, C 1-8 Haloalkyl, halogen, -OH, -NH2, CO2H, -O(C 1-9 alkyl), -O(C 1-8 haloalkyl), -O(C 3-15 cycloalkyl), -O(heterocyclyl), -O(aryl), -O(5-10 membered heteroaryl), -NH(C 1-9 Alkyl), -NH(C 1-8 haloalkyl), -NH(C 3-15 cycloalkyl), -NH(heterocyclyl), -NH(aryl), -NH(5-10 membered heteroaryl), -N(C 1-9 Alkyl)2,-N(C 3-15 Cycloalkyl)2,-NHC(O)(C 1-8 haloalkyl), -NHC(O)(C 3-15 cycloalkyl), -NHC(O)(heterocyclyl), -NHC(O)(aryl), -NHC(O)(5-10 membered heteroaryl), -NHC(O)O(C 1-9 alkyl), -NHC(O)O(C 1-8 haloalkyl), -NHC(O)O(C 2-6 Alkynyl), -NHC(O)O(C 3-15 Cycloalkyl), -NHC(O)O(heterocyclyl), -NHC(O)O(aryl), -NHC(O)O(5-10 membered heteroaryl), -NHC(O)NH(C 1-9Alkyl), S(O)2(C 1-9 Alkyl), -S(O)2(C 1-8 haloalkyl), -S(O)2(C 3-15 Cycloalkyl), -S(O)2(heterocyclyl), -S(O)2(aryl), -S(O)2(5-10 membered heteroaryl), -S(O)(NH)(C 1-9 alkyl), -S(O)2NH(C 1-9 alkyl), or -S(O)2N(C 1-9 Alkyl)2;

[0102] Each R 1b , R 1c , R 2a , R 2b , R 4a , R 4b , R 4c , R 9c , R 9d , R 12a , R 12b , and R 12c are independently H, -OH, C 1-9 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-15 Cycloalkyl, heterocyclic, C 6-10 aryl, or 5-10 membered heteroaryl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or 5-10 membered heteroaryl can be substituted by 1 to 4 Z 1b Replacement; and

[0103] Each R 3e Independently H, C 1-6 Alkyl, C 1-6 Haloalkyl, -C 14 Alkyl-N(R 9a )(R 9b ), -C 14 Alkyl-C(O)N(R 9a )(R 9b ), -C 1-4 Alkyl-OC(O)-O-C1-4alkyl, -C 14 Alkyl-OC(O)-C 1-4 Alkyl-N(R 9a )(R 9b ), -C 1-4 Alkyl-C 3-8 Cycloalkyl, -C 1-4 Alkyl-heterocyclyl, C 3-10 Cycloalkyl, heterocyclic, C 6-10 Aryl, 5-10 membered heteroaryl, -P(O)(OR9c )2,-CH2P(O)(OR 9c )2,-OCH2P(O)(OR 9c )2,-C(O)OCH2P(O)(OR 9c )2,-P(O)(R 9c )(OR 9d ), -OP(O)(R 9c )(OR 9d ), -CH2P(O)(R 9c )(OR 9d ), -C(O)OCH2P(O)(R 9c )(OR 9d ), -P(O)(N(R 9c )2)2,-CH2P(O)(N(R 9c )2)2,-C(O)OCH2P(O)(N(R 9c )2)2,-P(O)(N(R 9c )2)(OR 9d ), -CH2P(O)(N(R 9c )2)(OR 9d ), -C(O)OCH2P(O)(N(R 9c )2)(OR 9d ), -P(O)(R 9c )(N(R 9d )2), -CH2P(O)(R 9c )(N(R 9d )2), or-C(O)OCH2P(O)(R 9c )(N(R 9d )2); wherein the alkyl, alkenyl, cycloalkyl, heterocyclyl, aryl or 5-10 membered heteroaryl are each optionally substituted by 1 to 4 Z 1b substituted; wherein each 5-10 membered heteroaryl has a 5- to 12-membered structure and has 1 to 4 heteroatoms that are each independently N, O or S; and wherein each heterocyclyl has a 3- to 12-membered structure and has 1 to 4 heteroatoms that are each independently N, O or S.

[0104] In some embodiments, each Z in Formula IA-1 1 or a pharmaceutically acceptable salt thereof is independently C 1-9 Alkyl, C 1-8 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkoxyalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen, C3-15 Cycloalkyl, heterocyclic, C 6-10 Aryl, 5-10 membered heteroaryl, oxo, -NO2, -N3, -CN, -OR 12a 、-C(O)-R 12a 、-C(O)OR 12a 、-C(O)-N(R 12a )(R 12b ) or -N(R 12a )(R 12b ).

[0105] In some embodiments, each Z in Formula IA-1 1a or its pharmaceutically acceptable salts are independently H, -OH, C 1-9 Alkyl, C 1-8 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkoxyalkyl or halogen.

[0106] In some embodiments, each Z in Formula IA-1 1b or a pharmaceutically acceptable salt thereof is independently H, C 1-9 Alkyl, C 1-8 Haloalkyl, halogen, oxo, -OH or -CN.

[0107] In some embodiments, each R in Formula IA-1 8 or a pharmaceutically acceptable salt thereof is independently H, oxo, OH, C 1-9 Alkyl, C 1-8 Haloalkyl, halogen, -O(C 1-3 alkyl) or -O(C 1-3 haloalkyl).

[0108] In some embodiments, the compound has the structure of Formula IA-2 or Formula IA-3, or a pharmaceutically acceptable salt thereof:

[0109]

[0110] Among them, ring C is C 3-10 Cycloalkyl, heterocyclic, C 6-10 aryl or 5-10 membered heteroaryl, each of which may be substituted by 1-4 Z 1 replace;

[0111] Y1-V is N-CH2, N-CH(CH3), N-CF2, CH-CH2, CH-CF2, CH-NH, NS(O), NS(O)2, NC(O), CH-C(O) or cyclopropyl;

[0112] Y2 is C, CH or N;

[0113] R 2 Yes H, C 1-6 Alkyl, -C 1-6 Alkyl-alkyl, -C 1-6 Alkyl-cycloalkoxy, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Cycloalkyl, heterocyclic, C 6-10 Aryl, 5-10 membered heteroaryl, -CN, -OR 2a , -SR 2a , -S(O)R 2a , -S(O)(NH)R 2a , -S(O)2R 2a ,-S(O)2N(R 2a )(R 2b ), or -S(O)(NR 2a )R 2b , wherein the alkyl, alkoxy, cycloalkyloxy, haloalkyl, cycloalkyl, heterocyclyl, aryl or 5-10 membered heteroaryl groups can each be substituted by 1 to 4 Z 1 Replace, and any two Z 1 can combine with the atoms to which they are attached to form C 3-10 Cycloalkyl or heterocyclic or C 6-10 Aryl or 5-10 membered heteroaryl.

[0114] X is independently -N=, -C(H)=, or -C(R 8 )=;

[0115] Each R 3 and R 3’ Independently H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen, C 3-10 Cycloalkyl, heterocyclic, C 6-10 Aryl, 5-10 membered heteroaryl, -CN, -NO2, -OR 3a , -C(O)R 3a ,-CH2C(O)OR 3a , -C(O)OR 3a ,-C(O)N(R 3a )(R 3b ), -N(R 3a )C(O)R 3b , -N(R 3a )C(O)OR3b , -N(R 3a )C(O)N(R 3b )2,-C(O)NHS(O)2R 3a , -C(O)NR 3a S(O)2R 3b , -C(O)NR 3a S(O)2NR 3b R 3c , -C(O)NR 3a -S(O)(=NR 3b )R 3c , -S(O)2R 3a , -S(O)2OR 3a ,-S(O)2N(R 3a )(R 3b ), -N(R 3a )S(O)2R 3b ,-S(O)2NHC(O)R 3a , -S(O)(=NR 3a )R 3b , -S(O)(=NR 3a )NR 3b ,-S(=NR 3a )(=NR 3b )R 3c , -P(O)(OR 3a )(R 3b ), -P(O)(OR 3a )(OR 3b ), -B(OR 3a )(OR 3b ), or -OC 1-6 Alkyl-C(O)OR 3a , wherein the alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or 5-10 membered heteroaryl can be each substituted by 1 to 4 R 3d replace;

[0116] Each R 3a , R 3b and R 3c Independently H, C 1-6 Alkyl, C 6-10 Aryl, 5-10 membered heteroaryl, C 1-6 Haloalkyl, C 2-8 Alkoxyalkyl, -C 1-4 Alkyl-N(R 9a )(R 9b ), -C 1-4 Alkyl-N(R 9a )C(O)-OC 1-4Alkyl-OP(O)(OR 9c )2, -C 1-4 Alkyl-C(O)N(R 9a )(R 9b ), -C 1-4 Alkyl-OC(O)-OC 14 Alkyl, -C 14 Alkyl-OC(O)-C 1-4 Alkyl-N(R 9a )(R 9b ), -C 1-4 Alkyl-OC(O)-C 1-4 Alkyl-OP(O)(OR 9c )2, -C 1-4 Alkyl-C 3-8 Cycloalkyl, -C 1-4 Alkyl-heterocyclyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Cycloalkyl, heterocyclyl, -CH2CH(N(R 9a )2)C(O)OR 9b , C 1-6 Alkyl-heterocyclyl, C 1-6 Alkyl-aryl or C 1-6 Alkyl-(5-10 membered) heteroaryl, wherein the alkyl, alkenyl, cycloalkyl, heterocyclyl, aryl or 5-10 membered heteroaryl can be substituted by 1 to 4 Z 1b replace;

[0117] Each R5a and R 5b Independently H, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 2-6 Alkoxyalkyl, halogen, C 3-10 Cycloalkyl, heterocyclyl, -C 1-6 Alkyl-N(R 9a )(R 9b ), -CN, -OR 5a1 , or -N(R 5a1 )(R 5a2 ); or, R 5a and R 5b Combine with the atoms to which they are attached to form C 3-10 Cycloalkyl or heterocyclic group, each of which may be replaced by 1 to 4 R 5a3 Replacement

[0118] Each R 5a1 and R 5a2 Independently H, C 1-6 Alkyl, C 2-6Alkenyl, C 2-6 Alkynyl, C 3-10 Cycloalkyl, heterocyclic, C 6-10 Aryl or 5-10 membered heteroaryl, wherein the cycloalkyl, heterocyclyl, aryl or 5-10 membered heteroaryl may be substituted by 1 to 4 halogens;

[0119] Each R 3d and R 5a3 Independently H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkoxyalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen, C 3-10 Cycloalkyl, heterocyclic, C 6-10 Aryl, 5-10 membered heteroaryl, oxo, -OH, -CN, -CO2R 3e , -NO2, or -C(O)N(R 2a )(R 2b ), wherein the heterocyclic group or the 5-10 membered heteroaryl group may be C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 Haloalkoxy substitution;

[0120] Each R 8 Independently for C 1-9 Alkyl, C 1-8 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen, oxo, -OH, -CN, CO2R 3e ,-NO2,-NH2,-N3,-SH,-O(C 1-9 alkyl), -O(C 1-8 haloalkyl), -NH(C 1-9 Alkyl), -NH(C 1-8 haloalkyl), -N(C 1-9 Alkyl)2,-N(C 1-8 Haloalkyl)2;

[0121] Each R 9a and R 9b Independently H, C 1-9 Alkyl, C 1-8 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkoxyalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen, C3-15 Cycloalkyl, heterocyclic, C 6-10 Aryl, 5-10 membered heteroaryl, oxo, -NO2, -CN, -N3, -OR 12a , -C(O)R 12a , -C(O)OR 12a ,-C(O)N(R 12a )(R 12b ), -N(R 12a )(R 12b ), -N(R 12a )2(R 12b ) + , -N(R 12a )-C(O)R 12b , -N(R 12a )C(O)O(R 12b ), -N(R 12a )C(O)N(R 12b )(R 12c ), -N(R 12a )S(O)2(R 12b ), -N(R 12a )S(O)2-N(R 12b )(R 12c ), -N(R 12a )S(O)2O(R 12b ), -OC(O)R 12a , -OC(O)OR 12a ,-OC(O)-N(R 12a )(R 12b ), -SR 12a , -S(O)R 12a , -S(O)(NH)R 12a , -S(O)2R 12a ,-S(O)2N(R 12a )(R 12b ), -S(O)(NR 12a )R 12b , or -Si(R 12a )3; or R 9a and R 9b Fusion forms a 3-10 membered heterocyclic group which may be substituted by: C 1-9 Alkyl, C 1-8 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkoxyalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen, C 3-15 Cycloalkyl, heterocyclic, C6-10 Aryl, 5-10 membered heteroaryl, oxo, -NO2, -CN, -N3, -OR 12a , -C(O)R 12a , -C(O)OR 12a ,-C(O)N(R 12a) (R 12b ), -N(R 12a )(R 12b ), -N(R 12a )2(R 12b ) + , -N(R 12a )-C(O)R 12b , -N(R 12a )C(O)O(R 12b ), -N(R 12a )C(O)N(R 12b )(R 12c ), -N(R 12a )S(O)2(R 12b ), -N(R 12a )S(O)2-N(R 12b )(R 12c ), -N(R 12a )S(O)2O(R 12b ), -OC(O)R 12a , -OC(O)OR 12a ,-OC(O)-N(R 12a )(R 12b ), -SR 12a , -S(O)R 12a , -S(O)(NH)R 12a12a , -S(O)2R 12a ,-S(O)2N(R 12a )(R 12b ), -S(O)(NR 12a )R 12b , or -Si(R 12a )3 replaced;

[0122] Each Z 1 Independently C 1-9 Alkyl, C 1-8 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkoxyalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen, C 3-15 Cycloalkyl, heterocyclic, C 6-10Aryl, 5-10 membered heteroaryl, oxo, -NO2, -N3, -CN, or -OR 12a , wherein the alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or 5-10 membered heteroaryl can be each substituted by 1 to 4 Z 1a replace;

[0123] Each Z 1a Independently H, C 1-9 Alkyl, C 1-8 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkoxyalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen, C 3-15 Cycloalkyl, heterocyclic, C 6-10 Aryl, 5-10 membered heteroaryl, oxo, -NO2, -CN, -N3, -OR 12a , -C(O)R 12a , -C(O)OR 12a ,-C(O)N(R 12a )(R 12b ), -N(R 12a )(R 12b ), -N(R 12a )2(R 12b ) + , -N(R 12a )-C(O)R 12b , -N(R 12a )C(O)O(R 12b ), -N(R 12a )C(O)N(R 12b )(R 12c ), -N(R 12a )S(O)2(R 12b ), -N(R 12a )S(O)2-N(R 12b )(R 12c ), -N(R 12a )S(O)2O(R 12b ), -OC(O)R1 2a , -OC(O)OR 12a ,-OC(O)-N(R 12a )(R 12b ), -SR 12a , -S(O)R 12a , -S(O)(NH)R 12a , -S(O)2R 12a ,-S(O)2N(R 12a )(R12b ), -S(O)(NR 12a )R 12b , or -Si(R 12a )3; wherein the alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl or 5-10 membered heteroaryl can be each substituted by 1 to 4 Z 1b replace;

[0124] Each Z 1b Independently H, C 1-9 Alkyl, C 1-8 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen, C 3-15 Cycloalkyl, heterocyclic, C 6-10 Aryl, 5-10 membered heteroaryl, oxo, -OH, -CN, CO2R 3 e, -NO2, -NH2, -N3, -SH, -O(C 1-9 alkyl), -O(C 1-8 haloalkyl), -O(C 2-6 alkenyl), -O(C 2-6 Alkynyl), -O(C 3-15 Cycloalkyl), -O(heterocyclyl), -O(C 6-10 aryl), -O(5-10 membered heteroaryl), -NH(C 1-9 Alkyl), -NH(C 1-8 haloalkyl), -NH(C 2-6 alkenyl), -NH(C 2-6 Alkynyl), -NH(C 3-15 Cycloalkyl), -NH(heterocyclyl), -NH(C 6-10 aryl), -NH(5-10 membered heteroaryl), -N(cyclo-alkyl), -N(C 1-9 Alkyl)2,-N(C 1-8 Haloalkyl)2,-N(C 2-6 Alkenyl)2,-N(C 2-6 Alkynyl)2,-N(C 3-15 Cycloalkyl)2,-N(heterocyclyl)2,-N(C 6-10 Aryl)2,-N(5-10 membered heteroaryl)2,-N(C 1-9 Alkyl)(C 1-8 haloalkyl), -N(C 1-9 Alkyl)(C 2-6 alkenyl), -N(C 1-9 Alkyl)(C 2-6 Alkynyl), -N(C 1-9 Alkyl)(C 3-15 Cycloalkyl), -N(C 1-9alkyl)(heterocyclyl),-N(C 1-9 Alkyl)(C 6-10 Aryl), -N(C 1-9 alkyl)(5-10 membered heteroaryl), -C(O)(C 1-9 alkyl), -C(O)(C 1-8 haloalkyl), -C(O)(C 2-6 alkenyl), -C(O)(C 2-6 Alkynyl), -C(O)(C 3-15 Cycloalkyl), -C(O)(heterocyclyl), -C(O)(C 6-10 aryl), -C(O)(5-10 membered heteroaryl), -C(O)O(C 1-9 alkyl), -C(O)O(C 1-8 haloalkyl), -C(O)O(C 2-6 alkenyl), -C(O)O(C 2-6 Alkynyl), -C(O)O(C 3-15 Cycloalkyl), -C(O)O(heterocyclyl), -C(O)O(C 6-10 aryl), -C(O)O(5-10 membered heteroaryl), -C(O)NH2, -C(O)NH(C 1-9 alkyl), -C(O)NH(C 1-8 haloalkyl), -C(O)NH(C 2-6 alkenyl), -C(O)NH(C 2-6 Alkynyl), -C(O)NH(C 3-15 Cycloalkyl), -C(O)NH(heterocyclyl), -C(O)NH(C 6-10 aryl), -C(O)NH(5-10 membered heteroaryl), -C(O)N(C 1-9 Alkyl)2,-C(O)N(C 1-8 Haloalkyl)2,-C(O)N(C 2-6 alkenyl)2,-C(O)N(C 2-6 Alkynyl)2,-C(O)N(C 3-15 Cycloalkyl)2,-C(O)N(heterocyclyl)2,-C(O)N(C 6-10 Aryl)2,-C(O)N(5-10 membered heteroaryl)2,-NHC(O)(C 1-9 alkyl), -NHC(O)(C 1-8 haloalkyl), -NHC(O)(C 2-6 alkenyl), -NHC(O)(C 2-6 Alkynyl), -NHC(O)(C 3-15 Cycloalkyl), -NHC(O)(heterocyclyl), -NHC(O)(C 6-10aryl), -NHC(O)(5-10 membered heteroaryl), -NHC(O)O(C 1-9 alkyl), -NHC(O)O(C 1-8 haloalkyl), -NHC(O)O(C 2-6 alkenyl), -NHC(O)O(C 2-6 Alkynyl), -NHC(O)O(C 3-15 Cycloalkyl), -NHC(O)O(heterocyclyl), -NHC(O)O(C 6-10 aryl), -NHC(O)O(5-10 membered heteroaryl), -NHC(O)NH(C 1-9 alkyl), -NHC(O)NH(C 1-8 haloalkyl), -NHC(O)NH(C 2-6 alkenyl), -NHC(O)NH(C 2-6 Alkynyl), -NHC(O)NH(C 3-15 Cycloalkyl), -NHC(O)NH(heterocyclyl), -NHC(O)NH(C 6-10 aryl), or -NHC(O)NH(5-10 membered heteroaryl), wherein the alkyl, cycloalkyl, heterocyclyl, aryl or 5-10 membered heteroaryl may be substituted by 1 to 3 of the following: 1-9 Alkyl, C 1-8 Haloalkyl, halogen, -OH, -NH2, CO2H, -O(C 1-9 alkyl), -O(C 1-8 haloalkyl), -O(C 3-15 cycloalkyl), -O(heterocyclyl), -O(aryl), -O(5-10 membered heteroaryl), -NH(C 1-9 Alkyl), -NH(C 1-8 haloalkyl), -NH(C 3-15 cycloalkyl), -NH(heterocyclyl), -NH(aryl), -NH(5-10 membered heteroaryl), -N(C 1-9 Alkyl)2,-N(C 3-15 Cycloalkyl)2,-NHC(O)(C 1-8 haloalkyl), -NHC(O)(C 3-15 cycloalkyl), -NHC(O)(heterocyclyl), -NHC(O)(aryl), -NHC(O)(5-10 membered heteroaryl), -NHC(O)O(C 1-9 alkyl), -NHC(O)O(C 1-8 haloalkyl), -NHC(O)O(C 2-6 Alkynyl), -NHC(O)O(C 3-15cycloalkyl), -NHC(O)O(heterocyclyl), -NHC(O)O(aryl), -NHC(O)O(5-10 membered heteroaryl), or -NHC(O)NH(C 1-9 alkyl);

[0125] Each R 1b , R 1c , R 2a , R 2b , R 4c , R 9c , R 12a , R 12b and R 12c are independently H, -OH, C1-9 alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-15 Cycloalkyl, heterocyclic, C 6-10 aryl, or 5-10 membered heteroaryl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or 5-10 membered heteroaryl can be substituted by 1 to 4 Z 1b Replacement; and

[0126] Each R 3e Independently H, C 1-6 Alkyl, C 1-6 Haloalkyl, -C 1-4 Alkyl-N(R 9a )(R 9b ), -C 1-4 Alkyl-C(O)N(R 9a )(R 9b ), -C 1-4 Alkyl-OC(O)-OC 1-4 Alkyl, -C 1-4 Alkyl-OC(O)-C 1-4 Alkyl-N(R 9a )(R 9b ), -C 1-4 Alkyl-C 3-8 Cycloalkyl, -C1-4 alkyl-heterocyclyl, C 3-10 Cycloalkyl, heterocyclic, C 6-10 Aryl, or 5-10 membered heteroaryl; wherein the alkyl, alkenyl, cycloalkyl, heterocyclyl, aryl or 5-10 membered heteroaryl can be substituted by 1 to 4 Z 1b substituted; wherein each 5-10 membered heteroaryl has a 5- to 12-membered ring structure and has 1 to 4 heteroatoms which are each independently N, O or S; and wherein each heterocyclyl has a 3- to 12-membered ring structure and has 1 to 4 heteroatoms which are each independently N, O or S.

[0127] In some embodiments, the compound is a compound having the structure of Formula IA-4 or Formula IA-5, or a pharmaceutically acceptable salt thereof:

[0128]

[0129]

[0130] Wherein ring C is C 3-10 Cycloalkyl, heterocyclic, C 6-10 Aryl and 5-10 membered heteroaryl, each of which may be substituted by 1-4 Z 1 replace;

[0131] Y1-V is N-CH2, N-CH(CH3), N-CF2, or CH-CH2, CH-CF2, CH-NH, NS(O), NS(O)2, NC(O), CH-C(O) or cyclopropyl;

[0132] Y2 is C, CH or N;

[0133] R 2 Yes H, C 1-6 Alkyl, C 1-6 Alkyl-alkoxy, C 1-6 Alkyl-cycloalkoxy, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Cycloalkyl, heterocyclic, C 6-10 Aryl, 5.10-membered heteroaryl, -CN, -OR 2a , -SR 2a , -S(O)R 2a , -S(O)(NH)R 2a , -S(O)2R 2a ,-S(O)2N(R 2a )(R 2b ), or -S(O)(NR 2a )R 2b , wherein the alkyl, alkoxy, cycloalkyloxy, haloalkyl, cycloalkyl, heterocyclyl, aryl or 5-10 membered heteroaryl groups can each be substituted by 1 to 4 Z 1 Replace, and any two Z 1 can combine with the atoms to which they are attached to form C 3-10 Cycloalkyl or heterocyclic or C 6-10 Aryl or 5-10 membered heteroaryl.

[0134] X is independently -N=, -C(H)=, or -C(R 8 )=;

[0135] Each R 3 and R 3’ Independently H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen, C 3-10 Cycloalkyl, heterocyclic, C 6-10 Aryl, 5-10 membered heteroaryl, -CN, -NO2, -OR 3a , -C(O)R 3a ,-CH2C(O)OR 3a , -C(O)OR 3a ,-C(O)N(R 3a )(R 3b ), -N(R 3a )C(O)R 3b , -N(R 3a )C(O)OR 3b , -N(R 3a )C(O)N(R 3b )2,-C(O)NHS(O)2R 3a , -C(O)NR 3a S(O)2R 3b , -C(O)NR 3a S(O)2NR 3b R 3c , -C(O)NR 3a -S(O)(=NR 3b )R 3c , -S(O)2R 3a , -S(O)2OR 3a ,-S(O)2N(R 3a )(R 3b ), -N(R 3a )S(O)2R 3b ,-S(O)2NHC(O)R 3a , -S(O)(=NR 3a )R 3b , -S(O)(=NR 3a )NR 3b ,-S(=NR 3a )(=NR 3b )R 3c , -P(O)(OR 3a )(R 3b ), -P(O)(OR 3a )(OR 3b ), -B(OR 3a )(OR 3b ), or -OC1-6 Alkyl-C(O)OR 3a , wherein the alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or 5-10 membered heteroaryl can be each substituted by 1 to 4 R 3d replace;

[0136] Each R 3a , R 3b and R 3c Independently H, C 1-6 Alkyl, C 6-10 Aryl, 5-10 membered heteroaryl, C 1-6 Haloalkyl, C 2-8 Alkoxyalkyl, -C 1-4 Alkyl-N(R 9a )(R 9b ), -C 1-4 Alkyl-N(R 9a )C(O)-OC 1-4 Alkyl-OP(O)(OR 9c )2, -C 1-4 Alkyl-C(O)N(R 9a )(R 9b ), -C 1-4 Alkyl-OC(O)-OC 1-4 Alkyl, -C 1-4 Alkyl-OC(O)-C 1-4 Alkyl-N(R 9a )(R 9b ), -C1-4 alkyl-OC(O)-C1-4 alkyl-OP(O)(OR 9c )2, -C 1-4 Alkyl-C 3-8 Cycloalkyl, -C 1-4 Alkyl-heterocyclyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Cycloalkyl, heterocyclyl, -CH2CH(N(R 9a )2)C(O)OR 9b , C 1-6 Alkyl-heterocyclyl, C 1-6 Alkyl-aryl or C 1-6 Alkyl-(5-10 membered) heteroaryl, wherein the alkyl, alkenyl, cycloalkyl, heterocyclyl, aryl or 5-10 membered heteroaryl is each substituted by 1 to 4 Z 1b Selective substitution;

[0137] R 5a Independently H, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C2-6 Alkoxyalkyl, halogen, C 3-10 Cycloalkyl, heterocyclyl, -C 1-6 Alkyl-N(R 9a )(R 9b ), -CN, -OR 5a1 , or -N(R 5a1 )(R 5a2 );

[0138] Each R 5a1 and R 5a2 Independently H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Cycloalkyl, heterocyclic, C 6-10 Aryl or 5-10 membered heteroaryl, wherein the cycloalkyl, heterocyclyl, aryl or 5-10 membered heteroaryl may be substituted by 1 to 4 halogens;

[0139] R 3d Independently H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkoxyalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen, C 3-10 Cycloalkyl, heterocyclic, C 6-10 Aryl, 5-10 membered heteroaryl, oxo, -OH, -CN, -CO2R 3e , -NO2, or -C(O)N(R 2a )(R 2b ), wherein the heterocyclic group or the 5-10 membered heteroaryl group may be C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 Haloalkoxy substitution;

[0140] Each R 8 Independently C 1-9 Alkyl, C 1-8 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen, oxo, -OH, -CN, CO2R 3e ,-NO2,-NH2,-N3,-SH,-O(C 1-9 alkyl), -O(C 1-8 haloalkyl), -NH(C 1-9 Alkyl), -NH(C 1-8 haloalkyl), -N(C 1-9Alkyl)2,-N(C 1-8 Haloalkyl)2;

[0141] Each R 9a and R 9b Independently H, C 1-9 Alkyl, C 1-8 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkoxyalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen, C 3-15 Cycloalkyl, heterocyclic, C 6-10 Aryl, 5-10 membered heteroaryl, oxo, -NO2, -CN, -N3, -OR 12a , -C(O)R 12a , -C(O)OR 12a ,-C(O)N(R 12a )(R 12b ), -N(R 12a )(R 12b ), -N(R 12a )2(R 12b ) + , -N(R 12a )-C(O)R 12b , -N(R 12a )C(O)O(R 12b ), -N(R1 2a )C(O)N(R 12b )(R 12c ), -N(R 12a )S(O)2(R 12b ), -N(R 12a )S(O)2-N(R 12b )(R 12c ), -N(R 12a )S(O)2O(R 12b ), -OC(O)R 12a , -OC(O)OR 12a ,-OC(O)-N(R 12a )(R 12b ), -SR 12a , -S(O)R 12a , -S(O)(NH)R 12a , -S(O)2R 12a ,-S(O)2N(R 12a )(R 12b ), -S(O)(NR 12a )R 12b , or -Si(R12a )3; or R 9a and R 9b Fusion forms a 3-10 membered heterocyclic group which may be substituted by: C 1-9 Alkyl, C 1-8 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkoxyalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen, C 3-15 Cycloalkyl, heterocyclic, C 6-10 Aryl, 5-10 membered heteroaryl, oxo, -NO2, -CN, -N3, -OR 12a , -C(O)R 12a , -C(O)OR 12a ,-C(O)N(R 12a )(R 12b ), -N(R 12a )(R 12b ), -N(R 12a )2(R 12b ) + , -N(R 12a )-C(O)R 12b , -N(R 12a )C(O)O(R 12b ), -N(R 12a )C(O)N(R 12b )(R 12c ), -N(R 12a )S(O)2(R 12b ), -N(R 12a )S(O)2-N(R 12b )(R 12c ), -N(R 12a )S(O)2O(R 12b ), -OC(O)R 12a , -OC(O)OR 12a ,-OC(O)-N(R 12a )(R 12b ), -SR 12a , -S(O)R 12a , -S(O)(NH)R 12a , -S(O)2R 12a ,-S(O)2N(R 12a )(R 12b ), -S(O)(NR 12a )R 12b , or -Si(R 12a )3;

[0142] Each Z 1 Independently C 1-9 Alkyl, C 1-8 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkoxyalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen, C 3-15 Cycloalkyl, heterocyclic, C 6-10 Aryl, 5-10 membered heteroaryl, oxo, -NO2, -N3, -CN, or -OR 12a , wherein the alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or 5-10 membered heteroaryl can be each substituted by 1 to 4 Z 1a replace;

[0143] Each Z 1a Independently H, C 1-9 Alkyl, C 1-8 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkoxyalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen, C 3-15 Cycloalkyl, heterocyclic, C 6-10 Aryl, 5-10 membered heteroaryl, oxo, -NO2, -CN, -N3, -OR 12a , -C(O)R 12a , -C(O)OR 12a ,-C(O)N(R 12a )(R 12b ), -N(R 12a )(R 12b ), -N(R 12a )2(R 12b ) + , -N(R 12a )-C(O)R 12b , -N(R 12a )C(O)O(R 12b ), -N(R 12a )C(O)N(R 12b )(R 12c ), -N(R 12a )S(O)2(R 12b ), -N(R 12a )S(O)2-N(R 12b )(R 12c ), -N(R 12a )S(O)2o(R12b ), -OC(O)R 12a , -OC(O)OR 12a ,-OC(O)-N(R 12a )(R 12b ), -SR 12a , -S(O)R 12a , -S(O)(NH)R 12a , -S(O)2R 12a ,-S(O)2N(R 12a )(R 12b ), -S(O)(NR 12a )R 12b , or -Si(R 12a )3, wherein the alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or 5-10 membered heteroaryl can be each substituted by 1 to 4 Z 1b replace;

[0144] Each Z 1b Independently H, C 1-9 Alkyl, C 1-8 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen, C 3-15 Cycloalkyl, heterocyclic, C 6-10 Aryl, 5-10 membered heteroaryl, oxo, -OH, -CN, CO2R 3 e, -NO2, -NH2, -N3, -SH, -O(C 1-9 alkyl), -O(C 1-8 haloalkyl), -O(C 2-6 alkenyl), -O(C 2-6 Alkynyl), -O(C 3-15 Cycloalkyl), -O(heterocyclyl), -O(C 6-10 aryl), -O(5-10 membered heteroaryl), -NH(C 1-9 Alkyl), -NH(C 1-8 haloalkyl), -NH(C 2-6 alkenyl), -NH(C 2-6 Alkynyl), -NH(C 3-15 Cycloalkyl), -NH(heterocyclyl), -NH(C 6-10 aryl), -NH(5-10 membered heteroaryl), -N(cyclo-alkyl), -N(C 1-9 Alkyl)2,-N(C 1-8 Haloalkyl)2,-N(C 2-6 Alkenyl)2,-N(C 2-6 Alkynyl)2,-N(C 3-15 Cycloalkyl)2,-N(heterocyclyl)2,-N(C6-10 Aryl)2,-N(5-10 membered heteroaryl)2,-N(C 1-9 Alkyl)(C 1-8 haloalkyl), -N(C 1-9 Alkyl)(C 2-6 alkenyl), -N(C 1-9 Alkyl)(C 2-6 Alkynyl), -N(C 1-9 Alkyl)(C 3-15 Cycloalkyl), -N(C 1-9 alkyl)(heterocyclyl),-N(C 1-9 Alkyl)(C 6-10 Aryl), -N(C 1-9 alkyl)(5-10 membered heteroaryl), -C(O)(C 1-9 alkyl), -C(O)(C 1-8 haloalkyl), -C(O)(C 2-6 alkenyl), -C(O)(C 2-6 Alkynyl), -C(O)(C 3-15 Cycloalkyl), -C(O)(heterocyclyl), -C(O)(C 6-10 aryl), -C(O)(5-10 membered heteroaryl), -C(O)O(C 1-9 alkyl), -C(O)O(C 1-8 haloalkyl), -C(O)O(C 2-6 alkenyl), -C(O)O(C 2-6 Alkynyl), -C(O)O(C 3-15 Cycloalkyl), -C(O)O(heterocyclyl), -C(O)O(C 6-10 aryl), -C(O)O(5-10 membered heteroaryl), -C(O)NH2, -C(O)NH(C 1-9 alkyl), -C(O)NH(C 1-8 haloalkyl), -C(O)NH(C 2-6 alkenyl), -C(O)NH(C 2-6 Alkynyl), -C(O)NH(C 3-15 Cycloalkyl), -C(O)NH(heterocyclyl), -C(O)NH(C 6-10 aryl), -C(O)NH(5-10 membered heteroaryl), -C(O)N(C 1-9 Alkyl)2,-C(O)N(C 1-8 Haloalkyl)2,-C(O)N(C 2-6 alkenyl)2,-C(O)N(C 2-6 Alkynyl)2,-C(O)N(C 3-15 Cycloalkyl)2,-C(O)N(heterocyclyl)2,-C(O)N(C6-10 Aryl)2,-C(O)N(5-10 membered heteroaryl)2,-NHC(O)(C 1-9 alkyl), -NHC(O)(C 1-8 haloalkyl), -NHC(O)(C 2-6 alkenyl), -NHC(O)(C 2-6 Alkynyl), -NHC(O)(C 3-15 Cycloalkyl), -NHC(O)(heterocyclyl), -NHC(O)(C 6-10 aryl), -NHC(O)(5-10 membered heteroaryl), -NHC(O)O(C 1-9 alkyl), -NHC(O)O(C 1-8 haloalkyl), -NHC(O)O(C 2-6 alkenyl), -NHC(O)O(C 2-6 Alkynyl), -NHC(O)O(C 3-15 Cycloalkyl), -NHC(O)O(heterocyclyl), -NHC(O)O(C 6-10 aryl), -NHC(O)O(5-10 membered heteroaryl), -NHC(O)NH(C 1-9 alkyl), -NHC(O)NH(C 1-8 haloalkyl), -NHC(O)NH(C 2-6 alkenyl), -NHC(O)NH(C 2-6 Alkynyl), -NHC(O)NH(C 3-15 Cycloalkyl), -NHC(O)NH(heterocyclyl), -NHC(O)NH(C 6-10 aryl), or -NHC(O)NH(5-10 membered heteroaryl), wherein the alkyl, cycloalkyl, heterocyclyl, aryl or 5-10 membered heteroaryl may be substituted by 1 to 3 of the following: 1-9 Alkyl, C 1-8 Haloalkyl, halogen, -OH, -NH2, CO2H, -O(C 1-9 alkyl), -O(C 1-8 haloalkyl), -O(C 3-15 cycloalkyl), -O(heterocyclyl), -O(aryl), -O(5-10 membered heteroaryl), -NH(C 1-9 Alkyl), -NH(C 1-8 haloalkyl), -NH(C 3-15 cycloalkyl), -NH(heterocyclyl), -NH(aryl), -NH(5-10 membered heteroaryl), -N(C 1-9 Alkyl)2,-N(C 3-15 Cycloalkyl)2,-NHC(O)(C 1-8 haloalkyl), -NHC(O)(C3-15 cycloalkyl), -NHC(O)(heterocyclyl), -NHC(O)(aryl), -NHC(O)(5-10 membered heteroaryl), -NHC(O)O(C 1-9 alkyl), -NHC(O)O(C 1-8 haloalkyl), -NHC(O)O(C 2-6 Alkynyl), -NHC(O)O(C 3-15 cycloalkyl), -NHC(O)O(heterocyclyl), -NHC(O)O(aryl), -NHC(O)O(5-10 membered heteroaryl), or -NHC(O)NH(C 1-9 alkyl);

[0145] Each R 1b , R 1c , R 2a , R 2b , R 4c , R 9c , R 12a , R 12b , and R 12c are independently H, -OH, C 1-9 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-15 Cycloalkyl, heterocyclic, C 6-10 aryl, or 5-10 membered heteroaryl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or 5-10 membered heteroaryl can be substituted by 1 to 4 Z 1b Replace; at the same time

[0146] Each R 3e Independently H, C 1-6 Alkyl, C 1-6 Haloalkyl, -C 14 Alkyl-N(R 9a )(R 9b ), -C 1-4 Alkyl-C(O)N(R 9a )(R 9b ), -C 1-4 Alkyl-OC(O)-OC 1-4 Alkyl, -C 1-4 Alkyl-OC(O)-C 1-4 Alkyl-N(R 9a )(R 9b ), -C 1-4 Alkyl-C 3-8 Cycloalkyl, -C 1-4 Alkyl-heterocyclyl, C 3-10 Cycloalkyl, heterocyclic, C 6-10aryl, or 5-10 membered heteroaryl, wherein the alkyl, alkenyl, cycloalkyl, heterocyclyl, aryl or 5-10 membered heteroaryl can be substituted by 1 to 4 Z 1b substituted; wherein each 5-10 membered heteroaryl has a 5- to 12-membered ring structure and has 1 to 4 heteroatoms which are each independently N, O or S; and wherein each heterocyclyl has a 3- to 12-membered ring structure and has 1 to 4 heteroatoms which are each independently N, O or S.

[0147] In some embodiments, the compound is a compound having the structure of Formula IA-6 or Formula IA-7, or a pharmaceutically acceptable salt thereof:

[0148]

[0149] Wherein ring C is C 3-10 Cycloalkyl, heterocyclic, C 6-10 aryl or 5-10 membered heteroaryl, each of which may be replaced by 1 to 4 Z 1 replace;

[0150] V is CH2, CH(CH3), NH, C(O), S(O), S(O)2;

[0151] n is 0, 1, 2, 3, or 4;

[0152] R 2 Yes H, C 1-6 Alkyl, C 1-6 Alkyl-alkoxy, C 1-6 Alkyl-cycloalkoxy, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Cycloalkyl, heterocyclic, C 6-10 Aryl, 5-10 membered heteroaryl, -CN, -OR 2a , -SR 2a , -S(O)R 2a , -S(O)(NH)R 2a , -S(O)2R 2a ,-S(O)2N(R 2a )(R 2b ), or -S(O)(NR 2a )R 2b , wherein the alkyl, alkoxy, cycloalkyloxy, haloalkyl, cycloalkyl, heterocyclyl, aryl or 5-10 membered heteroaryl groups can each be substituted by 1 to 4 Z 1 Replace, and any two Z 1 can combine with the atoms to which they are attached to form C 3-10 Cycloalkyl or heterocyclic or C 6-10Aryl or 5-10 membered heteroaryl;

[0153] X is independently -N=, -C(H)=, or -C(R 8 )=;

[0154] Each R 3 and R 3’ Independently H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen, C3- 10 Cycloalkyl, heterocyclic, C 6-10 Aryl, 5-10 membered heteroaryl, -CN, -NO2, -OR 3a , -C(O)R 3a ,-CH2C(O)OR 3a , -C(O)OR 3a ,-C(O)N(R 3a )(R 3b ), -N(R 3a )C(O)R 3b , -N(R 3a )C(O)OR 3b , -N(R 3a )C(O)N(R 3b )2,-C(O)NHS(O)2R 3a , -C(O)NR 3a S(O)2R 3b , -C(O)NR 3a S(O)2NR 3b R 3c , -C(O)NR 3a -S(O)(=NR 3b )R 3c , -S(O)2R 3a , -S(O)2OR 3a ,-S(O)2N(R 3a )(R 3b ), -N(R 3a )S(O)2R 3b ,-S(O)2NHC(O)R 3a , -S(O)(=NR 3a )R 3b , -S(O)(=NR 3a )NR 3b ,-S(=NR 3a )(=NR 3b )R 3c , -P(O)(OR 3a )(R3b ), -P(O)(OR 3a )(OR 3b ), -B(OR 3a )(OR 3b ), or -OC 1-6 Alkyl-C(O)OR 3a , wherein the alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or 5-10 membered heteroaryl can be each substituted by 1 to 4 R 3d replace;

[0155] Each R 3a , R 3b , and R 3c Independently H, C 1-6 Alkyl, C 6-10 Aryl, 5-10 membered heteroaryl, C 1-6 Haloalkyl, C 2-8 Alkoxyalkyl, -C 1-4 Alkyl-N(R 9a )(R 9b ), -C 1-4 Alkyl-N(R 9a )C(O)-OC 1-4 Alkyl-OP(O)(OR 9c )2, -C 1-4 Alkyl-C(O)N(R 9a )(R 9b ), -C 1-4 Alkyl-OC(O)-OC 1-4 Alkyl, -C 1-4 Alkyl-OC(O)-C 1-4 Alkyl-N(R 9a )(R 9b ), -C 1-4 Alkyl-OC(O)-C 1-4 Alkyl-OP(O)(OR 9c )2, -C 1-4 Alkyl-C 3-8 Cycloalkyl, -C 1-4 Alkyl-heterocyclyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Cycloalkyl, heterocyclic, C 6-10 Aryl, 5-10 membered aromatic heterocyclic ring, -CH2CH(N(R 9a )2)C(O)OR 9b , C 1-6 Alkyl-heterocyclyl, C 1-6 Alkyl-aryl or C 1-6Alkyl (5-10 membered) heteroaryl, wherein the alkyl, alkenyl, cycloalkyl, heterocyclyl, aryl or 5-10 membered heteroaryl can be substituted by 1 to 4 Z 1b replace;

[0156] Each R 4 are independently H, -OH, CH2OH, C 1-9 Alkyl, C 1-8 Haloalkyl, C 1-6 Haloalkoxy, C 2-6 Alkoxyalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen, C 3-15 Cycloalkyl, heterocyclic, C 6-10 Aryl, 5-10 membered heteroaryl, oxo, -NO2, -CN, -N3, -OR 4a , -C(O)R 4a , -C(O)OR 4a ,-C(O)N(R 4a )(R 4b ), -N(R 4a )(R 4b ), -N(R 4a )2(R 4b ) | , -N(R 4a )-C(O)R 4b , -N(R 4a )C(O)O(R 4b ), -N(R 4a )C(O)N(R 4b )(R 4c ), -N(R 4a )S(O)2(R 4b ), -N(R 4a )S(O)2-N(R 4b )(R 4c ), -N(R 4a )S(O)2O(R 4b ), -OC(O)R 4a , -OC(O)OR 4a ,-OC(O)-N(R 4a )(R 4b ), -SR 4a , -S(O)R 4a , -S(O)(NH)R 4a , -S(O)2R 4a ,-S(O)2N(R 4a )(R 4b ), -S(O)(NR 4a )R 4b, or -Si(R 4a )3, wherein the alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or 5-10 membered heteroaryl can be each substituted by 1 to 4 Z 1b or, two R attached to adjacent ring atoms 4 The groups combine with the atoms to which they are attached to form C s-10 Cycloalkyl or heterocyclic group, each of which may be replaced by 1 to 4 Z 1b replace;

[0157] Each R 5a and R 5b Independently H, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 2-6 Alkoxyalkyl, halogen, C 3-10 Cycloalkyl, heterocyclyl, -C 1-6 Alkyl-N(R 9a )(R 9b ), -CN, -OR 5a1 , or -N(R 5a1 )(R 5a2 ), or, R 5a and R 5b Combine with the atoms to which they are attached to form C 3-10 Cycloalkyl or heterocyclic group, each of which may be replaced by 1 to 4 R 5a3 replace;

[0158] Each R 5a1 and R 5a2 Independently H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Cycloalkyl, heterocyclic, C 6-10 Aryl or 5-10 membered heteroaryl, wherein the cycloalkyl, heterocyclyl, aryl or 5-10 membered heteroaryl may be substituted by 1 to 4 halogens;

[0159] Each R 3d and R5 a3 Independently H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkoxyalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen, C 3-10 Cycloalkyl, heterocyclic, C 6-10 Aryl, 5-10 membered heteroaryl, oxo, -OH, -CN, CO2R3e , -NO2, or -C(O)N(R 2a )(R 2b ), wherein the heterocyclic group or the 5-10 membered heteroaryl group may be C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 Haloalkoxy substitution;

[0160] Each R 8 Independently C 1-9 Alkyl, C 1-8 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen, oxo, -OH, -CN, CO2R 3e ,-NO2,-NH2,-N3,-SH,-O(C 1-9 alkyl), -O(C 1-8 haloalkyl), -NH(C 1-9 Alkyl), -NH(C 1-8 haloalkyl), -N(C 1-9 Alkyl)2,-N(C 1-8 Haloalkyl)2;

[0161] Each R 9a and R 9b Independently H, C 1-9 Alkyl, C 1-8 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkoxyalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen, C 3-15 Cycloalkyl, heterocyclic, C 6-10 Aryl, 5-10 membered heteroaryl, oxo, -NO2, -CN, -N3, -OR 12a , -C(O)R 12a , -C(O)OR 12a ,-C(O)N(R 12a )(R 12b ), -N(R 12a )(R 12b ), -N(R 12a )2(R 12b ) + , -N(R 12a )-C(O)R 12b , -N(R 12a )C(O)O(R 12b ), -N(R 12a )C(O)N(R 12b )(R12c ), -N(R 12a )S(O)2(R 12b ), -N(R 12a )S(O)2-N(R 12b )(R 12c ), -N(R 12a )S(O)2O(R 12b ), -OC(O)R 12a , -OC(O)OR 12a ,-OC(O)-N(R 12a )(R 12b ), -SR 12a , -S(O)R 12a , -S(O)(NH)R 12a , -S(O)2R 12a ,-S(O)2N(R 12a )(R 12b ), -S(O)(NR 12a )R 12b , or -Si(R 12a )3; or R 9a and R 9b Fusion forms a 3-10 membered heterocyclic group, each of which may be substituted by: C 1-9 Alkyl, C 1-8 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkoxyalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen, C 3-15 Cycloalkyl, heterocyclic, C 6-10 Aryl, 5-10 membered heteroaryl, oxo, -NO2, -CN, -N3, -OR 12a , -C(O)R 12a , -C(O)OR 12a ,-C(O)N(R 12a )(R 12b ), -N(R 12a )(R 12b ), -N(R 12a )2(R 12b ) + , -N(R 12a )-C(O)R 12b , -N(R 12a )C(O)O(R 12b ), -N(R 12a )C(O)N(R 12b )(R 12c ), -N(R 12a)S(O)2(R 12b ), -N(R 12a )S(O)2-N(R 12b )(R 12c ), -N(R 12a )S(O)2O(R 12b ), -OC(O)R 12a , -OC(O)OR 12a ,-OC(O)-N(R 12a )(R 12b ), -SR 12a , -S(O)R 12a , -S(O)(NH)R 12a , -S(O)2R 12a ,-S(O)2N(R 12a )(R 12b ), -S(O)(NR 12a )R 12b , or -Si(R 12a )3;

[0162] Each Z 1 Independently C 1-9 Alkyl, C 1-8 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkoxyalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen, C 3-15 Cycloalkyl, heterocyclic, C 6-10 Aryl, 5-10 membered heteroaryl, oxo, -NO2, -N3, -CN, -OR 12a , wherein the alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or 5-10 membered heteroaryl can be each substituted by 1 to 4 Z 1a replace;

[0163] Each Z 1a are independently H, C1-9 alkyl, C1-8 haloalkyl, C1-6 alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkoxyalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen, C 3-15 Cycloalkyl, heterocyclic, C 6-10 Aryl, 5-10 membered heteroaryl, oxo, -NO2, -CN, -N3, -OR 12a , -C(O)R 12a , -C(O)OR 12a ,-C(O)N(R 12a)(R 12b ), -N(R 12a )(R 12b ), -N(R 12a )2(R 12b ) + , -N(R 12a )-C(O)R 12b , -N(R 12a )C(O)O(R 12b ), -N(R 12a )C(O)N(R 12b )(R 12c ), -N(R 12a )S(O)2(R 12b ), -N(R 12a )S(O)2-N(R 12b )(R 12c ), -N(R 12a )S(O)2O(R 12b ), -OC(O)R 12a , -OC(O)OR 12a ,-OC(O)-N(R 12a )(R 12b ), -SR 12a , -S(O)R 12a , -S(O)(NH)R 12a , -S(O)2R 12a ,-S(O)2N(R 12a )(R 12b ), -S(O)(NR 12a )R 12b , or -Si(R 12a )3, wherein the alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or 5-10 membered heteroaryl can be each substituted by 1 to 4 Z 1b replace;

[0164] Each Z 1b Independently H, C 1-9 Alkyl, C 1-8 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen, C 3-15 Cycloalkyl, heterocyclic, C 6-10 Aryl, 5-10 membered heteroaryl, oxo, -OH, -CN, CO2R 3 e, -NO2, -NH2, -N3, -SH, -O(C 1-9 alkyl), -O(C 1-8 haloalkyl), -O(C 2-6 alkenyl), -O(C 2-6Alkynyl), -O(C 3-15 Cycloalkyl), -O(heterocyclyl), -O(C 6-10 aryl), -O(5-10 membered heteroaryl), -NH(C 1-9 Alkyl), -NH(C 1-8 haloalkyl), -NH(C 2-6 alkenyl), -NH(C 2-6 Alkynyl), -NH(C 3-15 Cycloalkyl), -NH(heterocyclyl), -NH(C 6-10 aryl), -NH(5-10 membered heteroaryl), -N(cyclo-alkyl), -N(C1-9 alkyl)2, -N(C 1-8 Haloalkyl)2,-N(C 2-6 Alkenyl)2,-N(C 2-6 Alkynyl)2,-N(C 3-15 Cycloalkyl)2,-N(heterocyclyl)2,-N(C 6-10 Aryl)2,-N(5-10 membered heteroaryl)2,-N(C 1-9 Alkyl)(C 1-8 haloalkyl), -N(C 1-9 Alkyl)(C 2-6 alkenyl), -N(C 1-9 Alkyl)(C 2-6 Alkynyl), -N(C 1-9 Alkyl)(C 3-15 Cycloalkyl), -N(C 1-9 alkyl)(heterocyclyl),-N(C 1-9 Alkyl)(C 6-10 Aryl), -N(C 1-9 alkyl)(5-10 membered heteroaryl), -C(O)(C 1-9 alkyl), -C(O)(C 1-8 haloalkyl), -C(O)(C 2-6 alkenyl), -C(O)(C 2-6 Alkynyl), -C(O)(C 3-15 Cycloalkyl), -C(O)(heterocyclyl), -C(O)(C 6-10 aryl), -C(O)(5-10 membered heteroaryl), -C(O)O(C 1-9 alkyl), -C(O)O(C 1-8 haloalkyl), -C(O)O(C 2-6 alkenyl), -C(O)O(C 2-6 Alkynyl), -C(O)O(C 3-15 Cycloalkyl), -C(O)O(heterocyclyl), -C(O)O(C 6-10aryl), -C(O)O(5-10 membered heteroaryl), -C(O)NH2, -C(O)NH(C 1-9 alkyl), -C(O)NH(C 1-8 haloalkyl), -C(O)NH(C 2-6 alkenyl), -C(O)NH(C 2-6 Alkynyl), -C(O)NH(C 3-15 Cycloalkyl), -C(O)NH(heterocyclyl), -C(O)NH(C 6-10 aryl), -C(O)NH(5-10 membered heteroaryl), -C(O)N(C 1-9 Alkyl)2,-C(O)N(C 1-8 Haloalkyl)2,-C(O)N(C 2-6 alkenyl)2,-C(O)N(C 2-6 Alkynyl)2,-C(O)N(C 3-15 Cycloalkyl)2,-C(O)N(heterocyclyl)2,-C(O)N(C 6-10 Aryl)2,-C(O)N(5-10 membered heteroaryl)2,-NHC(O)(C 1-9 alkyl), -NHC(O)(C 1-8 haloalkyl), -NHC(O)(C 2-6 alkenyl), -NHC(O)(C 2-6 Alkynyl), -NHC(O)(C 3-15 Cycloalkyl), -NHC(O)(heterocyclyl), -NHC(O)(C 6-10 aryl), -NHC(O)(5-10 membered heteroaryl), -NHC(O)O(C 1-9 alkyl), -NHC(O)O(C 1-8 haloalkyl), -NHC(O)O(C 2-6 alkenyl), -NHC(O)O(C 2-6 Alkynyl), -NHC(O)O(C 3-15 Cycloalkyl), -NHC(O)O(heterocyclyl), -NHC(O)O(C 6-10 aryl), -NHC(O)O(5-10 membered heteroaryl), -NHC(O)NH(C 1-9 alkyl), -NHC(O)NH(C 1-8 haloalkyl), -NHC(O)NH(C 2-6 alkenyl), -NHC(O)NH(C 2-6 Alkynyl), -NHC(O)NH(C 3-15 Cycloalkyl), -NHC(O)NH(heterocyclyl), -NHC(O)NH(C 6-10aryl), -NHC(O)NH(5-10 membered heteroaryl), wherein the alkyl, cycloalkyl, heterocyclyl, aryl or 5-10 membered heteroaryl may be substituted by 1 to 3 of the following: 1-9 Alkyl, C 1-8 Haloalkyl, halogen, -OH, -NH2, CO2H, -O(C 1-9 alkyl), -O(C 1-8 haloalkyl), -O(C 3-15 cycloalkyl), -O(heterocyclyl), -O(aryl), -O(5-10 membered heteroaryl), -NH(C 1-9 Alkyl), -NH(C 1-8 haloalkyl), -NH(C 3-15 cycloalkyl), -NH(heterocyclyl), -NH(aryl), -NH(5-10 membered heteroaryl), -N(C 1-9 Alkyl)2,-N(C 3-15 Cycloalkyl)2,-NHC(O)(C 1-8 haloalkyl), -NHC(O)(C 3-15 cycloalkyl), -NHC(O)(heterocyclyl), -NHC(O)(aryl), -NHC(O)(5-10 membered heteroaryl), -NHC(O)O(C 1-9 alkyl), -NHC(O)O(C 1-8 haloalkyl), -NHC(O)O(C 2-6 Alkynyl), -NHC(O)O(C 3-15 cycloalkyl), -NHC(O)O(heterocyclyl), -NHC(O)O(aryl), -NHC(O)O(5-10 membered heteroaryl), or -NHC(O)NH(C 1-9 alkyl);

[0165] Each R 1b , R 1c , R 2a , R 2b , R 4a , R 4b , R 4c , R 9c , R 12a , R 12b , and R 12c are independently H, -OH, C 1-9 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-15 Cycloalkyl, heterocyclic, C 6-10 aryl, or 5-10 membered heteroaryl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or 5-10 membered heteroaryl can be substituted by 1 to 4 Z 1breplace; and

[0166] Each R 3e Independently H, C 1-6 Alkyl, C 1-6 Haloalkyl, -C 1-4 Alkyl-N(R 9a )(R 9b ), -C 1-4 Alkyl-C(O)N(R 9a )(R 9b ), -C 14 Alkyl-OC(O)-OC 1-4 Alkyl, -C 1-4 Alkyl-OC(O)-C 1-4 Alkyl-N(R 9a )(R 9b ), -C 1-4 Alkyl-C 3-8 Cycloalkyl, -C 1-4 Alkyl-heterocyclyl, C 3-10 Cycloalkyl, heterocyclic, C 6-10 aryl, or 5-10 membered heteroaryl, wherein the alkyl, alkenyl, cycloalkyl, heterocyclyl, aryl or 5-10 membered heteroaryl are each optionally substituted by 1 to 4 Z 1b substituted; wherein each 5-10 membered heteroaryl has a 5- to 12-membered ring structure and has 1 to 4 heteroatoms which are each independently N, O or S; and wherein each heterocyclyl has a 3- to 12-membered ring structure and has 1 to 4 heteroatoms which are each independently N, O or S.

[0167] In some embodiments, the compound having the structure of Formula IA-2, IA-3, IA-5, IA-6, IA-7 or a pharmaceutically acceptable salt thereof, each R 5a and R 5b Independently H, C 1-9 Alkyl, C 2-6 Alkoxyalkyl, wherein the alkyl or alkoxyalkyl each may be substituted by one or more halogens.

[0168] In some embodiments, the compound having the structure of Formula IA-2, IA-3, IA-4, IA-5, IA-6, IA-7 or a pharmaceutically acceptable salt thereof, Ring C is C 6-10 Aryl or 5-10 membered heteroaryl, which is selected from the group consisting of the following structures:

[0169]

[0170] Each of them may be substituted with 1 to 4 substituents, each of which is independently selected from the group consisting of H, OH, oxo, halogen, C1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 2-6 Alkoxyalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Cycloalkyl, heterocyclic, -NO2, -N3, -CN, -OC 1-6 Alkyl, -C(O)-C 1-6 Alkyl, -C(O)-N(C 0-6 Alkyl)(C 0-6 alkyl), and -N(C 0-6 Alkyl)(C 0-6 alkyl), wherein the 1 to 4 substituents may each be substituted by one or more halogens.

[0171] In some embodiments, in the compound having the general structure of IA-1 or a pharmaceutically acceptable salt thereof, Ring A is one of the following:

[0172]

[0173] Each of them can be 1-4 Z 1a replace.

[0174] In some embodiments, the compound having the structure of Formula IA-1, IA-2, IA-3, IA-4, IA-5, IA-6, IA-7 or a pharmaceutically acceptable salt thereof, Z 1a are independently H, halogen, C 1-9 Alkyl, C 1-6 Alkoxy, C2-6 alkoxyalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-15 The cycloalkyl group or the heterocyclic group may each be substituted by one or more halogens.

[0175] In some embodiments, a compound having the general formula IA-1, IA-2, IA-3, IA-4, IA-5, IA-6, IA-7 or a pharmaceutically acceptable salt thereof, wherein R 2 It is C 1-6 Alkyl, -C 1-6 Alkyl-alkoxy, -C 1-6 Alkyl-cycloalkoxy, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Cycloalkyl, heterocyclic, C 6-10 aryl, or 5-10 membered heteroaryl, each of which may be substituted by 1 to 4 Z1 Preferably, R 2 Is one of the following:

[0176]

[0177] Each of them can be 1 to 4 Z 1 replace;

[0178] In some embodiments, the compound having the structure of Formula IA-1, IA-2, IA-3, IA-4, IA-5, IA-6, IA-7 or a pharmaceutically acceptable salt thereof, R 2’ It is H, C 1-6 Alkyl, C 1-6 Haloalkyl, -C 1-6 Alkyl or -cycloalkoxy, each of which may be substituted by one or more halogens.

[0179] In some embodiments, the compound having the structure of Formula IA-1, IA-2, IA-3, IA-4, IA-5, IA-6, IA-7 or a pharmaceutically acceptable salt thereof, each R3 and R3' is independently H, C 6-10 Aryl, 5-10 membered heteroaryl, -C(O)R 3a ,-CH2C(O)OR 3a ,-C(O)N(R 3a )(R 3b ), -N(R 3a )C(O)R 3b , -N(R 3a )C(O)OR 3b , -N(R 3a )C(O)N(R 3b )2,-C(O)NHS(O)2R 3a , -C(O)NR 3a S(O)2R 3b , -C(O)NR 3a S(O)2NR 3b R 3c , -C(O)NR 3a -S(O)(=NR 3b )R 3c ,-S(O)2N(R 3a )(R 3b ), -N(R 3a )S(O)2R 3b ,-S(O)2NHC(O)R 3a , or -OC 1-6 Alkyl-C(O)OR 3a , each of which can be 1 to 4 R3d replace.

[0180] Preferably, each R 3 and R 3’ Independently selected from H, C(O)NR 3a (CH2) m R 3b , C(O)NR 3a (CH2) m C(O)R 3b , NR 3a C(O)(CH2) m R 3b , NR 3a (CH2) m R 3b , NR 3a (CH2) m C(O)R 3b , C(O)NR 3a R 3b , or NR 3a C(O)R 3b , each of which can be 1 to 4 R 3d Optionally substituted, wherein m is 0, 1, 2, or 3. Preferably, each R3 and R3' is independently selected from H, C(O)NHR 3b , or NHC(O)R 3b .

[0181] In some embodiments, the compound having the structure of Formula IA-1, IA-2, IA-3, IA-4, IA-5, IA-6, IA-7 or a pharmaceutically acceptable salt thereof, R 3b Independently selected from H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-8 Alkoxyalkyl, -C 1-4 Alkyl-N(R 9a )(R 9b ), -C 1-4 Alkyl-C(O)N(R 9a )(R 9b ), -C 1-4 Alkyl-OC(O)-OC 1-4 Alkyl, -C 1-4 Alkyl-OC(O)-C 1-4 Alkyl-N(R 9a )(R 9b ), -C 1-4 Alkyl-C 3-8 Cycloalkyl, -C 1-4 Alkyl-heterocyclyl, C 2-6 Alkenyl, C2-6 Alkynyl, C 3-10 Cycloalkyl, heterocyclic, C 6-10 Aryl, 5-10 membered heteroaryl, -CH2CH(N(R 9a )2)C(O)OR 9b , C 1-6 Alkyl-heterocyclyl, C 1-6 Alkyl-aryl or C 1-6 Alkyl-(5-10 membered) heteroaryl, wherein the alkyl, alkenyl, cycloalkyl, heterocyclyl, aryl or 5-10 membered heteroaryl can be substituted by 1 to 4 Z 1b replace.

[0182] Preferably, R 3b is replaced by C 5-10 aryl or substituted 5-10 membered heteroaryl, each of which may be replaced by 1 to 5 R 3f Substitute, where each R 3f Selected from H, OH, oxo, NH2, halogen, -NO2, -N3, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkoxyalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Cycloalkyl, heterocyclyl, -OC 1-6 Alkyl, -C(O)-C 1-6 Alkyl, -C(O)-N(R 12a )(R 12b ), -N(R 12a )(R 12b ), C 6-10 aryl, 5-10 membered heteroaryl, and wherein R 3f Each may be substituted by one or more of the following: halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy or C 1-6 Halogenated alkoxy.

[0183] More preferably, R 3b Choose one of the following:

[0184]

[0185] Each of which can be 1 to 5 R 3f replace.

[0186] In some embodiments, the compound having the general structure of IA-1 or a pharmaceutically acceptable salt thereof, R4 Independently selected from H, -OH, C 1-9 Alkyl, C 1-8 Haloalkyl, C 1-6 Haloalkoxy, C 2-6 Alkoxyalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen, C 3-15 Cycloalkyl, heterocyclic, C 6-10 Aryl, 5-10 membered heteroaryl, oxo, -NO2, -CN, -N3, -OC 1-9 Alkyl or -C(O)C 1-9 Alkyl, each of which may be replaced by 1 to 4 Z 1b or, two R attached to adjacent ring atoms 4 The groups combine with the atoms to which they are attached to form C 5-10 Cycloalkyl or heterocyclic group, each of which may be replaced by 1 to 4 Z 1b replace.

[0187] Preferably, R 4 independently selected from H, halogen, C 1-9 Alkyl, C 1-8 Haloalkyl, C 1-6 Haloalkoxy, C 2-6 Alkoxyalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, or C 3-15 Cycloalkyl.

[0188] In some embodiments, the compound of Formula IA-1, IA-2, IA-3, IA-4, IA-5, IA-6, IA-7, or a pharmaceutically acceptable salt thereof, has a structure selected from the group consisting of:

[0189]

[0190]

[0191]

[0192]

[0193]

[0194]

[0195]

[0196]

[0197]

[0198]

[0199]

[0200]

[0201]

[0202] III. Drug Formulation

[0203] Another aspect of the present application relates to a pharmaceutical composition containing the compound of the present application. In some embodiments, the present application provides a pharmaceutical composition comprising the compound of the present application and one or more pharmaceutically acceptable excipients.

[0204] In some embodiments, the pharmaceutical composition comprises a compound of Formula IA-1 or a pharmaceutically acceptable salt thereof.

[0205] In some embodiments, the pharmaceutical composition comprises a compound of Formula IA-2 or a pharmaceutically acceptable salt thereof.

[0206] In some embodiments, the pharmaceutical composition comprises a compound of Formula IA-3 or a pharmaceutically acceptable salt thereof.

[0207] In some embodiments, the pharmaceutical composition comprises a compound of Formula IA-4 or a pharmaceutically acceptable salt thereof.

[0208] In some embodiments, the pharmaceutical composition comprises a compound of Formula IA-5 or a pharmaceutically acceptable salt thereof.

[0209] In some embodiments, the pharmaceutical composition comprises a compound of Formula IA-6 or a pharmaceutically acceptable salt thereof.

[0210] In some embodiments, the pharmaceutical composition comprises a compound of Formula IA-7 or a pharmaceutically acceptable salt thereof.

[0211] In some embodiments, the pharmaceutical composition of the present application further comprises one or more additional therapeutic agents. Examples of additional therapeutic agents include, but are not limited to, those listed in the combined therapy section of the present application.

[0212] The pharmaceutical composition of the present application can be in any form suitable for the intended method of administration. In some embodiments, when used for oral administration, the pharmaceutical composition is in the form of tablets, sachets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, syrups or elixirs.

[0213] In some embodiments, the pharmaceutical composition of the present application is presented in unit dosage form, including but not limited to capsules, sachets or tablets, wherein each capsule, sachet or tablet contains a predetermined amount of active ingredient. In one embodiment, the pharmaceutical composition is a tablet.

[0214] The pharmaceutical composition can be prepared by any method known in the pharmaceutical field. These methods include the step of combining the active ingredient (e.g., the compound of the present application or a pharmaceutically acceptable salt thereof) with one or more pharmaceutically acceptable excipients. In some embodiments, the pharmaceutical composition is prepared by uniformly and closely combining the active ingredient with a liquid excipient or a finely divided solid excipient or both, and then, if necessary, molding the product. Technology and formulations can generally be found in Remington: The Science and Practice of Pharmacy, 21st Edition, Lippincott Wiliams and Wilkins, Philadelphia, Pa., 2006.

[0215] Examples of one or more excipients include, but are not limited to, fillers, binders, fillers, abrasives, sweeteners, flavoring agents, colorants, and preservatives. In some embodiments, the pharmaceutical composition is in tablet form and contains one or more pharmaceutically acceptable excipients suitable for preparing tablets. These excipients can be, for example, inert diluents such as calcium carbonate or sodium carbonate, lactose, lactose monohydrate, cross-linked carboxymethylcellulose sodium, povidone, calcium phosphate or sodium phosphate; granulation and disintegrants such as corn starch or alginic acid; binders such as cellulose, microcrystalline cellulose, starch, gelatin or gum arabic; and lubricants such as magnesium stearate, stearic acid or talc. Tablets can be uncoated or can be coated by known techniques, including microencapsulation, to delay disintegration and adsorption in the gastrointestinal tract, thereby providing a longer sustained effect. For example, time-delay materials such as glyceryl monostearate or glyceryl distearate can be used alone or with wax.

[0216] The amount of active ingredients that can be combined with inactive ingredients to produce a dosage form can vary depending on the intended treatment subject and mode of administration. For example, in some embodiments, a dosage form for oral administration to humans can contain about 1 to 1000 mg of an active substance formulated with an appropriate and convenient amount of a pharmaceutically acceptable excipient. In some embodiments, the pharmaceutically acceptable excipient comprises about 5% to about 95% (weight:weight) of the total composition.

[0217] In some embodiments, the pharmaceutical composition of the present application does not include a reagent that affects the metabolic rate of the active ingredient. Therefore, it should be understood that in one aspect, the pharmaceutical composition comprising the compound of the present application does not include a reagent that affects (for example, slowing down, hindering or delaying) the compound of the present application or any other active ingredient that is separated, sequentially or simultaneously administered with the compound of the present application. It should also be understood that in one aspect, any method, kit, product, etc. described in detail herein do not include a reagent that affects (for example, slowing down, hindering or delaying) the compound of the present application or any other active ingredient that is separated, sequentially or simultaneously administered with the compound of the present disclosure.

[0218] IV. Treatment Methods

[0219] Another aspect of the present application relates to a method for preventing, treating or ameliorating the symptoms of a disease or condition mediated by GLP-1R using the compounds of the present application. In some embodiments, the method comprises administering to a subject in need of such treatment an effective amount of a compound of Formula IA-1, IA-2, IA-3, IA-4, IA-5, I-A6, IA-7 or a pharmaceutically acceptable salt thereof.

[0220] Examples of diseases or conditions mediated by GLP-1R include, but are not limited to, chronic intrahepatic or certain forms of extrahepatic cholestasis of the present application, liver fibrosis, acute intrahepatic cholestasis, obstructive or chronic inflammatory diseases caused by inappropriate bile composition, gastrointestinal diseases caused by reduced intake of dietary fat and fat-soluble dietary vitamins, inflammatory bowel disease, lipid and lipoprotein diseases, type II diabetes and clinical complications of type I and type II diabetes, chronic fatty and fibrotic degeneration of organs due to forced lipid and especially triglyceride accumulation and subsequent activation of profibrotic pathways, obesity and metabolic syndrome (a syndrome of dyslipidemia, diabetes and abnormally high body mass index), acute myocardial infarction, acute stroke, thrombosis as an end point of chronic obstructive atherosclerosis, persistent infection with intracellular bacteria or parasitic protozoa, non-malignant hyperproliferative diseases, malignant hyperproliferative diseases, colon adenocarcinoma and hepatocellular carcinoma, hepatic steatosis and related syndromes, liver failure or insufficiency following chronic liver disease or surgical liver resection, hepatitis B infection, hepatitis C Infection and / or alcohol-induced cirrhosis or virally transmitted hepatitis, type 1 diabetes, prediabetes, idiopathic type 1 diabetes, underlying autoimmune diabetes, juvenile onset diabetes, early onset diabetes, diabetes associated with malnutrition, gestational diabetes, hyperglycemia, insulin resistance, hepatic insulin resistance, impaired glucose tolerance, diabetic neuropathy, diabetic nephropathy, kidney disease, diabetic retinopathy, adipocyte dysfunction, visceral fat deposition, obesity, eating disorders, sleep apnea, weight gain Add, sugar craving, dyslipidemia, hyperinsulinemia, congestive heart failure, myocardial infarction, stroke, hemorrhagic stroke, ischemic stroke, traumatic brain injury, pulmonary hypertension, restenosis after angioplasty, intermittent claudication, postprandial hyperlipidemia, metabolic acidosis, ketosis, arthritis, left ventricular hypertrophy, Parkinson's disease, peripheral arterial disease, macular degeneration, cataract, glomerulosclerosis, chronic renal failure, metabolic syndrome, angina pectoris, premenstrual syndrome, thrombosis, atherosclerosis, impaired glucose metabolism or vascular restenosis.

[0221] In some embodiments, the disease or condition mediated by GLP-1R is selected from one or more of the following: type I diabetes (T1D), type II diabetes (T2DM), prediabetes, idiopathic TID, late-onset autoimmune diabetes in adulthood (LADA), early-onset T2DM (EOD), atypical diabetes of the young (YOAD), maturity-onset diabetes of the young (MODY), malnutrition-related diabetes, gestational diabetes, hyperglycemia, insulin resistance, hepatic insulin resistance, impaired glucose tolerance, diabetic neuropathy, diabetic nephropathy, kidney disease, diabetic retinopathy, adipocyte dysfunction, visceral fat deposition, sleep apnea, obesity, eating disorders, weight gain due to use of other medications, excessive sugar cravings, dyslipidemia, hyperinsulinemia, NAFLD, NASH, fibrosis, cirrhosis, hepatocellular carcinoma, cardiovascular disease, atherosclerosis, coronary artery disease, peripheral vascular disease, Hypertension, endothelial dysfunction, impaired vascular compliance, congestive heart failure, myocardial infarction, stroke, hemorrhagic stroke, ischemic stroke, traumatic brain injury, pulmonary hypertension, restenosis after angioplasty, intermittent claudication, postprandial hyperlipidemia, metabolic acidosis, ketosis, arthritis, osteoporosis, Parkinson's disease, left ventricular hypertrophy, peripheral arterial disease, macular degeneration, cataract, glomerulosclerosis, chronic renal failure, metabolic syndrome, syndrome X, premenstrual syndrome, Prevention or treatment of angina pectoris, thrombosis, atherosclerosis, transient ischemic attack, vascular restenosis, impaired glucose metabolism, impaired fasting glucose, hyperuricemia, gout, erectile dysfunction, skin and connective tissue diseases, psoriasis, foot ulcers, ulcerative colitis, hyperbetalipoproteinemia, Alzheimer's disease, schizophrenia, cognitive impairment, inflammatory bowel disease, short bowel syndrome, Crohn's disease, colitis, irritable bowel syndrome, polycystic ovary syndrome, and withdrawal treatment.

[0222] In some embodiments, the disease or condition mediated by GLP-1R is a liver disease, such as liver fibrosis, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), cirrhosis, compensated liver fibrosis, decompensated liver fibrosis, hepatocellular carcinoma, primary biliary cirrhosis (PBC), or primary sclerosing cholangitis (PSC).

[0223] In some embodiments, the disease or condition mediated by GLP-1R is a metabolic disease.

[0224] In some embodiments, the present application relates to a method for treating and / or preventing NAFLD, comprising administering an effective amount of a compound of Formula IA-1 or a pharmaceutically acceptable salt thereof to a subject in need thereof.

[0225] In some embodiments, the present application relates to a method for treating and / or preventing NASH. In some embodiments, the method comprises administering an effective amount of a compound of Formula IA-1 to a subject in need thereof.

[0226] In some embodiments, the present application relates to the prevention and post-traumatic treatment of cardiovascular diseases, such as acute myocardial infarction, acute stroke or thrombosis, which are the endpoints of chronic obstructive atherosclerosis. In some embodiments, the method comprises administering an effective amount of a compound of formula IA-1 to a subject in need thereof.

[0227] In some embodiments, the present application relates to a method for treating and / or preventing obesity and related diseases, such as metabolic syndrome (a variety of diseases including dyslipidemia, diabetes, and abnormally high body mass index), which can be overcome by GLP1R-mediated reduction of serum triglycerides and blood glucose and increased insulin sensitivity, as well as GLP1R-mediated weight loss. In some embodiments, the method comprises administering an effective amount of a compound of formula IA-1 to a subject in need thereof.

[0228] In some embodiments, the present application relates to a method for preventing and / or treating clinical complications of type I and type II diabetes. Such complications include diabetic nephropathy, diabetic retinopathy, diabetic neuropathy or peripheral arterial occlusive disease (PAOD), and other clinical complications of diabetes are also included in the present application. In some embodiments, the method comprises administering an effective amount of a compound of formula IA-1 to a subject in need thereof.

[0229] In addition, by administering the compounds or pharmaceutical compositions of the present application, conditions and diseases caused by chronic fatty infiltration and fibrotic degeneration of organs due to the gradual accumulation of lipids and / or triglycerides and the subsequent activation of profibrotic pathways can also be prevented and / or treated. These conditions and diseases include, but are not limited to, NASH and chronic cholestasis of the liver, glomerulosclerosis and diabetic nephropathy of the kidneys, macular degeneration and diabetic retinopathy of the eyes, and neurodegenerative diseases such as Alzheimer's disease of the brain or diabetic neuropathy of the peripheral nervous system.

[0230] In some embodiments, the present application relates to a method for treating and / or preventing conditions and diseases caused by chronic fatty infiltration and fibrotic degeneration of organs caused by gradual accumulation of lipids and / or triglycerides and subsequent activation of profibrotic pathways. In some embodiments, the method comprises administering an effective amount of a compound of formula IA-1 to a subject in need thereof.

[0231] In some embodiments, the compounds of the present application are used in the form of prodrugs or other appropriately modified forms that release the active ingredient in vivo.

[0232] The compound of the present application (also referred to as active ingredient herein) or the pharmaceutical composition of the present application can be administered by any route suitable for the condition to be treated. Suitable routes include oral, rectal, nasal, topical (including oral and sublingual), transdermal, vaginal and parenteral (including subcutaneous, intramuscular, intravenous, intradermal, intratumoral, intrathecal and epidural) etc. It is understood that the preferred route may vary with, for example, the condition of the recipient. The advantage of some compounds disclosed herein is that they are orally bioavailable and can be administered orally.

[0233] The compound of the present application can be administered to an individual in a desired time period or duration according to an effective dosing regimen, for example, at least about 1 month, at least about 2 months, at least about 3 months, at least about 6 months, or at least about 12 months or longer. In one embodiment, the compound is administered in a daily or intermittent manner over the duration of an individual's life.

[0234] The dosage or administration frequency of the compound of the present application can be adjusted during the course of treatment based on the judgment of the administering physician.

[0235] The compound can be administered to an individual (eg, a human) in an effective amount. In some embodiments, the compound is administered once a day.

[0236] The compound can be administered by any useful approach and means, for example, by oral or parenteral (e.g., intravenous) administration. The therapeutically effective amount of the compound can include from about 0.00001 mg / kg body weight to about 10 mg / kg body weight every day, for example, from about 0.0001 mg / kg body weight to about 10 mg / kg body weight every day, or as from about 0.001 mg / kg body weight to about 1 mg / kg body weight every day, or as from about 0.01 mg / kg body weight to about 1 mg / kg body weight every day, or as from about 0.05 mg / kg body weight to about 0.5 mg / kg body weight every day, or as from about 0.3 mg every day to about 30 mg every day, or as from about 30 mg every day to about 300 mg every day.

[0237] The compound of the present application can be combined with one or more additional therapeutic agents with the amount of any dosage of the compound of the present disclosure (for example, from 1 milligram to 1000 milligrams of compound). The therapeutically effective amount may include from about 1 milligram per dose to about 1000 milligrams per dose, for example from about 50 milligrams per dose to about 500 milligrams per dose, or such as from about 100 milligrams per dose to about 400 milligrams per dose, or such as from about 150 milligrams per dose to about 350 milligrams per dose, or such as from about 200 milligrams per dose to about 300 milligrams per dose. Other therapeutically effective amounts of compounds disclosed herein are about 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475 or about 500 milligrams per dose. Other therapeutically effective amounts of the compounds disclosed herein are about 100 mg per dose, or about 125, 150, 175, 200, 225, 250, 275, 300, 350, 400, 450 or about 500 mg per dose. A single dose can be administered hourly, daily or weekly. For example, a single dose can be administered once every 1 hour, 2, 3, 4, 6, 8, 12, 16 or 24 hours. A single dose can also be administered once every 1 day, 2, 3, 4, 5, 6 or 7 days. A single dose can also be administered once every 1 week, 2, 3 or 4 weeks. In some embodiments, a single dose can be administered once a week. A single dose can also be administered once a month.

[0238] The application also relates to a kit comprising the compound or an acceptable salt thereof. In one embodiment, a kit further includes a label and / or instructions for use recording the compound treatment indication (e.g., a disease or symptom described above in the present application). In one embodiment, the kit comprises a compound of the present application or a pharmaceutically acceptable salt thereof and one or more (e.g., one, two, three, four, one or two, or one to three, or one to four) additional therapeutic agents.

[0239] V. Combination Therapy

[0240] The present application also provides the use of the compound of the present application in combination therapy with one or more additional therapeutic agents that have synergistic effects with the compound of the present application.

[0241] In some embodiments, the one or more additional therapeutic agents include an apoptosis signal regulating kinase (ASK-1) inhibitor, a farnesoid X receptor (FXR) agonist, a peroxisome proliferator-activated receptor alpha (PPARα) agonist, fish oil, an acetyl coenzyme (ACC) inhibitor, or a TGFβ antagonist, or a combination thereof.

[0242] In some embodiments, the one or more additional therapeutic agents are selected from one or more of the following: ACE inhibitors, 2-acylglycerol O-acyltransferase 2 (DGAT2) inhibitors, acetaldehyde dehydrogenase inhibitors, acetyl-CoA carboxylase inhibitors, adrenergic receptor agonists, Alstrom syndrome protein 1 (ALMS1) / PKCα-protein interaction inhibitors, Apelin receptor agonists, diacylglycerol O-acyltransferase 2 inhibitors, adenosine A3 receptor agonists, adenosine A3 receptor antagonists, adiponectin receptor agonists, aldehyde dehydrogenase 2 stimulators, AKT protein kinase inhibitors, AMP-activated protein kinase (AMPK), AMP kinase activators, ATP citrate lyase inhibitors, AMP-activated protein kinase agonists, endothelial nitric oxide synthase agonists, NAD-dependent deacetylase sirtuin-1 agonists, androgen receptor agonists, amylin receptor agonists, angiotensin II AT-1 receptor antagonists, autophagy protein regulators, autotaxin inhibitors, Ax1 tyrosine kinase receptor inhibitors, Bax protein stimulators, β-catenin inhibitors, bioactive lipids, calcitonin agonists, cannabinoid receptor modulators, caspase inhibitors, caspase-3 stimulators, cathepsin inhibitors, caveolin-1 inhibitors, CCK receptor antagonists, CCL26 gene inhibitors, CCR2 chemokine antagonists, CCR2 chemokine antagonists, angiotensin II AT-1 receptor antagonists, CCR3 chemokine antagonists, CCR5 chemokine antagonists, CD3 antagonists, CDGSH iron-sulfur domain protein regulators, chitinase inhibitors, chloride channel stimulators, chitotriosidase 1 inhibitors, CNR1 inhibitors, connective tissue growth factor ligand inhibitors, cyclin D1 inhibitors,Cytochrome P4507A1 inhibitors, DGAT1 / 2 inhibitors, diacylglycerol O-acyltransferase 1 inhibitors (DGAT1), cytochrome P4502E1 inhibitors (CYP2E1), CXCR4 chemokine antagonists, dihydroceramide δ4 desaturase inhibitors, dihydrolactate dehydrogenase inhibitors, dipeptidyl peptidase IV inhibitors, endothelin modulators, eotaxin ligand inhibitors, extracellular matrix protein modulators, farnesoid X receptor agonists, fatty acid synthase inhibitors, FGF1 receptor agonists, fibroblast growth factor (FGF-15, FGF-19, FGF-21) ligands, fibroblast activation protein inhibitors, free fat Acid receptor 1 agonist, galectin-3 inhibitor, GDNF family receptor alpha-like agonist, glucagon receptor agonist, glucagon-like peptide 1 agonist, glucocorticoid receptor antagonist, glucose 6-phosphate 1-dehydrogenase inhibitor, G-protein coupled bile acid receptor 1 agonist, G-protein coupled receptor 119 agonist, G-protein coupled receptor 84 antagonist, hedgehog (Hh) modulator, hepatitis C virus NS3 protease inhibitor, hepatocyte nuclear factor 4 alpha regulator (HNF4A), hepatocyte growth factor regulator, histone deacetylase inhibitor, STAT-3 modulator, HMG-CoA reductase inhibitor, HSD17B13 gene inhibitor, 5-HT 2a receptor antagonists, hydrolase inhibitors, hypoxia-inducible factor-2α inhibitors, IL-10 agonists, IL-17 antagonists, IL-22 agonists, ileal sodium-bile acid cotransporter inhibitors, insulin sensitizers, insulin ligand agonists, insulin receptor agonists, integrin modulators, integrin antagonists, integrin α-V / β-1 antagonists, integrin α-V / β-6 antagonists, interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors, IL-6 receptor agonists, interleukin-17 ligand inhibitors, Jak2 tyrosine kinase inhibitors, Jun N-terminal kinase-1 inhibitors, Kelch-like ECH-related protein 1 modulators, ketohexokinase (KHK) inhibitors, Klothoβ stimulators, leukotriene A4 hydrolase inhibitors, 5-lipoxygenase inhibitors, lipoprotein lipase inhibitors, liver X receptor, LPL gene stimulators, lysophosphatidic acid-1 receptor antagonists, lysyl oxidase homolog 2 inhibitors, LXR inverse agonists, macrophage mannose receptor 1 modulators, matrix metalloproteinase (MMPs) inhibitors, MEKK-5 protein kinase inhibitors, MCH receptor 1 antagonists, membrane copper amine oxidase (VAP-1) inhibitors, methionine aminopeptidase-2 inhibitors, methyl CpG binding protein 2 modulators,MicroRNA-132 (miR-132) antagonists, MicroRNA-21 (miR-21) inhibitors, mitochondrial uncouplers, mixed lineage kinase-3 inhibitors, motile sperm domain protein 2 inhibitors, myelin basic protein stimulators, NACHT LRR PYD domain protein 3 (NLRP3) inhibitors, NAD-dependent deacetylase sirtuin stimulators, NADPH oxidase inhibitors (NOX), NFE2L2 gene inhibitors, nicotinic acid receptor 1 agonists, opioid receptor μ antagonists, P2Y13 purinergic receptor agonists, nuclear erythroid 2-related factor 2 agonists, nuclear receptor modulators, P2X7 purinergic receptor modulators, PACAP type I receptor agonists, PDE3 inhibitors, PDE4 inhibitors, PDE 5 inhibitors, PDGF receptor β modulators, phenylalanine hydroxylase stimulators, phospholipase C inhibitors, phosphodiesterase inhibitors, PPARα agonists, PPARδ agonists, PPARγ agonists, peptidylprolyl cis-trans isomerase A inhibitors, PNPLA3 gene inhibitors, PPARγ modulators, protease-activated receptor-2 antagonists, protein kinase modulators, protein NOV homology regulators, PTGS2 gene inhibitors, renin inhibitors, resistin / CAP1 (adenylate cyclase-associated protein 1) interaction inhibitors, Rho-associated protein kinase inhibitors, S-nitrosylated glutathione reductase (GSNOR) enzyme inhibitors, sodium glucose transporter-2 inhibitors, sphingolipid delta 4 desaturase DES1 inhibitors, S REBP transcription factor inhibitors, STAT-1 inhibitors, stearoyl-CoA desaturase-1 inhibitors, STK25 inhibitors, cytokine signaling inhibitor-1 stimulators, cytokine signaling inhibitor-3 stimulators, telomerase stimulators, TERT gene modulators, TGF-β (TGFB1) ligand inhibitors, TNF antagonists, transforming growth factor β (TGF-β), transforming growth factor β-activated kinase 1 (TAK1), thyroid hormone receptor β agonists, TLR-4 antagonists, transglutaminase inhibitors, tyrosine kinase receptor modulators, GPCR modulators, nuclear hormone receptor modulators, TLR-9 antagonists, VDR agonists, WNT modulators or YAP / TAZ modulators and zonulin inhibitors.

[0243] Non-limiting examples of one or more additional therapeutic agents include:

[0244] -ACE inhibitors, such as enalapril;

[0245] - aldehyde dehydrogenase inhibitors, such as ADX-629;

[0246] -Acetyl-CoA carboxylase (ACC) inhibitors, such as NDI-010976 (firsocostat), DRM-01, gemcabene, GS-834356, PF-05175157, QLT-091382, PF-05221304;

[0247] -Acetyl-CoA carboxylase / diacylglycerol O-acyltransferase 2 inhibitors, such as PF-07055341;

[0248] - Adenosine receptor agonists, such as CF-102 (namodason), CF-101, CF-502, CGS21680;

[0249] - Adenosine A3 receptor antagonists, such as FM-101;

[0250] - Adiponectin receptor agonists, such as ADP-355, ADP-399;

[0251] -Adrenergic receptor antagonists, such as bromocriptine, phentermine, VI-0521

[0252] - aldehyde dehydrogenase 2 stimulators, such as FP-045;

[0253] - alpha-glucosidase inhibitors (such as voglitose, acarbose, or miglitol);

[0254] - Amylin / calcitonin receptor agonists, such as KBP-042, KBP-089;

[0255] -AMP-activated protein kinase stimulators, such as C-455, PXL-770, O-304;

[0256] -AMP kinase activators / ATP citrate lyase inhibitors, such as bepedic acid (ETC-1002, ESP-55016) -AMP-activated protein kinase / endothelial nitric oxide synthase / NAD-dependent deacetylase sirtuin-1 stimulators, such as NS-0200 (leucine + metformin + sildenafil); -Androgen receptor agonists, such as LPCN-1144, LPCN-1148, testosterone prodrugs; -Angiotensin II AT-1 receptor antagonists, such as irbesartan; Angiopoietin-related protein-3 inhibitors, such as vupanorsen (IONI-ANGPTL3-LRx);

[0257] -Apelin receptor agonists, such as CB-5064 and MBT-2;

[0258] -Autophagy protein modulators, such as A-2906;

[0259] - Autotaxin (ectonucleotide pyrophosphatase / phosphodiesterase 2 (NPP2 or ENPP2)) inhibitors, such as FP10.47, PAT-505, PAT-048, GLPG-1690, X-165, PF-8380, TJC-0265, TJC-0316, AM-063, BBT-877;

[0260] -Axl tyrosine kinase receptor inhibitors, such as bemotinib (BGB-324, R-428);

[0261] - Bax protein stimulators, such as CBL-514;

[0262] - Bioactive lipids, such as DS-102;

[0263] - Cannabinoid receptor modulators, such as nabciximab (nimoxibulin), GWP-42004, REV-200, CRB-4001, INV-101, SCN-002;

[0264] - Caspase inhibitors, such as enricasin;

[0265] - Pan-cathepsin B inhibitors, such as VBY-376;

[0266] - Pan-cathepsin inhibitors, such as VBY-825;

[0267] -CCK receptor antagonists, such as proglumide;

[0268] - CCL26 gene inhibitors, such as mosimod, KDDF-201410-10;

[0269] -CCR2 / CCR5 chemokine antagonists, such as BMS-687681, cilniciclovir, maraviroc, CCX-872, lelizumab, WXSH-0213;

[0270] -CCR2 / CCR5 chemokine antagonists and FXR agonists, such as LJC-242 (topifiso + cenewiro); -CCR2 chemokine antagonists, such as propiongermanium;

[0271] -CCR2 chemokine / angiotensin II AT-1 receptor antagonists, such as DMX-200, DMX-250;

[0272] - CCR3 chemokine antagonists, such as bacitrazumab;

[0273] -CD3 antagonists, such as NI-0401 (forumab);

[0274] -CDGSH iron-sulfur domain protein modulators, such as EYP-002;

[0275] - Chitinase inhibitors, such as OATD-01;

[0276] - Chitotriosidase 1 inhibitors, such as OAT-2068;

[0277] - Chloride channel stimulators, such as cobalaprostone and rubiprostone;

[0278] - Casein kinase-1 (CK1) delta / epsilon inhibitors, such as PF-05006739;

[0279] - Connective tissue growth factor ligand inhibitors, such as PBI-4050;

[0280] -CXCR4 chemokine antagonists, such as AD-214;

[0281] - diglyceride acyltransferase 2 (DGAT2) inhibitors, such as IONIS-DGAT2Rx, PF-06865571;

[0282] - diglyceride acyltransferase 1 (DGAT1) inhibitors, such as GSK-3008356;

[0283] - Diacylglycerol O-acyltransferase 1 (DGAT1) / cytochrome P4502E1 (CYP2E1) inhibitors, such as SNP-610;

[0284] -Dihydroorotate dehydrogenase inhibitors, such as vedofrudine;

[0285] -Dipeptidyl peptidase IV inhibitors, such as linagliptin and ipragliptin;

[0286] -Eotaxin ligand inhibitors, such as bacitrazumab, CM-101;

[0287] - Extracellular matrix protein modulators, such as CNX-024;

[0288] - Farnesoid X receptor (FXR) agonists, such as AGN-242266, AGN-242256, ASC-42, EDP-297 (EP-024297), RDX-023, BWL-200, AKN-083, EDP-305, GNF-5120, cilofexol tromethamine (GS-9674), HPG-1860, IOT-022, LMB-763, phenylcholic acid, Px-102, Px-103, M790, M780, M450, M-480, MET-409, MET-642, PX20606, SYHA-1805, vonafexor (EYP-001), TERN-101, TC-100, INT-2228, TQA-3526, ZG-5266;

[0289] - Farnesoid X receptor (FXR) / G protein-coupled bile acid receptor 1 (TGR5) agonists, such as INT-767;

[0290] -Fatty acid synthase inhibitors, such as TVB-2640, FT-8225;

[0291] - Fibroblast growth factor 19 (rhFGF19) / cytochrome P450 (CYP) 7A1 inhibitors, such as aldafermin (NGM-282);

[0292] - Fibroblast growth factor 21 (FGF-21) ligand modulators, such as AP-025, BMS-986171, B-1654, BIO89-100, BOS-580,

[0293] -Pegbelfermin(BMS-986036), B-1344;

[0294] - Fibroblast growth factor 21 (FGF-21) / glucagon-like peptide 1 (GLP-1) agonists, such as YH-25723 (YH-25724; YH-22241), iluxiframine (AKR-001);

[0295] - FGF receptor agonists / Klothoβ stimulators, such as BFKB-8488A (RG-7992);

[0296] - Free fatty acid receptor 1 agonists, such as SCO-267;

[0297] -Galectin-3 inhibitors, such as belaglutinin (GR-MD-02), GB-1107 (Gal-300), GB-1211 (Gal-400);

[0298] - GDNF family receptor alpha-like agonists, such as NGM-395

[0299] - Glucagon-like peptide 1 (GLP-1R) agonists, such as ALT-801, AC-3174, liraglutide, costatin (MEDI-0382), SAR-425899, LY-3305677, HM-15211, YH-25723, YH-GLP1, RPC-8844, PB-718, PF-06882961, semaglutide;

[0300] - Glucagon-like peptide 1 receptor agonists; Oxymodulin ligands; Glucagon receptor agonists, such as efinopegdutide;

[0301] -Gastric inhibitory polypeptide / glucagon-like peptide-1 (GIP / GLP-1) receptor co-agonists, such as tiriparatide (LY-3298176);

[0302] -PEGylated long-acting glucagon-like peptide-1 / glucagon (GLP-1R / GCGR) receptor dual agonists, such as DD-01;

[0303] - Glucagon / GLP1 receptor agonists, such as BI-456906;

[0304] - glucocorticoid receptor antagonists, such as CORT-118335 (millikrone);

[0305] - Glucose 6-phosphate 1-dehydrogenase inhibitors, such as ST001;

[0306] -Glucokinase stimulators, such as doxagliliptin, vagliflozin (RO-5305552)

[0307] - G protein-coupled bile acid receptor 1 (TGR5) agonists, such as RDX-009, INT-777, and HY-209;

[0308] - G protein-coupled receptor 84 antagonists, such as PBI-4547;

[0309] - G protein-coupled receptor 119 agonists, such as DA-1241;

[0310] - Heat shock protein 47 (HSP47) inhibitors, such as ND-L02-s0201;

[0311] - Hedgehog and / or TGF-β ligand inhibitors, such as Oxy-210

[0312] - Histone deacetylase inhibitors / STAT-3 modulators, such as SFX-01;

[0313] -HMG-CoA reductase inhibitors, such as atorvastatin, fluvastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin;

[0314] -HSD17B13 gene inhibitors, such as ALN-HSD, ARO-HSD

[0315] - Hydrolase inhibitors, such as ABD-X;

[0316] - Hypoxia-inducible factor-2α inhibitors, such as PT-2567;

[0317] -IL-10 agonists, such as polyethylene glycol-iloticus;

[0318] -Ileal sodium-bile acid co-transport inhibitors, such as odevixibat (A-4250), walixibate potassium glycolate hydrate (SHP-262), GSK2330672, CJ-14199, eloxibat (A-3309); -Insulin sensitizers, such as KBP-042, azaimidazole potassium (MSDC-0602K), ion-224, MSDC-5514, Px-102, RG-125 (AZD4076), tolimidene, VVP-100X, CB-4211, ETI-101, pioglitazone;

[0319] - Insulin ligands / insulin receptor agonists, such as ORMD-0801;

[0320] - Integrin antagonists, such as IDL-2965;

[0321] -IL-6 receptor agonists, such as KM-2702;

[0322] - Dual inhibitors of integrin α-V / β-6 and α-V / β-1; for example, PLN-74809;

[0323] - Interleukin 17 ligand inhibitors, such as nitrazepam

[0324] -Jak1 / 2 tyrosine kinase inhibitors, such as baricitinib

[0325] -Jun N-terminal kinase-1 inhibitors, such as CC-90001

[0326] - Kelch-like ECH-related protein 1 modulators, such as α-cyclodextrin-stabilized sulforaphane;

[0327] - Ketohexokinase (KHK) inhibitors, such as PF-06835919, LY-3478045;

[0328] -β-Klotho (KLB)-FGF1c agonists, such as MK-3655 (NGM-313);

[0329] - Leukotriene A4 hydrolase inhibitors, such as LYS-006;

[0330] -5-lipoxygenase inhibitors, such as tepirukast (MN-001), epoluton (DS-102, (AF-102); -lipoprotein lipase inhibitors, such as CAT-2003;

[0331] - LPL gene stimulators, such as alipokine;

[0332] - Liver X receptor (LXR) inhibitors, such as PX-665, PX-L603, PX-L493, BMS-852927, T-0901317, GW-3965, SR-9238;

[0333] - Lysophosphatidic acid-1 receptor antagonists, such as BMT-053011, UD-009 (CP-2090), AR-479, ITMN-10534, BMS-986020, KI-16198;

[0334] - Lysyl oxidase homolog 2 inhibitors, such as cintuzumab, PXS-5382A (PXS-5338); - Macrophage mannose receptor 1 modulators, such as temanocept-Cy3 (technetium Tc 99m temanocept);

[0335] -Matrix metalloproteinase inhibitors, such as ALS-L1023;

[0336] - Membrane copper amine oxidase (VAP-1) inhibitors, such as TERN-201 and TT-01025; - MEKK-5 protein kinase (ASK-1) inhibitors, such as CJ-16871, CS-17919, silanol (GS-4997), SRT-015, GS-444217, GST-HG-151, and TERN-301;

[0337] -MCH receptor-1 antagonists, such as CSTI-100 (ALB-127158);

[0338] - Semicarbazide-sensitive amine oxidase / vascular adhesion protein-1 (SSAO / VAP-1) inhibitors, such as PXS-4728A (BI-1467335);

[0339] -Methionine aminopeptidase-2 inhibitors, such as ZGN-1061, ZGN-839, ZN-1345;

[0340] -Methyl CpG binding protein 2 modulators, such as thiols;

[0341] -Mineralocorticoid receptor antagonists (MCRA), such as MT-3995 (aparetone);

[0342] - Mitochondrial uncouplers, such as 2,4-dinitrophenol, HU6, Mito-99-0053;

[0343] - Mixed lineage kinase-3 inhibitors, such as URMC-099-C;

[0344] - Motile sperm domain protein 2 inhibitors, such as VB-601;

[0345] -Myelin basic protein stimulators, such as olesulfonamide;

[0346] -Myeloperoxidase inhibitors, such as PF-06667272, AZM-198;

[0347] -NADPH oxidase inhibitors, such as GKT-831, GenKyoTex, APX-311, setanercept;

[0348] - Nicotinic acid receptor 1 agonists, such as ARI-3037MO;

[0349] -NACHT LRRPYD domain protein 3 (NLRP3) inhibitors, such as KDDF-201406-03, NBC-6, IFM-514, JT-194 (JT-349);

[0350] -NFE2L2 gene inhibitors, such as GeRP-amiR-144

[0351] - Nuclear receptor modulators, such as DUR-928 (DV-928);

[0352] - Opioid receptor β antagonists, such as methylnaltrexone;

[0353] - P2X7 purinergic receptor modulators, such as SGM-1019;

[0354] -P2Y13 purinergic receptor agonists, such as CER-209;

[0355] - PDE 3 / 4 inhibitors, such as tipirukast (MN-001);

[0356] - PDE 5 inhibitors, such as sildenafil, MSTM-102;

[0357] -PDGF receptor β modulators, such as BOT-191, BOT-509;

[0358] - Peptidylprolyl cis-trans isomerase inhibitors, such as CRV-431 (CPI-432-32), NVP-018, NV-556 (NVP-025);

[0359] -Phenylalanine hydroxylase stimulators, such as heparin;

[0360] - Phosphodiesterase inhibitors, such as ZSP-1601;

[0361] - PNPLA3 gene inhibitors, such as AZD-2693;

[0362] - PPAR agonists, such as chiglitazole, elabenot (GFT-505), celadepa lysine (MBX-8025), deuterated pioglitazone R-enantiomer, pioglitazone, PXL-065 (DRX-065),

[0363] Sarogreza, Ranilano (IVA-337), CHS-131, Pemabet (K-877), ZG-0588, ZSP-0678; ZSYM-008;

[0364] - protease-activated receptor-2 antagonists, such as PZ-235;

[0365] - Protein kinase modulators, such as CNX-014;

[0366] - Protein NOV homologous regulators, such as BLR-200;

[0367] -PTGS2 gene inhibitors, such as STP-705 and STP-707;

[0368] - Renin inhibitors, such as PRO-20;

[0369] - Resistin / CAP1 (adenylate cyclase-associated protein 1) interaction inhibitors, such as DWJ-211

[0370] -Rev protein modulators, such as ABX-464;

[0371] - Rho-associated protein kinase (ROCK) inhibitors, such as REDX-10178 (REDX-10325), KD-025, RXC-007, TDI-01;

[0372] - Glutathione reductase (GSNOR) inhibitors, such as SL-891;

[0373] - Sodium glucose transporter-2 (SGLT2) inhibitors, such as epraglipizide, epraglipizide, ertegliflozin, dapagliflozin, tofogliflozin, sotagliflozin,

[0374] - sodium-glucose transporter-1 / 2 (SGLT 1 / 2) inhibitors, such as liraglutide di(proline) (LIK-066);

[0375] -SREBP transcription factor inhibitors, such as CAT-2003, HPN-01, MDV-4463;

[0376] - Stearoyl-CoA desaturase-1 inhibitors, such as linalool;

[0377] -Thyroid hormone receptor beta agonists, such as ALG-009, ASC-41, CNPT-101101; CNPT-101207, CS-27186, KY-41111, resmetirol (MGL-3196), MGL-3745, TERN-501, VK-2809;

[0378] -TLR-2 / TLR-4 antagonists, such as VB-201 (CI-201);

[0379] -TLR-4 antagonists, such as JKB-121, JKB-122, naltrexone;

[0380] -Tyrosine kinase receptor modulators, such as CNX-025, GFE-2137 (repurposed nitrazopyranil);

[0381] -TLR-9 antagonists, such as GNKS-356

[0382] -TNF antagonists, such as ALF-421

[0383] - GPCR modulators, such as CNX-023;

[0384] - Nuclear hormone receptor modulators, such as Px-102;

[0385] - VDR agonists, such as CK-15;

[0386] -Xanthine oxidase inhibitors, such as ACQT-1127;

[0387] - Xanthine oxidase / urate anion exchanger 1 (URAT1) inhibitors, such as RLBN-1001, RLBN-1127; and

[0388] -Zonin inhibitors, such as lauroxetine acetate (INN-202).

[0389] In some embodiments, the one or more additional therapeutic agents are selected from A-4250, AC-3174, acetylsalicylic acid, AK-20, alipegin, AMX-342, AN-3015, anti-TAGE antibodies, arachidylaminocholanic acid, ARI-3037MO, ASP-8232, AZD-2693, betilimumab, anhydrous betaine, BI-1467335, BMS-986036, BMS-986171, BMT-053011, BOT-191, BTT-1023, budesonide, BX-003, CAT-2003, cilniciclovir, CBW-511, CER-209, CF-102, CGS21680, CNX-014, CNX-023, CNX-024, CNX-025, cobiprostone, colesevelam hydrochloride, dabigatran etexilate mesylate, dapagliflozin, DCR-LIV1, R-enantiomer of deuterated pioglitazone, 2,4-dinitrophenol, DRX-065, DS-102, DUR-928, EDP-305, elafibrano (GFT-505), enlicasin, enalapril, erpagliflozin, emigliptin, F-351, fluostezone (ST-002), FT-4101, GDD-3898, GH-509, GKT-831, GNF-5120, GRI-0621, GR-MD-02, GS-300, GS-49 97, GS-9674, HEC-96719, HTD-1801, HS-10356, HSG-4112, HST-202, HST-201, HU-6, hydrochlorothiazide, ixalbutamate (PRC-4016), eicosapentaenoic acid ethyl, IMM-124-E, INT-767, IN-240, IONIS-DGAT2Rx, ipagliptin, irbesartan, propagermanium, IVA-337, J2H-1702, JKB-121, KB-GE-001, KBLP-004, KBLP-009, KBP-042, KD-025, M790, M780, M450, metformin, sildenafil, LB-7 00, LC-280126, linagliptin, liraglutide, (LJN-452) (topifexol), LM-011, LM-002 (CVI-LM-002), LMB-763, LYN-100, MB-N-008, MBX-8025, MDV-4463, mercaptoamine, MGL-3196, MGL-3745, MP-301, MSDC-0602K, namacizumab, NC-101, NDI-010976, ND-L02-s0201 (BMS-986263), NGM-282, NGM-313, NGM-386, NGM-395, NP-011, NP-135,NP-160, norursodeoxycholic acid, NV-422, NVP-022, O-304, obeticholic acid (OCA), 25HC3S, olesoxime, PAT-505, PAT-048, PBI-4547, pegylated interleukin-10, pioglitazone, pirfenidone, PRI-724, PX20606, Px-102, PX-L603, PX-L493, PXS-472 8A, PZ-235, PZH-2109, RCYM-001, RDX-009, repagliflozin, RG-125 (AZD4076), RPI-500, S-723595, sarcogliflozin magnesium salt, SBP-301, semaglutide, SH-2442, SHC-028, SHC-023, cintuzumab, solithromycin, sogliflozin, statins (atorvastatin, fluvastatin, Pitavastatin, Pravastatin, Rosuvastatin, Simvastatin), Symbiotics, TCM-606F, TEV-45478, TQA-3526, TQA-3563, Telukast (MN-001), TLY-012, TRX-318, TVB-2640, TXR-612, TS-20004, UD-009, UN-03, Ursodeoxycholic Acid, VBY-376, VBY-825, VK-2809, Vimodegib, Wallisibat Glycolate Potassium Hydrate (SHP-626), VVP-100X, WAV-301, WNT-974, WXSH-0038, WXSH-0078, XEN-103, XRx-117, XTYW-003, XW-003, XW-004, ZGN-839, ZG-5216, ZSYM-008, ZYSM-007.

[0390] In some embodiments, the compounds of the present application are combined with one or more therapeutic agents selected from the group consisting of anti-obesity therapeutic agents, peptide YY or its analogs, neuropeptide Y receptor type 2 (NPYR2) agonists, NPYR1 agonists, NPYR5 antagonists, cannabinoid receptor type 1 (CB1R) antagonists, lipase inhibitors (e.g., orlistat), human insulin peptide (HIP), melanocortin receptor 4 agonists (e.g., semaphoride), antagonists of melanin concentrating hormone receptor 1, farnesoid X receptor (FXR) agonists (e.g., obeticholic acid), apoptosis inhibitors. signal-regulated kinase (ASK-1) inhibitors, zonisamide, phentermine (alone or in combination with topiramate), norepinephrine / dopamine reuptake inhibitors (such as baclofen), opioid receptor antagonists (such as naltrexone), combinations of norepinephrine / dopamine reuptake inhibitors and opioid receptor antagonists (such as baclofen and naltrexone), GDF-15 analogs, sibutramine, cholecystokinin agonists, amylase and its analogs (such as pramlint), leptin and its analogs (such as thyroxine), serotonergic agents (such as lorcaserin), methionine aminopeptidase 2 (Met AP2) inhibitors (such as bilonib or ZGN-1061), phendimetrazine, amfepramone, benzphetamine, SGLT2 inhibitors (such as empagliflozin, canagliflozin, dapagliflozin, ipragliflozin, togliflozin, sergliflozin etabonate, repagliflozin etabonate, or erpagliflozin), SGLTL1 inhibitors, dual SGLTL2 / SGLT1 inhibitors, fibroblast growth factor receptor (FGFR) modulators, AMP-activated protein kinase (AMPK) activators, biotin, MAS receptor modulators, glucagon receptor agonists (used alone or with another GLP-1R agonists are used in combination, such as liraglutide, exenatide, dulaglutide, albiglutide, lixisenatide, or semaglutide), insulin sensitizers such as thiazolidinediones (TZDs), peroxisome proliferator-activated receptor alpha (PPARα) agonists, fish oils, acetyl coenzyme (ACC) inhibitors, transforming growth factor β (TGFβ) antagonists, GDNF family α receptor (GFRAL) agonists, melanocortin-4 receptor (MC4R) agonists, including pharmaceutically acceptable salts of the specifically named agents and pharmaceutically acceptable solubilized substances of the agents and salts. Example

[0391] synthesis

[0392] The compounds of the present disclosure can be prepared using the methods disclosed herein and conventional modifications thereof, which are obvious in view of the methods disclosed herein and methods well known in the art. In addition to the teachings herein, conventional and well-known synthetic methods can also be used. The synthesis of typical compounds of Formula IA-1 or pharmaceutically acceptable salts thereof, such as compounds having one or more structures described in Formula IA-1, or other formulas or compounds disclosed herein, can be accomplished as described in the following examples.

[0393] General Synthesis Methods

[0394] Typical embodiments of compounds according to the present disclosure can be synthesized using the general reaction schemes and / or examples described below. In view of the description herein, it is apparent that the general scheme can be altered by replacing the starting materials with other materials having similar structures, thereby producing correspondingly different products. The synthesis description that follows provides many examples of how the starting materials are varied to provide corresponding products. The starting materials are typically obtained from commercial sources or synthesized using published methods for synthesizing compounds that are embodiments of the present disclosure, and inspection of the structure of the compound to be synthesized will provide the identity of each substituent, and in view of the examples here, the identity of the final product will typically make the identity of the necessary starting materials apparent through a simple inspection process. The group labels (such as R1, R2) used in the reaction schemes herein are for illustrative purposes only and, unless otherwise stated, are not necessarily consistent in name or function with labels used elsewhere to describe compounds of the general formula IA-1 or aspects or fragments thereof.

[0395] Synthesis reaction parameters

[0396] The compounds disclosed herein can be prepared from readily available starting materials using, for example, the following general methods and procedures. It will be appreciated that typical or preferred process conditions (i.e., reaction temperature, time, molar ratio of reactants, solvent, pressure, etc.) are given; unless otherwise indicated, other process conditions may also be used. The optimal reaction conditions may vary with the use of specific reactants or solvents, but such conditions can be determined by those skilled in the art through conventional optimization procedures.

[0397] In addition, for those skilled in the art, traditional protecting groups may be necessary to prevent certain functional groups from undesirable reactions. Protecting groups for various functional groups and suitable conditions for protecting and deprotecting specific functional groups are well known in the art. For example, many protecting groups are described in TW Greene and GM Wuts (1999) Protecting Groups in Organic Synthesis, 3rd edition, Wiley, New York, and the literature cited therein.

[0398] In addition, the compounds of the present disclosure may contain one or more chiral centers. Therefore, if desired, such compounds may be prepared or separated into pure stereoisomers, i.e., as single enantiomers or diastereomers or as a mixture enriched in stereoisomers. Unless otherwise indicated, all of these stereoisomers (and enriched mixtures) are included within the scope of this statement. Pure stereoisomers (or enriched mixtures) may be prepared with, for example, optically active starting materials or stereoselective reagents well known in the art. In addition, the racemic mixture of such compounds may be separated with, for example, chiral column chromatography, chiral decomposition agents, etc.

[0399] The starting materials for the following reactions are generally known compounds or can be prepared by known procedures or obvious modifications thereof. For example, many starting materials are available from commercial suppliers, such as Aldrich Chemical Co. (Milwaukee, Wisconsin, USA). Others can be prepared by procedures described in standard references or obvious modifications thereof, such as Fieser's Organic Synthetic Reagents: Volumes 1-15 (John Wiley and Sons, 1991); Rodd's Chemistry of Carbon Compounds: Volumes 1-5, and Supplementary Editions (Elsevier Science Publishers, 1989); Organic Reactions Volumes 1-40 (John Wiley and Sons, 1991), March's Advanced Organic Chemistry (John Wiley, and Sons, Fifth Edition, 2001), and Larock's Comprehensive Organic Transformations (VCH Publishing Company, 1989).

[0400] The term "solvent", "inert organic solvent" or "inert solvent" refers to an inert solvent under the reaction conditions associated therewith (for example, including benzene, toluene, acetonitrile, tetrahydrofuran ("THF"), N,N-dimethylformamide ("DMF"), chloroform, dichloromethane (or methylene chloride), diethyl ether, methanol, pyridine, etc.). Unless otherwise specified, the solvent used in the reactions of the present disclosure is an inert organic solvent, and the reactions are carried out under an inert gas, preferably nitrogen.

[0401] The term "qs" refers to the addition of an amount sufficient to achieve a stated function, eg, to bring a solution to a desired volume (ie, 100%).

[0402] The compounds provided herein can be synthesized according to the general schemes provided below. In the schemes below, it should be understood that each compound shown therein can have a protecting group as required in any step. Standard protecting groups are within the scope of those skilled in the art.

[0403] Example 1: Synthesis of Compounds of Formula IA-1

[0404] In another aspect, the present invention provides a method for preparing a compound of formula IA-1, a pharmaceutically acceptable salt, ester or stereoisomer thereof, which method includes six general routes (Route 1, Route 2, Route 3, Route 4, Route 5 and Route 6).

[0405] Route 1:

[0406]

[0407] Route 2:

[0408]

[0409] Route 3:

[0410]

[0411] Route 4:

[0412]

[0413] Route 5:

[0414]

[0415] Route 6:

[0416]

[0417] Preparation of intermediates The intermediates can be synthesized by the following five routes: Route 1

[0418]

[0419] Route 3

[0420]

[0421] Route 4

[0422]

[0423] Route 5

[0424]

[0425] Preparation of 3,7-dimethyl-1H-indazol-5-amine (Int A)

[0426]

[0427] At room temperature (RT), NIS (N-iodosuccinimide) (29.0 g, 1.1 eq.) was added to a solution of 5-bromo-7-methyl-1H-indazole (25.0 g) in DCE (1,2-dichloroethane) (200 mL), and the mixture was stirred at 80° C. for 12 hours. After cooling to room temperature, the reaction mixture was diluted with THF (tetrahydrofuran), washed with Na2S2SO3 (aq.) and brine. After drying over anhydrous Na2SO4 and concentrating, the desired product Int A-2 (35.0 g, yield: 87.7%) was obtained by washing with PE (petroleum ether) as a yellow solid.

[0428] Under stirring at 0°C, Int A-2 (40 g) and SemCl (40 g, 2.1 eq.) were added to THF (250 mL) solution, and NaH (11.5 g, 2.5 eq.) was added. The reaction mixture was stirred at 25°C for 2 hours, and water (300 ml) was added to quench the reaction mixture. The mixture was extracted with EA (ethyl acetate), and the organic phase was concentrated in vacuo to obtain Int A-3, 45.4 g, yield: 81.9%.

[0429] Pd2(dppf)Cl2 (0.9 g), K3PO4 (11.04 g, 2.7 eq.) and CH3B(OH)2 (1.96 g, 1.7 eq.) were added to a dioxane solution containing Int A-3 (9.0 g) under stirring at 25°C. The mixture was stirred at 95°C for 3 hours. After the mixture was cooled, the solid was filtered out, and the filtrate was concentrated in vacuo and purified by silica gel column chromatography (EA / PE) to obtain Int A-4 as a colored solid, 5.4 g, yield: 78.9%.

[0430] At room temperature, NH2Boc (5.2 g, 4 eq.), Cs2CO3 (14.4 g, 4 eq.), Pd2(dba)3 (1.2 g, 0.15 eq.) and X-phos (1.8 g, 0.3 eq.) were added to a solution of Int A-4 (4.0 g) in dioxane (100 mL), and the mixture was stirred at 100°C under nitrogen for 4 hours. After cooling to room temperature, water (100 mL) was added to quench the mixture, and the mixture was extracted with EA (100 ml x 2). The residue was purified by silica gel column chromatography (EA / PE = 1 / 40-1 / 10) to obtain Int A-5, 3.6 g, yield: 81.7%.

[0431] To a solution of Int A-5 (3.6 g) in MeOH (5 mL) was added HCl / EA (2 M, 10 mL). The mixture was stirred at 40°C for 4 h. A white solid was precipitated and filtered to give Int A, 1.4 g, yield: 94.5%. 1H NMR (500 MHz, CHLOROFORM-d) δ 11.40 (s, 1H), 6.85 (d, J = 2.2 Hz, 1H), 6.68 (d, J = 2.0 Hz, 1H), 4.35 (d, J = 5.1 Hz, 1H), 4.33 (d, J = 5.1 Hz, 1H), 2.95 (s, 3H), 2.65 (s, 3H).

[0432] Preparation of 7-fluoro-3-methyl-1H-indazol-5-amine (Int B)

[0433]

[0434] Int B-1 (5.0 g) and hydrazine hydrate solution (98%, 2.7 g, 2.5 eq) were added to NMP (N-methylpyrrolidone) (15 mL). The mixture was stirred at 150°C under nitrogen for 4 hours, cooled to room temperature, precipitated and filtered to obtain white solid Int B-2, 3.8 g, 78.0%.

[0435] The following series of reactions were carried out with reference to the preparation of Int A to obtain 7-fluoro-3-methyl-1H-indazol-5-amine.

[0436] Preparation of 3,7-dimethyl-1H-indazole-5-carboxylic acid (Int C)

[0437]

[0438] Int C-1 (2.0 g), trimethylamine (2.24 g, 2.5 eq), 2,2′-bis(diphenylphosphine)-1,10-binaphthyl (0.55 g, 0.1 eq) and PdCl2 (0.31 g, 0.2 eq) were added to a mixed solution of methanol (20 mL) and acetonitrile (20 mL), and the mixture was placed under a carbon monoxide (40 bar) environment and vigorously stirred at 100° C. for 18 hours. The reaction mixture was cooled to room temperature, opened to the atmosphere, filtered through diatomaceous earth, the solvent was removed under vacuum, and NaOH solution (4 M, 5 mL) was added to the filtrate and stirred for 30 min. HCl (2 M) was added to the mixture to adjust the pH to 6, and a white solid was precipitated, which was filtered to obtain Int C, 0.7 g, yield: 41.4%. 1 H NMR (500 MHz, chloroform-d) δ 8.44 (d, J = 2.2 Hz, 1H), 7.84 (d, J = 2.0 Hz, 1H), 2.97 (s, 3H), 2.66 (s, 3H).

[0439] Preparation of 3-cyclopropyl-7-methyl-1H-indazol-5-amine (Int D)

[0440]

[0441]

[0442] To a solution of boron trichloride (20 mL, 0.02 mol, 1 M, dissolved in toluene) in dichloromethane was added a solution of 2-isopropylaniline (Int D-1, 2.14 g, 0.02 mol) in 1,2-dichloroethane (10 mL) at 0°C. Aluminum chloride (2.96 g, 0.022 mol) and cyclopropanenitrile (2.01 g, 0.03 mol) were added to the mixture, and the reaction mixture was refluxed at 80°C for 20 h. The reaction mixture was cooled to 0°C, and then 2N HCl (10 mL) was added. The reaction mixture was heated to 80°C and stirred for 30 minutes. The reaction mixture was cooled to room temperature, extracted with dichloromethane, and the organic layer was washed with 1N NaOH (10 mL) and saturated brine, dried over anhydrous MgSO4, concentrated under reduced pressure to remove the solvent, and the residue was purified by flash column chromatography to obtain the title compound Int D-2 (2.1 g, 60%) as a yellow solid.

[0443] At 0°C, Int D-2 (2.0 g, 11.4 mmol) was added to a H2SO4 (98%, 8 mL) solution, and KNO3 (1.38 g, 13.7 mmol) was slowly added and stirred for 2 hours. The mixture was slowly added to ice water (50 mL), and ethyl acetate (50 mL) was added for extraction to generate an organic layer. The organic layer was removed by concentration under reduced pressure to obtain Int D-3 (1.9 g, 76%) as a yellow solid.

[0444] At 0℃, under nitrogen conditions, To an aqueous solution (2 mL) of D-3 (1.9 g, 8.6 mmol) and hydroxylamine hydrochloride (1.8 g, 25.8 mmol) and ethanol (8 mmol) was added sodium hydroxide (2.7 g, 68.8 mmol), and the mixture was refluxed at 80°C for 1 hour. The mixture was concentrated, water (14 mL) was added, and the mixture was extracted with ethyl acetate (20 mL×2) to obtain an organic layer, which was concentrated in vacuo. The concentrate was dissolved in dichloromethane (10 mL), triethylamine (1.74 g, 17.2 mmol) was slowly added, and the mixture was stirred at ambient temperature for 15 minutes, and then cooled to 05°C in an ice / water bath; methanesulfonyl chloride (1.25 g, 10.9 mmol) was added to 30 mL of dichloromethane, and the resulting solution was cooled to 0-5°C, and the cold methanesulfonyl chloride solution was added dropwise to the mixture, and the mixture was stirred at 0-5°C for 1.5 hours. Silica gel was added, and the green / brown solution was concentrated by rotary evaporation. The residue was purified by flash column chromatography to obtain the title compound Int D-4 (1.65 g, 88%), as a yellow solid.

[0445] In a 50 mL single-necked round-bottom flask, a methanol (10 mL) solution containing Int D-4 (1.65 g, 7.6 mmol) and Pd / C (0.16 g, 10% w / w, 30% water) was added, and a hydrogen balloon was loaded onto the single-necked flask and stirred for 4 hours until the yellow color disappeared. After filtration, the filtrate was concentrated in vacuo to obtain Int D (1.25 g, 88%) as a brown oil. LCMS (ESI): C11H13N3[M+H]+: calculated value: 188.1, found value: 188.1. 1 H NMR (500 MHz, CHLOROFORM-d) δ 7.15 (d, J = 2.2 Hz, 1H), 6.84 (d, J = 2.2 Hz, 1H), 4.42-4.32 (m, 2H), 2.66 (s, 3H), 2.24-2.19 (m, 1H), 1.03-0.87 (m, 4H).

[0446] Preparation of 7-fluoro-3-methyl-1H-indazole-5-carboxylic acid (Int E)

[0447]

[0448] Boron trichloride (20 mL, 20 mmol, 1 M toluene solution) was added to a dichloromethane solution at 0°C, and a solution of 4-amino-3-fluorobenzenecarboxylic acid methyl ester (Int E-1, 3.38 g, 0.20 mol) in 1,2-dichloroethane (10 mL) was added with stirring. Aluminum chloride (2.94 g, 22 mol) and acetonitrile (1.2 g, 30 mmol) were added to the mixture, and the reaction mixture was refluxed at 80°C for 20 hours. After cooling, 2N HCl (10 mL) was added, and the reaction mixture was heated to 80°C and stirred for 30 minutes. The reaction mixture was then cooled to room temperature and extracted with dichloromethane. The organic layer was washed with 1N NaOH (10 mL) and brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure to remove the solvent. The residue was purified by flash column chromatography to give Int E-2 (2.98 g, 70.65%) as a yellow solid.

[0449] To a mixed solution of water (2 mL) and ethanol (8 mL) containing Int E-2 (2.0 g, 9.5 mmol) and hydroxylamine hydrochloride (1.97 g, 28.5 mmol) was added sodium hydroxide (2.3 g, 57.6 mmol) at 0°C under nitrogen, and the reaction solution was refluxed at 80°C for 1 hour. The mixture was concentrated, and the concentrate was dissolved in water (14 mL) and extracted with ethyl acetate (20 mL×2). The organic layer was separated, concentrated in vacuo and then dissolved in dichloromethane (10 mL), and triethylamine (1.6 g, 14.8 mmol) was slowly added. The reaction mixture was stirred at ambient temperature for 15 minutes, then cooled to 0-5°C in an ice / water bath, and methanesulfonyl chloride (1.08 g, 9.5 mmol) was added to 30 mL of dichloromethane, and the resulting solution was cooled to 0-5°C. The cold methanesulfonyl chloride solution was added dropwise to the mixed solution. The resulting solution was stirred at 0-5°C for 1.5 hours, silica gel was added and the green / brown solution was concentrated by rotary evaporation. Purification by flash column chromatography gave Int E-3 (1.43 g, 73%) as a yellow solid.

[0450] Int E-3 (1.43 g, 6.87 mmol) and NaOH (1.1 g, 27.5 mmol) were added to a mixed solution of methanol (10 mL) and water (5 mL), stirred at 60°C for 1 hour, cooled and concentrated in vacuo, the concentrate was dissolved in water (10 mL), 1N HCl was added to adjust the pH value to 7, and then ethyl acetate (20 mL×2) was added to extract to obtain an organic layer, which was concentrated under reduced pressure to remove the solvent to obtain a white solid IntE (1.25 g, 94%). LCMS (ESI): C9H7FN202; [M+H] + : Calculated value: 195.0, Measured value: 195.0. 1 H NMR (500 MHz, chloroform-d) δ 11.22 (s, 1H), 8.36 (d, J=2.2 Hz, 1H), 7.705 (dd, J=7.9, 2.0 Hz, 1H), 2.95 (s, 3H).

[0451] Preparation of tert-butyl (2-(chloromethyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazol-5-yl)carbamate (IntF)

[0452]

[0453]

[0454] Di-tert-butyl dicarbonate (30.88 g, 141.66 mmol) was added in portions to a tert-butanol solution (250 mL) containing Int F-1 (17.0 g, 108.97 mmol). The reaction solution was stirred at 55 °C for 8 hours. The resulting mixture was concentrated in vacuo, and the crude product was slurried with petroleum ether (300 ml) at 0 °C to give Int F-2 as a light white solid (26 g 93.2%), LCMS m / z 257.2 [M+H] + .

[0455] To a DMF (N,N-dimethylformamide) solution (30 mL) containing intermediate Int F-2 (2.56 g, 10 mmol) was added 1-(1-ethyl-1H-imidazol-5-yl)methanamine dihydrochloride (2.18 g, 11 mmol) and K2CO3 (6.95 g, 50 mmol). The reaction mixture was stirred at 70°C for 16 hours, poured into water (300 mL), and then extracted with EtOAc (2 x 400 mL), the combined organic solution was washed with saturated brine (2 x 200 mL), dried over Na2SO4, filtered and concentrated under reduced pressure, and the crude product was purified by flash chromatography (0-5% MeOH / DCM (dichloromethane)) to give Int F-3 (2.2 g, 61%) as a light red solid, LCMS m / z 362.40 [M+H] + .

[0456] IntF-3 (181 mg, 0.501 mmol) was suspended in MeOH (150 ml), 10% palladium on carbon (20 mg) was added, and the mixture was stirred at room temperature under 50 psi H2 for 1 hour. The mixture was filtered and the filtrate was concentrated under reduced pressure to give Int F-4 (154 mg, 93%) as a light brown solid, which was used directly in the next step. LCMS m / z 332.20 [M+H+].

[0457] 2-Chloro-1,1,1-trimethoxyethane (143 mg, 0.93 mmol) and pyridin-1-ium 4-methylbenzenesulfonate (23.2 mg, 0.093 mmol) were added to a solution of Int F-4 (123 mg, 0.37 mmol) in MeCN (5 mL), and the mixture was heated to 70°C for 1 hour. The reaction was cooled to room temperature, concentrated under reduced pressure, triturated in 50% EtOAc / heptane, filtered, and the resulting brown solid Int F (102 mg, 70%) was collected. LCMS m / z 390.10 [M+H+].

[0458] Preparation of 2-bromo-6-((4-chloro-2-fluorobenzyl)oxy)pyridine (Int G)

[0459]

[0460] To a solution of intermediate Int G-1 (20.0 g, 124.6 mmol) in THF (150 mL) was added t-BuOK (21.0 g, 187 mmol), and the reaction mixture was stirred at 10-15°C for 45 min. Then, Int G-2 (20 g, 104 mmol) was added to the mixture and stirred at room temperature overnight. H2O (500 mL) was added and filtered to give Int G (22.0 g, yield: 79.7%).

[0461] Preparation of tert-butyl (2-(5-fluoro-2-(hydroxymethyl)-4-(4,4,5-trimethyl-1,3,2-dioxaborolan-2-yl)benzyl)-1-(((S)-oxolan-2-yl)methyl)-1H-benzo[d]imidazol-5-yl)carbamate (Int H)

[0462]

[0463]

[0464] Int H-1 (1.0 g, 2.88 mmol), Int H-2 (0.93 g, 3.17 mmol) and HATU (1.44 g, 3.45 mmol) were dissolved in N, N-dimethylformamide (10 mL), and N, N-diisopropylethylamine (2.5 mL, 14.4 mmol) was added, the mixture was stirred at room temperature for 1 hour, then diluted with saturated NH4CI aqueous solution (10 mL), and extracted with EtOAc (3x10 mL), the combined organics were dried over anhydrous MgSO4, concentrated in vacuo, and the resulting residue was dissolved in acetic acid (25 mL) and heated to 100°C for 1 hour. Thereafter, the mixture was cooled to room temperature, concentrated in vacuo, and the material was purified by normal phase column chromatography (eluent: EtOAc / PE) to give the product Int H-3 (1.2 g, yield: 66.9%).

[0465] Under nitrogen, Int H-3 (1.0 g, 1.92 mmol), bis(pinacolato)diboron (512.4 mg, 2.02 mmol), AcOK (282.3 mg, 2.88 mmol), Pd(dppf)Cl2 (139 mg, 0.2 mmol) were added to dioxane (10 mL), stirred at 90-95°C for 2 hours, cooled, added with water (10 mL) and extracted with EtOAc (3×10 mL), dried over anhydrous MgSO4, and concentrated in vacuo, the residue was purified by crystallization with EtOH (3 mL) to obtain Int H (0.85 g, yield: 78%). LCMS (ESI): C 30 H 39 Calculated for BFN306; [M+H] + : 568.3, measured value: 568.3.

[0466] Preparation of (S)-(2-(chloromethyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazol-5-yl)carbamate (IntI)

[0467]

[0468] Under stirring at 25°C, (Boc)2O (42.0 g, 192 mmol) was added to a solution of 4-fluoro-3-nitroaniline (15.0 g, 96.0 mmol) in tert-butyl alcohol (150 mL). The reaction mixture was heated to 40°C and stirred for 12 hours. The reaction solution was concentrated in vacuo, and the crude product was slurried with petroleum ether to obtain tert-butyl (4-fluoro-3-nitrophenyl)carbamate (21.6 g, yield 88%) as a yellow solid. LCMS (ESI): C 11 H 13 Calculated for FN2O4; [M+H] + : 256.2, measured value: 256.2.

[0469] To a stirred solution of [(2S)-oxepan-2-yl]methylamine (9.3 g, 106.5 mmol) and compound 2 (21.0 g, 81.9 mmol) in THF (150 mL) was added N-ethyl-N-isopropyl-propane-2-amine (26.5 g, 205.1 mmol) at 25°C. The reaction mixture was stirred at 60°C for 12 hours, and the mixture was diluted with EtOAc (100 mL) and H2O (200 mL). The layers were separated and washed with EtOAc (2x 4% ethanol). The aqueous layer was extracted with 100 mL of water, and the combined organic phases were washed with brine (200 mL), dried over anhydrous Na2SO4, filtered, and concentrated in vacuo. The crude product was slurried with methyl tert-butyl ether to give (S)-tert-butyl (3-nitro-4-((oxan-2-ylmethyl)amino)phenyl)carbamate (23.6 g, yield 89.1%) as a yellow solid. LCMS (ESI): C 15 H 21 N305 calculation; [M+H] + : 323.3, measured value: 323.3.

[0470] To a solution of compound Int I-3 (23.0 g, 71.1 mmol) in EtOAc:MeOH=1:1 (200 mL) was added 10% Pd / C (4.6 g) under stirring at 25°C. The reaction mixture was stirred at 25°C for 12 hours under hydrogen. The mixture was filtered, and the filter cake was washed with EtOAc (2x 100 mL). The combined organic phases were concentrated in vacuo to give (S)-tert-butyl (3-amino-4-((oxan-2-ylmethyl)amino)phenyl)carbamate (18.8 g, yield 90%) as a brown solid.

[0471] LCMS (ESI): C 15 H 23 Calculated for N3O3; [M+H] + : 293.4, measured value: 293.4.

[0472] To a solution of tert-butyl (S)-(3-amino-4-((oxan-2-ylmethyl)amino)phenyl)carbamate (18.0 g, 61.4 mmol) in CH3CN (150 mL) was added 2-chloro-1,1,1-trimethoxyethane (11.4 g, 73.6 mmol) and pyridinium p-toluenesulfonate (1.23 g, 4.9 mmol) under stirring at room temperature. The reaction mixture was warmed to 70°C and stirred for 2 hours. EtOAc (100 mL) and H2O (200 mL) were added to the mixture, the organic layer was separated, the aqueous layer was extracted with EtOAc (2 x 100 mL), the combined organic phases were washed with brine (200 mL), dried over anhydrous Na2SO4, filtered and concentrated in vacuo to give a crude product, which was purified by flash column chromatography (petroleum ether / ethyl acetate 3:1) to give Int I: tert-butyl (S)-(2-(chloromethyl)-1-(oxane-2-ylmethyl)-1H-benzo[d]imidazol-5-yl)carbamate (18.0 g, yield 83%) as a yellow solid. LCMS (ESI): C 17 H 22 Calculated for ClN303; [M+H]+: 352.1, found: 352.1.

[0473] Preparation of (S)-2-(chloromethyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-5-carboxylic acid methyl ester (IntJ)

[0474]

[0475] To a solution of [(2S)-oxepan-2-yl]methylamine (10.9 g, 125.5 mmol) and 4-fluoro-3-nitrobenzoic acid methyl ester (20.0 g, 100.5 mmol) in THF (100 mL) under stirring at 25° C. was added N-ethyl-N-isopropyl-propane-2-amine (25.9 g, 200.8 mmol), the reaction mixture was warmed to 60° C. and stirred for 4 hours. The mixture was diluted with EtOAc (100 mL) and H2O (200 mL), the layers were separated, the aqueous layer was extracted with EtOAc (2 x 100 mL), the combined organic phases were washed with brine (200 mL), dried over anhydrous Na2SO4, filtered and concentrated in vacuo to give a crude product, which was slurried with methyl tert-butyl ether to give compound Int J-3: Methyl (S)-3-nitro-4-((oxan-2-ylmethyl)amino)benzoate (24.6 g, yield 92.3%) as a yellow solid. LCMS (ESI): C 12 H 14 Calculated for N205; [M+H] + : 267.2, measured value: 267.2.

[0476] Under stirring at 25°C, 10% Pd / C (5.0 g) was added to a solution of EtOAc:MeOH=1:1 (200 mL) containing compound Int J-3 (24.0 g, 90.1 mmol), and the reaction mixture was stirred at 25°C for 12 hours under hydrogen. The mixture was filtered, and the filter cake was washed with EtOAc (2 x 100 mL). The organic phases were combined and concentrated in vacuo to obtain compound Int J-4 methyl (S)-3-amino-4-((oxan-2-ylmethyl)amino)benzoate (18.8 g, yield 88.1%, purity 93%) as a brown solid. LCMS (ESI): C 12 H 16 Calculated for N203; [M+H] + : 236.2, measured value: 237.2.

[0477] Under stirring at room temperature, 2-chloro-1,1,1-trimethoxyethane (14.1 g, 91.4 mmol) and 4-methylbenzenesulfonic acid (1.3 g, 7.62 mmol) were added to a CH3CN solution (150 mL) containing compound Int J-4 methyl (S)-3-amino-4-((oxan-2-ylmethyl)amino)benzoate (18.0 g, 76.2 mmol), and the reaction mixture was heated to 70°C and stirred for 2 hours. EtOAc (100 mL) and H2O (200 mL) were added to the mixture, and the organic phase was separated. The aqueous layer was extracted with EtOAc (2x100 mL), the combined organic phases were washed with brine (200 mL), dried over anhydrous Na2SO4, filtered and concentrated in vacuo to give a crude product, which was purified by flash column chromatography (petroleum ether / ethyl acetate 3:1) to give compound IntJ: methyl (S)-2-(chloromethyl)-1-(oxetane-2-ylmethyl)-1H-benzo[d]imidazole-5-carboxylate (18.0 g, yield 80%) as a yellow solid, LCMS (ESI): C 14 H 15 Calculated for ClN2O3; [M+H] + : 294.7, measured value: 295.7.

[0478] Preparation of 6-((4-chloro-2-fluorobenzyl)oxy)-1′,2′,3′,6′-tetrahydro-2,4′-bipyridine (Int K) and 2-((4-chloro-2-fluorobenzyl)oxy)-6-(piperidin-4-yl)pyridine (Int L)

[0479]

[0480] To a 500 mL round-bottom flask, tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydropyridine-1(2H)-carboxylate (27.3 g, 88.2 mmol, 1.2 eq), K2CO3 (20.3 g, 147 mmol, 2.0 eq), Pd(dppf)Cl2·DCM (5.7 g, 6.3 mmol, 0.085 eq), and H2O (40 mL) were added, and a solution of dioxane (200 mL) containing compound IntG (20.0 g, 73.5 mmol, 1.0 eq) was added. The mixture was heated to 90° C. under a nitrogen atmosphere and stirred for 3.5 hours. The reaction mixture was then cooled to room temperature and filtered, the filter cake was washed with EA (100 mL), brine (200 mL) was added to the filtrate and separated, and EA (100 mL) was used. x2) extract the aqueous phase, concentrate the combined organic phases in vacuo, and purify the concentrate by recrystallization from PE:EA=1:1 to obtain a crude compound, then decolorize with activated carbon at room temperature for 2 hours, filter the mixture through diatomaceous earth, wash the filter cake with EA, and concentrate in vacuo to obtain a crude compound. Recrystallize and purify the crude compound Int K-2 from EtOH / H2O=6 / 1 to obtain the desired product 6-((4-chloro-2-fluorobenzyl)oxy)-3',6'-dihydro-[2,4'-bipyridine]-1'(2'H)-carboxylic acid tert-butyl ester (20.1 g, yield 65%), as a light yellow solid. LCMS (ESI): C 22 H 24 Calculated for ClFN2O3; [M+H] + : 418.8, measured value: 419.1.

[0481] DCM (100 mL) containing compound Int K-2 (20.0 g, 47.8 mmol) was added to a 500 mL round-bottom flask, and then TFA (trifluoroacetic acid) (20 mL) was added. The reaction mixture was stirred at 25° C. for 2 hours, and DCM was added to dilute the reaction mixture. The reaction mixture was washed with sodium bicarbonate aqueous solution, water and saturated sodium chloride aqueous solution in sequence, dried over sodium sulfate, filtered, and concentrated in vacuo. The concentrate was recrystallized from CH3CN to purify the crude compound 2-12 to obtain the desired product IntK: 6-((4-chloro-2-fluorobenzyl)oxy)-1',2',3',6'-tetrahydro-2,4'-bipyridine (13.5 g, yield 88%), as a white solid. LCMS (ESI): C 17 H 16 Calculated for ClFN2O; [M+H] + : 318.8, measured value: 319.1.

[0482] Under stirring at 25°C, 10% Pd / C (3.9 g) was added to a solution of EtOAc:MeOH=1:1 (100 mL) containing compound Int K (13.0 g, 40.8 mmol), and the reaction mixture was stirred at 25°C for 6 hours under hydrogen. The mixture was filtered, and the filter cake was washed with EtOAc (2 x 100 mL). The organic phases were combined and concentrated in vacuo to obtain compound Int L: 2-((4-chloro-2-fluorobenzyl)oxy)-6-(piperidin-4-yl)pyridine (12.0 g, yield 91%), as a white solid. LCMS (ESI): C 17 H 18 Calculated for ClFN2O; [M+H] + : 320.8, measured value: 321.1.

[0483] Preparation of 4-(2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxolan-4-yl)-1,2,3,6-tetrahydropyridine (IntM)

[0484]

[0485]

[0486] Under nitrogen environment, 5-chloro-2-ethynylpyridine (1.80 g, 13.1 mmol), 3-bromobenzene-1,2-diol (2.47 g, 13.1 mmol) and triruthenium dodecacarbonyl (167 mg, 0.261 mmol) were added to a toluene (25 ml) solution and heated at 100°C for 16 hours. Ethyl acetate (30 ml) was added to dilute the reaction mixture and filtered through a celite pad; the filtrate was concentrated in vacuo and purified using silica gel chromatography (gradient: 0%-1% ethyl acetate in petroleum ether) to give a yellow oil Int M-2 (1.5 g, 37.5%).

[0487] To a solution of compound Int M-2 (2.0 g, 5.84 mmol, 1.0 eq) in dioxane (20 mL), tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydropyridine-1(2H)-carboxylate (2.17 g, 8.8 mmol, 1.2 eq), K2CO3 (1.6 g, 11.7 mmol, 2.0 eq), Pd(dppf)Cl2·DCM (0.4 g, 0.50 mmol, 0.085 eq), H2O (4 mL) were added, and the mixture was heated to 90° C. under a nitrogen atmosphere and stirred for 3.5 hours. The reaction mixture was then cooled to room temperature and filtered, the filter cake was washed with EA (20 mL), brine (20 mL) was added to the filtrate and separated, and EA (20 mL x 10% MgSO4) was added. 2) The aqueous phase was extracted, and the combined organic phases were concentrated in vacuo. The concentrate was purified by recrystallization using PE:EA=1:1 to obtain compound Int M-3 (2.1 g, 80.9%) as a light yellow solid. LCMS (ESI): C 24 H 25 Calculated for ClFNO4; [M+H]+: 446.15, found: 446.15.

[0488] DCM (10 mL) and compound Int M-3 (2.0 g, 4.5 mmol) were added to a 50 mL round-bottom flask, followed by TFA (2 mL). The reaction mixture was stirred at 25° C. for 2 hours, and DCM was added to dilute the reaction mixture. The reaction mixture was washed with aqueous sodium bicarbonate solution, water, and saturated aqueous sodium chloride solution, dried over sodium sulfate, filtered, and concentrated in vacuo. The crude compound was purified by recrystallization with CH3CN to obtain the desired product Int M (1.3 g, yield 83.8%) as a white solid. LCMS (ESI): C 19 H 17 Calculated for ClFNO2; [M+H] + : 346.1, measured value: 346.1.

[0489] Example Compound Preparation

[0490] Preparation 1. Preparation of 2-(4-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)benzyl)-N-(4-hydroxyphenethyl)-1-(2-methoxyethyl)-1H-benzo[d]imidazole-5-carboxamide (1)

[0491]

[0492] Referring to the following reaction equation (Scheme 1): Using a 500 ml round-bottom flask, potassium tert-butoxide (14.7 g, 0.13 mol, 2.4 eq.) was added to THF (200 mL), stirred for 5 min, then 3-fluoro-4-(hydroxymethyl)benzonitrile (14 g, 0.092 mol, 1.7 eq.) was added, and stirred at 15 ° C for 45 min, then 2,6-dichloropyridine (8.07 g, 0.055 mol, 1.0 eq.) was added, and stirred at 15 ° C for 18 h. Saturated aqueous ammonium chloride solution (18 eq) and EA (100 mL) were added to treat the reaction. The reaction mixture was filtered, the filtrate was extracted with EA (2 x 200 mL), the combined organic phase was washed with brine (200 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated in vacuo. The concentrate was purified by recrystallization from PE / EA=8 / 1 to obtain a crude compound 1-3, and the crude compound 1-3 was purified by recrystallization from EtOH / H2O=1 / 1 to obtain the desired product (10.3 g, yield 70%) as a light yellow solid. LCMS (ESI): C 13 Calculated value of H8CIFN2O [M+H] + : 262.6, measured value: 263.6.

[0493] A solution of compound 1-3 (10.0 g, 0.038 mol, 1.0 eq) in dioxane (100 mL, 10 V) was added to a 250 mL round-bottom flask, followed by ethyl 2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acetate (14.4 g, 0.050 mol, 1.3 eq), K2CO3 (10.8 g, 0.760 mol, 2.0 eq), Pd(dppf)Cl2·DCM (2.5 g, 0.003 mmol, 0.085 eq) and H2O (20 mL). The final mixture was maintained under nitrogen and stirred at 90°C for 3.5 h. The reaction mixture was cooled to room temperature and filtered, and the filter cake was washed with EA (100 mL). Add brine (100 mL) to the filtrate and separate, extract the aqueous phase with EA (100 mL x2), and concentrate the combined organic phases in vacuo. The concentrate was purified by recrystallization from PE:EA=1:1 to obtain crude product 1-5, which was then decolorized with activated carbon at room temperature for 2 h, filtered through a diatomaceous earth pad, the filter cake was washed with EA and concentrated in vacuo, and purified by recrystallization from EtOH / H2O=6 / 1 to obtain the desired product 1-5 (8.8 g, yield 65%) as a light yellow solid. LCMS (ESI): C 23 H 19 FN2O3; calculated value [M+H] + : 390.4, measured value: 391.4.

[0494] At 25°C, a solution of compound 1-5 (8.0 g, 20.49 mmol) in THF (20.0 mL), CH3CN (20.0 mL), water (20.0 mL) and lithium hydroxide (982 mg, 41 mmol) were added to a 250 mL round-bottom flask. The reaction mixture was stirred at 25°C for 12 hours. The organic solvent was then concentrated to remove the organic solvent, and 1 M hydrochloric acid was added to adjust the aqueous residue to pH 6. The resulting mixture was extracted with EA (3 x 60 mL), and the combined organic layers were dried over magnesium sulfate, filtered, and concentrated in vacuo to obtain a crude product. The crude compound 1-6 was then purified by recrystallization from EtOH to obtain the desired product (6.5 g, yield 87%) as a light yellow solid. LCMS (ESI): C 21 H 15 FN203[M+H] + : Calculated value: 362.3, measured value: 363.3.

[0495] Compound 1-6 (6.0 g, 16.56 mmol), compound 1-7 (3.71 g, 16.56 mmol) and O-(7-azabenzotriazole-1-yl)-N,N,N',N'-tetramethylureido hexafluorophosphate (HATU; 9.45 g, 33.12 mmol) were added to a solution of N,N-dimethylformamide (60 mL), stirred at 25 ° C for 30 min, then triethylamine (6.7 g, 66.23 mmol) was added, and stirring was continued at 25 ° C for 12 hours. The reaction mixture was then poured into water (300 mL) and extracted with ethyl acetate (3×200 mL). The combined organic layer was washed with saturated sodium chloride aqueous solution (3×200 mL), dried over sodium sulfate, filtered, and concentrated in vacuo. Purification by silica gel chromatography (eluent: 1:1 petroleum ether / ethyl acetate) gave compound 1-8 as a brown solid (7.8 g, yield 83%), which was directly used in the next step. LCMS (ESI): C 32 H 29 FN405[M+H] + : Calculated value: 568.6, measured value: 569.6.

[0496] Compound 1-8 (7.5 g, 13.19 mmol) was dissolved in acetic acid (50 mL), stirred at 75°C for 12 hours, and then concentrated in vacuo to obtain a brown solid crude product. Recrystallization from CH3CN gave the desired product, compound 1-9 (6.1 g, yield 85%), as a yellow solid. LCMS (ESI): C 32 H 27 FN404[M+H] + : Calculated value: 550.6, measured value: 551.6.

[0497] At 0°C, a solution of compound 1-9 (6.0 g, 10.9 mmol) in THF (20.0 mL) was added to a 250 mL round-bottom flask, followed by CH3CN (20.0 mL), water (20.0 mL) and lithium hydroxide (522 mg, 21.8 mmol), and the reaction mixture was stirred at 25°C for 12 hours. The organic solvent was then concentrated to remove the organic solvent, and the pH of the aqueous residue was adjusted to 6 with 1 M hydrochloric acid. Extracted with EA (3 x 60 mL), the combined organic layers were dried over magnesium sulfate, filtered, and concentrated in vacuo to give a crude product. The crude compound 1-10 was purified by recrystallization from CH3CN to give the desired product 1-10 (5.1 g, yield 87%) as a yellow solid. LCMS (ESI): calculated C 31 H 25 FN4O4; [M+H] + :536.5, result:537.6.

[0498] Compound 1-10 (100 mg, 1.86 mmol), N-hydroxybenzotriazole (HOBT; 37.78 mg, 2.79 mmol) and N-(3-dimethylaminopropyl)-n"-ethylcarbodiimide hydrochloride (EDCI; 9.45 g, 33.12 mmol) were added to N,N-dimethylformamide (2 mL), stirred at 25 ° C for 30 min, then N,N-diisopropylethylamine (48.18 mg, 3.73 mmol) and 4-(2-aminoethyl)phenol (37.8 mg, 1.86 mmol) were added, and stirring was continued at 25 ° C for 12 hours. The reaction mixture was then poured into water (10 mL) and extracted with ethyl acetate (3×10 mL). Saturated sodium chloride aqueous solution (3×10 mL) was used to obtain the mixture. The combined organic layers were washed with 10 mL of 4% paraformaldehyde (10 mL), dried over sodium sulfate, filtered, and concentrated in vacuo. The crude product was purified by preparative liquid chromatography to give compound 1 (67 mg, yield: 54.9%). LCMS (ESI): C 39 H 34 FN5O4; [M+H] + : Calculated value: 655.73, measured value: 656.2.

[0499] Preparation 2: Preparation of (2S,4R)-1-((2-((4-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)piperidin-1-yl)methyl)-1-(((S)-oxo-2-yl)methyl)-1H-benzo[d]imidazole-5-carbonyl)glycyl)-4-hydroxypyrrolidine-2-carboxylic acid (2)

[0500]

[0501] Refer to the following reaction equation (Scheme 2):

[0502] Under stirring conditions, compound Int J (12.2 g, 41.2 mmol) was added to a solution of compound Int L (12.0 g, 37.4 mmol) in acetonitrile (120 mL), and then potassium carbonate (15.5 g, 112 mmol) was added, and the reaction solution was stirred at 75°C for 3 hours. The reaction solution was filtered and washed with EA (100 mL), the filtrate was concentrated in vacuo, and the crude product was slurried with a mixed solution of petroleum ether and ethyl acetate (PE: EA = 5: 1) to obtain compound 2-14, methyl (S)-2-((4-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)piperidin-1-yl)methyl)-1-(oxetane-2-ylmethyl)-1H-benzo[d]imidazole-5-carboxylate (17.5 g, yield 82%), as a yellow solid. LCMS (ESI): C 31 H 32 ClFN404[M+H] + : Calculated value: 579.1, measured value: 579.2.

[0503] At 0°C, a solution of compound 2-14 (16.0 g, 10.9 mmol) in MeOH (80.0 mL), water (80.0 mL) and sodium hydroxide (5.5 g, 138.0 mmol) were added to a 250 mL round-bottom flask and stirred at 50°C for 2 hours. The organic solvent was then concentrated to remove the organic solvent, and the aqueous residue was adjusted to pH 6 with 1M hydrochloric acid. It was extracted with EA (3 x 100 mL), the combined organic layer was dried over magnesium sulfate, filtered, and concentrated in vacuo to give the crude product. It was then purified by CH3CN slurry to give the desired product compound 2-15, (S)-2-((4-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)piperidin-1-yl)methyl)-1-(oxepane-2-ylmethyl)-1H-benzo[d]imidazole-5-carboxylic acid (13.5 g, yield 84%), as a yellow solid.

[0504] LCMS(ESI): C 30 H 30 ClFN404; [M+H] + : Calculated value: 565.1, measured value: 565.2.

[0505] The solution of the above compound 2-15 (100 mg, 0.177 mmol), N-hydroxybenzotriazole (HOBT; 35.8 mg, 0.265 mmol) and N-(3-dimethylaminopropyl)-n"-ethylcarbodiimide hydrochloride (EDCI; 50.9 mg, 0.265 mmol) were added to N, N-dimethylformamide (2 mL), stirred at 25 ° C for 30 min, then N, N-diisopropylethylamine (58.0 mg, 0.442 mmol) and compound 2-16 (2S, 4R)-1-1-glyceryl-4-hydroxypyrrolidine-2-carboxylate (40.0 mg, 0.195 mmol) were added, and stirring was continued at 25 ° C for 12 hours. The reaction solution was poured into water (10 mL) and extracted with ethyl acetate (3×10 mL). Saturated sodium chloride aqueous solution (2× 10mL) washed with the combined organic layer, dried over sodium sulfate, filtered, and concentrated in vacuo. The concentrate was purified by preparative liquid chromatography to obtain compound 2-17, methyl (2S, 4R)-1-((2-((4-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)piperidin-1-yl)methyl)-1-(((S)-oxepan-2-yl)methyl)-1H-benzo[d]imidazole-5-carbonyl)glycyl)-4-hydroxypyrrolidine-2-carboxylate, 67 mg, yield: 51%. LCMS (ESI): C 38 H 42 ClFN6O7; [M+H] + : Calculated value: 749.2, measured value: 749.2.

[0506] At 0°C, a solution of compound 2-17 (60.0 mg, 0.08 mmol) in MeOH (1.0 mL), water (1.0 mL) and sodium hydroxide (16 mg, 0.40 mmol) were added to a 25 mL round-bottom flask and stirred at 50°C for 1.5 hours. The organic solvent was then concentrated to remove the organic solvent, and the aqueous residue was adjusted to pH 6 with 1 M hydrochloric acid. The organic layer was extracted with EA (3 x 10 mL), and the combined organic layer was dried over magnesium sulfate, filtered, and concentrated in vacuo to obtain a crude product. The product was purified by preparative liquid chromatography to obtain the desired product compound 2, (2S,4R)-1-((2-((4-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)piperidin-1-yl)methyl)-1-(((S)-oxepan-2-yl)methyl)-1H-benzo[d]imidazole-5-carbonyl)glycine)-4-hydroxypyrrolidine-2-carboxylic acid (35 mg, yield 60%), as a white solid. LCMS (ESI): C 37 H 40 ClFN607[M+H] + : Calculated value: 735.2, measured value: 735.2.

[0507] Preparation 3: Preparation of (S)-2-((6-((4-chloro-2-fluorobenzyl)oxy)-3',6'-dihydro-[2,4'-bipyridyl]-1'(2'H)-yl)methyl)-N-(3-methyl-1H-indol-5-yl)-1-(oxetane-2-ylmethyl)-1H-benzo[d]imidazole-5-carboxamide (3)

[0508]

[0509] Referring to the following reaction equation (Scheme 3): Under stirring conditions, compound Int J (10.2 g, 34 mmol) was added to a solution of compound Int K (10.0 g, 31.3 mmol) in acetonitrile (100 mL), followed by potassium carbonate (10.8 g, 78.4 mmol), and the reaction mixture was stirred at room temperature 75° C. for 3 hours. The reaction mixture was filtered, washed with EA (100 mL), the filtrate was concentrated in vacuo, and the crude product was purified by slurry (PE:EA=5:1) to obtain compound 3-1, methyl (S)-2-((6-((4-chloro-2-fluorobenzyl)oxy)-3',6'-dihydro-[2,4'-bipyridyl]-1'(2'H)-yl)methyl)-1-(oxaalkane-2-ylmethyl)-1H-benzo[d]imidazole-5-carboxylate (14.5 g, yield 80%) as a yellow solid. LCMS(ESI): C 31 H 30 ClFN404; [M+H] + : Calculated value: 577.1, measured value: 577.1.

[0510] A solution of compound 3-1 (14.0 g, 24.3 mmol) in MeOH (70.0 mL), water (70.0 mL) and sodium hydroxide (4.85 g, 121.3 mmol) were added to a 250 mL round-bottom flask at 0° C., and the reaction mixture was stirred at 50° C. for 2 hours. The organic solvent was then removed by concentration, and the pH of the aqueous residue was adjusted to 6 with 1 M hydrochloric acid. Extracted with EA (3 x 100 mL), dried the combined organic layers over magnesium sulfate, filtered, and concentrated in vacuo to give a crude product, which was slurried with CH3CN to give compound 3-2, (S)-2-((6-((4-chloro-2-fluorobenzyl)oxy)-3',6'-dihydro-[2,4'-bipyridyl]-1'(2'H)-yl)methyl)-1-(oxolan-2-ylmethyl)-1H-benzo[d]imidazole-5-carboxylic acid (11.7 g, yield 86%) as a yellow solid. LCMS (ESI): C 30 H 28 ClFN404; [M+H] + : Calculated value: 563.0, measured value: 563.1.

[0511] Compound 3-2 (100 mg, 0.177 mmol), N-hydroxybenzotriazole (HOBT; 35 mg, 0.265 mmol) and N-(3-dimethylaminopropyl)-n"-ethylcarbodiimide hydrochloride (EDCI; 50.9 mg, 0.265 mmol) were added to N,N-dimethylformamide (2 mL) and stirred at 25 ° C for 30 min. N,N-diisopropylethylamine (58.0 mg, 0.442 mmol) and 3-methyl-1H-indol-5-amine (28.8 mg, 0.195 mmol) were added and stirring was continued at 25 ° C for 12 hours. The reaction mixture was then poured into water (10 mL) and extracted with ethyl acetate (3×10 mL). Saturated sodium chloride aqueous solution (2× The combined organic layer was washed with 10 mL of 4% paraformaldehyde (10 mL), dried over sodium sulfate, filtered, and concentrated in vacuo. The crude product was purified by preparative liquid chromatography to obtain compound 3, (S)-2-((6-((4-chloro-2-fluorobenzyl)oxy)-3',6'-dihydro-[2,4'-bipyridyl]-1'(2'H)-yl)methyl)-N-(3-methyl-1H-indol-5-yl)-1-(oxetane-2-ylmethyl)-1H-benzo[d]imidazole-5-carboxamide, 64 mg, yield: 52%, as a white solid. LCMS (ESI): C 38 H 35 ClFN703[M+H] + : Calculated value: 692.1, measured value: 692.2. 1 H NMR (400 MHz, DMSO-d6).

[0512] Preparation 4: Preparation of (S)-N-(2-((6-((4-chloro-2-fluorobenzyl)oxy)-3′,6′-dihydro-[2,4′-bipyridyl]-1′(2′H)-yl)methyl)-1-(oxepan-2-ylmethyl)-1H-benzo[d]imidazol-5-yl)-3-methyl-1H-imidazole-5-carboxamide (4)

[0513]

[0514] Refer to the following reaction equation (Scheme 4):

[0515] To a stirred solution of compound Int I (14.0 g, 43.9 mmol) in acetonitrile (100 mL) was added compound Int K (17.0 g, 48.3 mmol) and then potassium carbonate (15.2 g, 109.8 mmol), and the reaction mixture was stirred at 75° C. for 3 hours. The reaction solution was filtered, the filter cake was washed with EA (100 mL), the filtrate was concentrated in vacuo, and the obtained crude product was slurried with a mixed solution of petroleum ether and ethyl acetate (PE: EA = 6: 1) to obtain compound 4-6, tert-butyl (S)-(2-((6-((4-chloro-2-fluorobenzyl)oxy)-3', 6'-dihydro-[2,4'-bipyridyl]-1'(2'H)-yl)methyl)-1-(oxaalkane-2-ylmethyl)-1H-benzo[d]imidazol-5-yl)carbamate (22.5 g, yield 80.6%) as an off-white solid. LCMS (ESI): C 34 H 37 ClFN504[M+H] + : Calculated value 634.1, measured value: 634.2.

[0516] A solution of compound 4-6 (20.0 g, 31.5 mmol) in DCM (100.0 mL) was added to a 500 mL round-bottom flask, followed by TFA (20 mL), and the reaction mixture was stirred at 25 ° C for 2 hours. The mixture was diluted with DCM, washed with sodium bicarbonate aqueous solution, water and saturated sodium chloride aqueous solution, dried over sodium sulfate, filtered and concentrated in vacuo. The concentrate was purified by recrystallization from PE: EA = 5: 1 to give compound 4-7, (S)-2-((6-((4-chloro-2-fluorobenzyl)oxy)-3', 6'-dihydro-[2,4'-bipyridyl]-1'(2'H)-yl)methyl)-1-(oxan-2-ylmethyl)-1H-benzo[d]imidazole-5-amine (13.5 g, yield 80%), as an off-white solid. LCMS (ESI): C 29 H 29 ClFN5O2[M+H] + : Calculated value: 534.1, measured value: 534.2.

[0517] Compound 4-8 (40 mg, 0.227 mmol), N-hydroxybenzotriazole (HOBT; 46.0 mg, 0.340 mmol) and N-(3-dimethylaminopropyl)-n"-ethylcarbodiimide hydrochloride (EDCI; 65.1 mg, 0.340 mmol) were added to N, N-dimethylformamide (2 mL) solution and stirred at 25 ° C for 30 mins, then N, N-diisopropylethylamine (58.0 mg, 0.442 mmol) and compound 4-7 (121.1 mg, 0.227 mmol) were added and stirred at 25 ° C for 12 hours. The reaction mixture was poured into water ( 10mL), and extracted with ethyl acetate (3×10mL). The combined organic layers were washed with saturated sodium chloride aqueous solution (2×10mL), dried over sodium sulfate, filtered, concentrated in vacuo, and purified by preparative liquid chromatography to obtain compound 4, (S)-N-(2-((6-((4-chloro-2-fluorobenzyl)oxy)-3′,6′-dihydro-[2,4′-bipyridyl]-1′(2′H)-yl)methyl)-1-(oxetane-2-ylmethyl)-1H-benzo[d]imidazol-5-yl)-3-methyl-1H-indazole-5-carboxamide, 81 mg, yield: 51.9%, as a white solid. LCMS (ESI): C 38 H 35 ClFN703[M+H]+: calculated value 692.1, found value: 692.2.

[0518] Preparation 5: Preparation of 2-((4-((S)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxetane-4-yl)-3,6-dihydropyridin-1(2H)-yl)methyl)-N-(3-methyl-1H-indazol-5-yl)-1-(((S)-oxetane-2-yl)methyl)-1H-benzo[d]imidazole-5-carboxamide (5)

[0519]

[0520] Refer to the following reaction equation (Scheme 5):

[0521] Under stirring conditions, compound Int J (1.0 g, 3.48 mmol) was added to a solution of compound Int M (1.0 g, 2.9 mmol) in acetonitrile (10 mL), followed by potassium carbonate (10.5 g, 7, 25 mmol), and the reaction mixture was stirred at 75°C for 3 hours. The reaction mixture was filtered, washed with EA (20 mL), and the filtrate was concentrated in vacuo to dryness to obtain a crude product, which was slurried with PE / EA = 5 / 1 to obtain a yellow solid compound 5-5 (1.5 g, 85.8% yield). LCMS (ESI): C 33 H 31ClFN305; [M+H] + : Calculated value: 604.2, measured value: 604.2.

[0522] At 0°C, compound 5-5 (1.4 g, 2.3 mmol), methanol (7.0 mL), water (7.0 mL) and sodium hydroxide (0.46 g, 11.5 mmol) were added to a 25 ml round-bottom flask, and the reaction mixture was stirred at 50°C for 2 hours. The organic solvent was removed by concentration, and the aqueous residue was adjusted to pH 6 with 1 M hydrochloric acid, extracted three times with EA (3x10 mL), and the organic phases were combined, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to obtain a crude product. The crude product 5-6 was slurried with acetonitrile to obtain a yellow solid 5-6 (1.2 g, yield 87.8%). LCMS (ESI): C 32 H 29 ClFN305; [M+H] + : Calculated value 590.2, measured value: 590.2.

[0523] A solution of compound 5-6 (100 mg, 0.17 mmol), N-hydroxybenzotriazole (HOBT; 35.8 mg, 0.265 mmol) and N-(3-dimethylaminopropyl)-n″-ethylcarbodiimide hydrochloride (EDCI; 50.9 mg, 0.265 mmol) were added to N,N-dimethylformamide (2.0 mL), and the mixture was stirred at 25°C for 30 min. Then, N,N-diisopropylethylamine (58.0 mg, 0.442 mmol) and 3-methyl-1H-indazol-5-amine (28.8 mg, 0.195 mmol) were added, and stirring was continued at 25°C for 12 hours. The reaction solution was added to 10 ml of water, extracted three times with EA (3x 10 mL), and then saturated brine (2x The combined organic layers were washed twice with 10 mL of 4% paraformaldehyde (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo to obtain a crude product, which was purified by preparative liquid chromatography to obtain a mixture of diastereomeric products 5-7. Chiral compound 5 was separated by SFC (supercritical fluid chromatography) [column: Chiral Technologies ChiralCel OD, 5 pm; mobile phase: 55:45 carbon dioxide / (methanol containing 0.1% ammonium hydroxide)] to obtain chiral compound 5, 23 mg, LCMS (ESI): C 40 H 36 ClFN604; [M+H] + : Calculated value: 719.3, found value: 719.3; Compound 5', 19 mg, LCMS (ESI): C 40 H 36 ClFN604; [M+H] + : Calculated value: 719.3, measured value: 719.3.

[0524] Preparation 6: Preparation of 2-(6-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-6-azaspiro[2.5]octan-1-yl)-1-(2-methoxyethyl)N-(3-methyl-1H-indazol-5-yl)-1H-benzo[d]imidazole-5-carboxamide (6)

[0525]

[0526]

[0527] Under N2 protection, compound 1-3 (2.0 g, 7.61 mmol), methyl 6-azaspiro[2.5]octane-1-carboxylate (1.42 g, 8.38 mmol), Cs2CO3 (4.97 g, 15.2 mmol), Pd2(dba)3 (696 mg, 0.77 mmol) and X-Phose (734 mg, 1.54 mmol) were added to dioxane (dioxane, 20 ml) and heated at 100°C for 4 hours. Ethyl acetate (30 ml) was added to dilute, filtered through diatomaceous earth, and the filtrate was concentrated in vacuo and purified by silica gel chromatography (gradient: 0% to 5% methanol dichloromethane) to obtain compound 6-2 (1.5 g, 49%) as a yellow solid.

[0528] The following series of reactions can be carried out according to Preparation 1, and compound 6 can be obtained through hydrolysis, condensation reaction, cyclization, hydrolysis, and condensation.

[0529] The following compounds were prepared according to the procedures described herein (and as noted under the procedures in Table 1), using appropriate starting materials and appropriate protecting group chemistry as necessary.

[0530] Table 1 Compound list

[0531]

[0532]

[0533]

[0534]

[0535]

[0536]

[0537]

[0538]

[0539]

[0540]

[0541]

[0542]

[0543]

[0544]

[0545]

[0546]

[0547]

[0548]

[0549]

[0550]

[0551]

[0552]

[0553]

[0554]

[0555]

[0556]

[0557]

[0558]

[0559]

[0560]

[0561]

[0562]

[0563]

[0564]

[0565]

[0566]

[0567]

[0568]

[0569]

[0570]

[0571]

[0572]

[0573]

[0574]

[0575]

[0576]

[0577]

[0578]

[0579]

[0580]

[0581]

[0582]

[0583]

[0584]

[0585]

[0586]

[0587]

[0588]

[0589]

[0590]

[0591]

[0592]

[0593]

[0594]

[0595]

[0596]

[0597]

[0598]

[0599]

[0600]

[0601]

[0602]

[0603]

[0604]

[0605]

[0606]

[0607]

[0608]

[0609]

[0610]

[0611]

[0612]

[0613]

[0614]

[0615]

[0616]

[0617]

[0618]

[0619]

[0620]

[0621]

[0622]

[0623]

[0624]

[0625]

[0626]

[0627]

[0628]

[0629]

[0630]

[0631]

[0632]

[0633]

[0634]

[0635]

[0636]

[0637]

[0638]

[0639]

[0640]

[0641]

[0642]

[0643]

[0644]

[0645]

[0646]

[0647]

[0648]

[0649]

[0650]

[0651]

[0652]

[0653]

[0654]

[0655] Example 2 In vitro activity evaluation

[0656] A. GLP-1R cAMP level test

[0657] 1. Materials

[0658] (1) Reagents

[0659] cAMP Assay Kit, Cisbio (Cat#62AM4PEJ)

[0660] 1M HEPES, Invitrogen(Cat#15630-106)

[0661] 1X HBSS, Invitrogen(Cat#14025)

[0662] BSA, Sigma (Cat# B2064-100G)

[0663] IBMX, Sigma (Cat#I5879)

[0664] GLP-1(7-37),Hao Yuan(HY-P0055)

[0665] (2) Culture medium

[0666] This cell line was constructed by WuXi. See the table below for details.

[0667] Target Host cell lines clone GLP-1R HEK293 N / A

[0668] (3) Instruments

[0669] OptiPlate-384, white, PerkinElmer (Cat#6007290);

[0670] 384-well plate, Labcyte (Cat# P-05525);

[0671] EnVision, PerkinElmer;

[0672] Vi-cell counter, Beckman (Cat#Vi-CELL TM XR Cell Viability Analyzer).

[0673] 2. Methods

[0674] a) Preparation of compound source plate:

[0675] Reference compound 7-37 was diluted 4-fold at 10 points, starting at 500 nM, using Bravo in DMSO. Test compound was diluted 3-fold at 10 points, starting at 10,000,000 nM, using Bravo in DMSO.

[0676] b) Transfer compounds:

[0677] 1) Use Echo to transfer 100 nL of compound to OptiPlate-384 plate.

[0678] 2) Centrifuge the plate at 1000 rpm for 5 seconds.

[0679] c) Preparation of cell suspension

[0680] 1) Rapidly thaw a GLP-1R cell cryopreservation tube in 37°C warm water.

[0681] 2) Transfer the cell suspension to a 15 mL centrifuge tube and gently rinse with 10 ml of HBSS.

[0682] 3) Centrifuge the tube at 1000 rpm at room temperature for 1 minute to pellet the cells.

[0683] 4) Gently aspirate the supernatant to avoid aspirating cells.

[0684] 5) Gently break up the cells at the bottom and gently rinse with 10 ml HBSS, centrifuge to sediment the cells, and finally resuspend the cells with experimental buffer.

[0685] 6) Use Vi-cell to measure cell density and activity.

[0686] 7) Resuspend the GLP-1R cells in the experimental buffer and dilute to a concentration of 1.0*10 5 / mL.

[0687] 8) Transfer 10 μL of GLP-1 cell suspension into OptiP1ate-384 plate.

[0688] d) HTRF cAMP agonist assay:

[0689] 1) Incubate the plate at room temperature for 30 minutes before adding detection reagents.

[0690] 2) Use an electronic multichannel pipette to add 10 μL of detection reagent each.

[0691] 3) Cover the 384 plate with TopSeal-A membrane and incubate at room temperature for 60 minutes. Remove TopSeal-A and read on EnVision.

[0692] 3. Analytical methods

[0693] A. Standard curve:

[0694] A new log(Inhibitor) vs response-Variable slope model was created in Prism5.0 software, the standard curve concentration (x) and its corresponding 665\615 data (y) were substituted into the model, the standard curve concentration (horizontal axis) was converted to x=log(x), and the standard curve was made using the converted xy.

[0695] B.cAMP level conversion:

[0696] Transpose the full plate 665\615 data into a column of data, substitute into y in the table of standard curve concentration (x) and 665\615 data (y), let the software automatically convert the corresponding x (interpolate x) and copy it out of the table, then convert it to cAMP level using the formula x=10^(x), and transpose the data back to 384 distribution.

[0697] C.Activity % calculation formula:

[0698] Activity % = (cAMP level - LC) / (HC - LC) * 100%

[0699] Z factor: 1-3*(STD_HC+STD_HC) / (HC-LC)

[0700] Detection window: HC / LC

[0701] LC: Average cAMP level in wells with DMSO added

[0702] HC: Average cAMP level in wells with the highest concentration of reference compound

[0703] D. Sample curve:

[0704] A new log(slope) vs response-Variable slope model was created in Prism5.0 software, the sample concentration (x) and its corresponding activity % data (y) were substituted into the model, the standard curve concentration (horizontal axis) was converted to x=log(x), and the sample curve was made using the converted xy.

[0705] Table 2 lists the biological activities of the compounds in the GLP-1R agonist cAMP stimulation assay.

[0706] Table 2 Biological activity of compounds in the GLP-1R agonist cAMP stimulation assay

[0707]

[0708]

[0709]

[0710]

[0711] B. Tag-lite binding assay

[0712] 1. Materials

[0713] (1) Reagents

[0714] Reagents supplier Catalog Number Part Number SNAP-Lumi4-Tb-5nmoles Cisbio SSNPTBD 13A GLP-1 receptor red agonist Cisbio L0030RED 08A Tag-lite labeling medium (5×) Cisbio LABMED 13A

[0715] DMEM, Gibco(Cat#11965-092);

[0716] FBS, Excell (Cat#FSP500);

[0717] Penicillin / streptomycin (100x), 10,000 units / ml, Hyclone-SV30010;

[0718] G418,Gibco(Cat#10131-027);

[0719] DPBS, Coming(Cat#21-031-CVC);

[0720] TE, Gibco (Cat#25300-062);

[0721] (2) Culture medium

[0722] The cell line was constructed by WuXi.

[0723] Host cells Target Culture medium HEK293 GLP-1 DMEM+10%FBS+1%PS+500G418

[0724] (3) Instruments

[0725] Vi-cell counter, Beckman (Cat#Vi-CELL TM XR Cell Viability Analyzer);

[0726] Incubator, Thermo (1153447);

[0727] Microplate, 384well, PS, F-Bottom, small volume, Hibase, Med.Binding, white, Greiner (Cat#784075);

[0728] EnVision, PerkinElmer(651436);

[0729] Bravo V11, Agilent(337076);

[0730] ECHO 655, Labcyte(2474218);

[0731] 2. Methods

[0732] Day 1: Cell plating

[0733] 1) Discard the cell culture medium by aspiration.

[0734] 2) Add DPBS to wash the cells and aspirate.

[0735] 3) Add 3 mL of 0.05% trypsin-EDTA.

[0736] 4) Incubate at 37°C for 1 minute and check the progress of enzyme treatment using an inverted phase contrast microscope.

[0737] 5) Tap the dish gently to remove the cells from the bottom, add 10 mL of cell culture medium, fully suspend the cells by pipetting, and wash any remaining cells from the bottom of the dish.

[0738] 6) Centrifuge the cells at 1000 rpm for 5 minutes at room temperature.

[0739] 7) Gently discard the culture medium, being careful not to touch the cells at the bottom.

[0740] 8) Resuspend the cell pellet in growth medium. Use a sterile pipette to pipette up and down to remove clumps.

[0741] 9) Use Vi-CELL TM Cells were counted and viability was determined using a cell counter and cell suspensions were prepared in culture medium / well.

[0742] 10) Distribute the cells into a cell plate (1.8M cells / well, 2 ml of culture medium is added to a 6-well plate, 4 wells in total).

[0743] 11) Incubate in a 5% CO2, 37°C incubator for 16-20 hours.

[0744] Day 2: Tag-lite binding assay

[0745] 1) Thaw a 5 ml vial of Tag-lite buffer (TLB 5x) and dilute 1:5.

[0746] 2) Dilute the vial of Tag-lite SNAP-Lumi4-Tb solution 1:1000 with the 100 μM stock solution.

[0747] 3) Remove the culture medium in the 6-well plate and add 1 mL / well of the prepared Tag-lite SNAP-Lumi4-Tb solution.

[0748] 4) Place in a 37°C 5% CO2 incubator for 1 hour for incubation.

[0749] 5) Wash cells twice with 1 mL Tag-lite buffer.

[0750] 6) Trypsinize the cells and resuspend them in 1X TLB to 1×10 6 cells / mL.

[0751] 7) The test compound and the reference compound were serially diluted 3-fold into 10 points by Echo, and 100 nL was transferred to the reaction plate.

[0752] 8) Add 10 μL of labeled cells to the reaction plate, with 10,000 cells per well, a volume of 10 μL, and centrifuge at 1000 rpm for 1 min.

[0753] 9) Incubate the plate at 23°C for 30 min.

[0754] 10) Use Echo to add 50 nL of red agonist to the target plate (final concentration: 4.917 nM).

[0755] 11) Incubate the reaction plate at 23°C for 2 h.

[0756] 12) Use Compatible readers read at 665nm and 620nm.

[0757] 3. Results Analysis

[0758] a) Inhibition rate % calculation formula:

[0759] Inhibition rate % = 100% - (ratio - LC) / (HC - LC) * 100%

[0760] Z factor: 1-3*(STD_HC+STD_HC) / (HC-LC)

[0761] Test window: HC / LC

[0762] Average ratio of HC:DMSO added wells

[0763] LC: Average ratio of wells spiked with the highest concentration of reference compound

[0764] b) The “log (inhibitor) vs. response--Variable slope” model in GraphPad Prism 5.0 was used to fit the dose-effect curve of each sample. The sample concentration (x) and its corresponding inhibition rate % data (y) were substituted into the model, the sample concentration (abscissa) was converted to x=log(x), and the sample curve was made using the converted xy to obtain the IC 50 .

[0765] c) According to sample IC 50 The sample Ki is calculated by combining the red agonist Kd and the red agonist Kd. In the formula, S is the actual concentration of the red agonist used.

[0766]

[0767] Table 3 shows the biological activity of the compounds in the GLP-1R agonist Tag-lite binding assay.

[0768] Table 3 Biological activity of compounds in Tag-lite binding assay

[0769] sample IC50(nM) Ki sample IC50(nM) Ki sample IC50(nM) Ki 2 345.2 164.55 151 1048 519.32 354 2137 1057.5 3 1750 876.24 153 1451 872.72 382 689.2 341.5 5 1705 910.51 154 1582.3 904.1 383 1477 899.3 62 2632 1317.87 166 2651 1324.4 384 109.9 68.32 80 2325 1164.15 178 875.32 429.66 385 158.1 82.7 85 143.2 71.7 196 152.3 87.9 386 119.6 69.9 88 1838 920.31 197 165.3 84 387 346.3 204.7 90 1898 950.35 203 158 90.3 391 115.8 70.3 100 1261 893.31 207 149 82.37 407 180.2 110.5 101 1281 641.41 229 121.5 75.91 408 105.9 68.4 103 1552 885.3 244 189.2 110.1 409 486.3 237.3 105 1945 1004.3 245 146 82.3 411 119.7 72.6 126 1398 806.2 276 2456 1005.6 413 28.02 14.13 127 1252 743.5 334 1213 692.3 414 31.7 15.56 134 1838 903.9 335 1107 615.4 415 232.78 116.63 142 2011 1001.42 340 123 88.5 416 54.3 29.33 145 1922 956.21 341 158.3 95.5 417 136.7 69.21 147 1749 841.2 342 140.4 72.2

Claims

1. Compounds of Formula IA-1: or a pharmaceutically acceptable salt thereof, wherein: R 1 It is C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Cycloalkyl, heterocyclic, C 6-10 Aryl, 5-10 membered heteroaryl, -SR 1b , -S(O)R 1b , -S(O)(NH)R 1b , -S(O)2R 1b ,-S(O)2N(R 1b )(R 1c ), -S(O)(NR 1b )R 1c ,-C(O)N(R 1b )(R 1c ), -C(O)R 1b , or -C(O)OR 1c wherein the alkyl, haloalkyl, cycloalkyl, aryl, 5-10 membered heteroaryl or heterocyclyl is each optionally substituted by one to four Z 1 Replace, and any two Z 1 can combine with the atoms to which they are attached to form C 3-10 Cycloalkyl or heterocyclic or C 6-10 Aryl or 5-10 membered heteroaryl; Ring A is C 3-10 Cycloalkyl, heterocyclic, C 6-10 Aryl or 5-10 membered heteroaryl, the C 3-10 Cycloalkyl, heterocyclic, C 6-10 The aryl or 5-10 membered heteroaryl groups are each substituted with 1 to 4 Z 1a Optional substitution; Ring B is C 3-10 Cycloalkyl, heterocyclic, C 6-10 Aryl or 5-10 membered heteroaryl, the C 3-10 Cycloalkyl, heterocyclic, C 6-10 The aryl or 5-10 membered heteroaryl groups are each supported by 1 to 4 R 4 Optional substitution; Ring A and Ring B each contain 0-3 double bonds; R 2 Yes H, C 1-6 Alkyl, -C 1-6 Alkyl-alkoxy, -C 1-6 Alkyl-cycloalkoxy, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Cycloalkyl, heterocyclic, C 6-10 Aryl, 5-10 membered heteroaryl, -CN, -OR 2a , -SR 2a , -S(O)R 2a , -S(O)(NH)R 2a , -S(O)2R 2a ,-S(O)2N(R 2a )(R 2b ), or -S(O)(NR 2a )R 2b wherein the alkyl, alkoxy, cycloalkyloxy, haloalkyl, cycloalkyl, heterocyclyl, aryl or 5-10 membered heteroaryl groups can each be substituted by 1 to 4 Z 1 Replace, and any two Z 1 can combine with the atoms to which they are attached to form C 3-10 Cycloalkyl or heterocyclic or C 6-10 Aryl or 5-10 membered heteroaryl; X is independently -N=, -C(H)=, or -C(R 8 )=; Each R 3 and R 3’ Independently H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen, C 3-10 Cycloalkyl, heterocyclic, C 6-10 Aryl, 5-10 membered heteroaryl, -CN, -NO2, -OR 3a , -C(O)R 3a ,-CH2C(O)OR 3a , -C(O)OR 3a ,-C(O)N(R 3a )(R 3b ), -N(R 3a )C(O)R 3b , -N(R 3a )C(O)OR 3b , -N(R 3a )C(O)N(R 3b )2,-C(O)NHS(O)2R 3a , -C(O)NR 3a S(O)2R 3b , -C(O)NR 3a S(O)2NR 3b R 3c , -C(O)NR 3a -S(O)(=NR 3b )R 3c , -S(O)2R 3a , -S(O)2OR 3a ,-S(O)2N(R 3a )(R 3b ), -N(R 3a )S(O)2R 3b ,-S(O)2NHC(O)R 3a , -S(O)(=NR 3a )R 3b , -S(O)(=NR 3a )NR 3b ,-S(=NR 3a )(=NR 3b )R 3c , -P(O)(OR 3a )(R 3b ), -P(O)(OR 3a )(OR 3b ), -B(OR 3a )(OR 3b ), or -OC 1-6 Alkyl-C(O)OR 3a wherein the alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or 5-10 membered heteroaryl groups are each substituted by 1 to 4 R 3d replace; Each R 3a , R 3b , and R 3c Independently H, C 1-6 Alkyl, C 6-10 Aryl, 5-10 membered heteroaryl, C 1-6 Haloalkyl, C 2-8 Alkoxyalkyl, -C 1-4 Alkyl-N(R 9a )(R 9b ), -C 1-4 Alkyl-N(R 9a )C(O)-OC 1-4 Alkyl-OP(O)(OR 9c )2, -C 1-4 Alkyl-C(O)N(R 9a )(R 9b ), -C 1-4 Alkyl-OC(O)-OC 1-4 Alkyl, -C 1-4 Alkyl-OC(O)-C 1-4 Alkyl-N(R 9a )(R 9b ), -C 1-4 Alkyl-OC(O)-C 1-4 Alkyl-OP(O)(OR 9c )2, -C 1-4 Alkyl-C 3-8 Cycloalkyl, -C 1-4 Alkyl-heterocyclyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Cycloalkyl, heterocyclyl, -CH2CH(N(R 9a )2)C(O)OR 9b , -P(O)(OR 9c )2, -OP(O)(OR 9c )2,-CH2P(O)(OR 9c )2,-CH2OP(O)(OR 9c )2,-OCH2P(O)(OR 9c )2,-C(O)OCH2P(O)(OR 9c )2,-P(O)(R 9c )(OR 9d ), -OP(O)(R 9c )(OR 9d ), -CH2P(O)(R 9c )(OR 9d ), -OCH2P(O)(R 9c )(OR 9d ), -C(O)OCH2P(O)(R 9c )(OR 9d ), -P(O)(N(R 9c )2)2,-OP(O)(N(R 9c )2)2,-CH2P(O)(N(R 9c )2)2,-OCH2P(O)(N(R 9c )2)2,-C(O)OCH2P(O)(N(R 9c )2)2,-P(O)(N(R 9c )2)(OR 9d ), -OP(O)(N(R 9c )2)(OR 9d ), -CH2P(O)(N(R 9c )2)(OR 9d ), -OCH2P(O)(N(R 9c )2)(OR 9d ), -C(O)OCH2P(O)(N(R 9c )2)(OR 9d ), -P(O)(R 9c )(N(R 9d )2),-OP(O)(R 9c )(N(R 9d )2), -CH2P(O)(R 9c )(N(R 9d )2), -OCH2P(O)(R 9c )(N(R 9d )2), -C(O)OCH2P(O)(R 9c )(N(R 9d )2), C 1-6 Alkyl-heterocyclyl, C 1-6 Alkyl-aryl or C 1-6 Alkyl-(5-10 membered) heteroaryl, wherein the alkyl, alkenyl, cycloalkyl, heterocyclyl, aryl or 5-10 membered heteroaryl can be substituted by 1 to 4 Z 1b replace; Each R 4 are independently H, -OH, CH2OH, C 1-9 Alkyl, C 1-8 Haloalkyl, C 1-6 Haloalkoxy, C 2-6 Alkoxyalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen, C 3-15 Cycloalkyl, heterocyclic, C 6-10 Aryl, 5-10 membered heteroaryl, oxo, -NO2, -CN, -N3, -OR 4a , -C(O)R 4a , -C(O)OR 4a ,-C(O)N(R 4a )(R 4b ), -N(R 4a )(R 4b ), -N(R 4a )2(R 4b ) + , -N(R 4a )-C(O)R 4b , -N(R 4a )C(O)O(R 4b ), -N(R 4a )C(O)N(R 4b )(R 4c ), -N(R 4a )S(O)2(R 4b ), -N(R 4a )S(O)2-N(R 4b )(R 4c ), -N(R 4a )S(O)2O(R 4b ), -OC(O)R 4a , -OC(O)OR 4a ,-OC(O)-N(R 4a )(R 4b ), -SR 4a , -S(O)R 4a , -S(O)(NH)R 4a , -S(O)2R 4a ,-S(O)2N(R 4a )(R 4b ), -S(O)(NR 4a )R 4b , or -Si(R 4a )3; wherein the alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or 5-10 membered heteroaryl are each optionally substituted by 1 to 4 Z 1b or, two R attached to adjacent ring atoms 4 The groups combine with the atoms to which they are attached to form C 5-10 Cycloalkyl or heterocyclic group, each of which may be replaced by 1 to 4 Z 1b replace; Each R 5a and R 5b Independently H, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 2-6 Alkoxyalkyl, halogen, C 3-10 Cycloalkyl, heterocyclyl, -C 1-6 Alkyl-N(R 9a )(R 9b ), -CN, -OR 5a1 , or -N(R 5a1 )(R 5a2 ); or, R 5a and R 5b Combine with the atoms to which they are attached to form C 3-10 Cycloalkyl or heterocyclic group, each of which may be replaced by 1 to 4 R 5a3 Replace; or, R 5a or R 5b Can combine with any substituent on ring A to form C 5-10 Cycloalkyl or heterocyclic group, each of which may be replaced by 1 to 4 R 5a3 replace; Each R 5a1 and R 5a2 Independently H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Cycloalkyl, heterocyclic, C 6-10 aryl or 5-10 membered heteroaryl, wherein the cycloalkyl, heterocyclyl, aryl or 5-10 membered heteroaryl can be each substituted by 1 to 4 R 5a4 replace; V is -C(O)-, -O-, -N(R 6a )-, or -C(R 6b )(R 6c )-; R 6a Yes H, C 1-6 Alkyl, C 3-10 Cycloalkyl, heterocyclyl, -S(O)2R 6a1 , or -S(O)2N(R 6a1 )(R 6a2 ), wherein the cycloalkyl or heterocyclic group may be C 1-6 Alkyl, F or -CN substitution; Each R 6b and R 6c Independently H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkoxyalkyl, halogen, C 3-10 Cycloalkyl, heterocyclyl, -C 1-6 Alkyl-N(R 9a )(R 9b ), -CN, -OR 6c1 , or -N(R 6c2 )(R 6c3 ), wherein the alkyl, cycloalkyl or heterocyclic group may be each substituted by 1 to 4 R 6b1 Replace; or R 6b and R 6c Combine with the atoms to which they are attached to form C 3-10 Cycloalkyl or heterocyclic group, each of which may be replaced by 1 to 4 R 6b1 Replace; or R 6a or R 6c With an R 4 The groups and the atoms to which they are attached combine to form C 5-10 Cycloalkyl or heterocyclic group, each of which may be replaced by 1 to 4 R 10 replace; Y is -N(R 7 )-, -O-, -S-, -S(O)-, -S(O)2-, -S(O)(=NH)-, or -S(O)(=NR 7 )-; Each R 3d , R 5a3 , R 5a4 , R 6b1 , and R 10 Independently H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkoxyalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen, C 3-10 Cycloalkyl, heterocyclic, C 6-10 Aryl, 5-10 membered heteroaryl, oxo, -OH, -CN, CO2R 3e , -NO2, or -C(O)N(R 2a )(R 2b ), wherein the heterocyclic group or the 5-10 membered heteroaryl group can be C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 Haloalkoxy substitution; Each R 6a1 , R 6a2 , R 6c1 , R 6c2 , R 6c3 and R 7 Independently H, C 1-6 Alkyl or C 3-10 Cycloalkyl; Each R 8 Independently C 1-9 Alkyl, C 1-8 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen, oxo, -OH, -CN, CO2R 3e ,-NO2,-NH2,-N3,-SH,-O(C 1-9 alkyl), -O(C 1-8 haloalkyl), -NH(C 1-9 Alkyl), -NH(C 1-8 haloalkyl), -N(C 1-9 Alkyl)2,-N(C 1-8 Haloalkyl)2; Each R 9a and R 9b Independently H, C 1-9 Alkyl, C 1-8 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkoxyalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen, C 3-15 Cycloalkyl, heterocyclic, C 6-10 Aryl, 5-10 membered heteroaryl, oxo, -NO2, -CN, -N3, -OR 12a , -C(O)R 12a , -C(O)OR 12a ,-C(O)N(R 12a )(R 12b ), -N(R 12a )(R 12b ), -N(R 12a )2(R 12b ) + , -N(R 12a )-C(O)R 12b , -N(R 12a )C(O)O(R 12b ), -N(R 12a )C(O)N(R 12b )(R 12c ), -N(R 12a )S(O)2(R 12b ), -N(R 12a )S(O)2-N(R 12b )(R 12c ), -N(R 12a )S(O)2O(R 12b ), -OC(O)R 12a , -OC(O)OR 12a ,-OC(O)-N(R 12a )(R 12b ), -SR 12a , -S(O)R 12a , -S(O)(NH)R 12a , -S(O)2R 12a ,-S(O)2N(R 12a )(R 12b ), -S(O)(NR 12a )R 12b , or -Si(R 12a )3; or R 9a and R 9b Fusion forms a 3-10 membered heterocyclic group which may be substituted by: C 1-9 Alkyl, C 1-8 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkoxyalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen, C 3-15 Cycloalkyl, heterocyclic, C 6-10 Aryl, heteroaryl, oxo, -NO2, -CN, -N3, -OR 12a , -C(O)R 12a , -C(O)OR 12a ,-C(O)N(R 12a )(R 12b ), -N(R 12a )(R 12b ), -N(R 12a )2(R 12b ) + , -N(R 12a )-C(O)R 12b , -N(R 12a )C(O)O(R 12b ), -N(R 12a )C(O)N(R 12b )(R 12c ), -N(R 12a )S(O)2(R 12b ), -N(R 12a )S(O)2-N(R 12b )(R 12c ), -N(R 12a )S(O)2O(R 12b ), -OC(O)R 12a , -OC(O)OR 12a ,-OC(O)-N(R 12a )(R 12b ), -SR 12a , -S(O)R 12a , -S(O)(NH)R 12a , -S(O)2R 12a ,-S(O)2N(R 12a )(R 12b ), -S(O)(NR 12a )R 12b , or -Si(R 12a )3; Each Z 1 Independently C 1-9 Alkyl, C 1-8 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkoxyalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen, C 3-15 Cycloalkyl, heterocyclic, C 6-10 Aryl, 5-10 membered heteroaryl, oxo, -NO2, -N3, -CN, -OR 12a , -C(O)-R 12a , -C(O)OR 12a ,-C(O)N(R 12a )(R 12b ), -N(R 12a )(R 12b ), -N(R 12a )2(R 12b ) + , -N(R 12a )-C(O)-R 12b , -N(R 12a )C(O)O(R 12b ), -N(R 12a )C(O)N(R 12b )(R 12c ), -N(R 12a )S(O)2(R 12b ), -NR 12a S(O)2N(R 12b )(R 12c ), -NR 12a S(O)2O(R 12b ), -OC(O)R 12a , -OC(O)OR 12a ,-OC(O)-N(R 12a )(R 12b ), -SR 12a , -S(O)R 12a , -S(O)(NH)R 12a , -S(O)2R 12a ,-S(O)2N(R 12a )(R 12b ), -S(O)(NR 12a )R 12b , or -Si(R 12a )3, wherein the alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or 5-10 membered heteroaryl groups can each be substituted by 1 to 4 Z 1a replace; Each Z 1a are independently H, -OH, C 1-9 Alkyl, C 1-8 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkoxyalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen, C 3-15 Cycloalkyl, heterocyclic, C 6-10 Aryl, 5-10 membered heteroaryl, oxo, -NO2, -CN, -N3, -OR 12a , -C(O)R 12a , -C(O)OR 12a ,-C(O)N(R 12a )(R 12b ), -N(R 12a )(R 12b ), -N(R 12a )2(R 12b ) + , -N(R 12a )-C(O)R 12b , -N(R 12a )C(O)O(R 12b ), -N(R 12a )C(O)N(R 12b )(R 12c ), -N(R 12a )S(O)2(R 12b ), -N(R 12a )S(O)2-N(R 12b )(R 12c ), -N(R 12a )S(O)2O(R 12b ), -OC(O)R 12a , -OC(O)OR 12a ,-OC(O)-N(R 12a )(R 12b ), -SR 12a , -S(O)R 12a , -S(O)(NH)R 12a , -S(O)2R 12a ,-S(O)2N(R 12a )(R 12b ), -S(O)(NR 12a )R 12b , or -Si(R 12a )3, wherein the alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or 5-10 membered heteroaryl groups can each be substituted by 1 to 4 Z 1b replace; Each Z 1b Independently H, C 1-9 Alkyl, C 1-8 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen, C 3-15 Cycloalkyl, heterocyclic, C 6-10 Aryl, 5-10 membered heteroaryl, oxo, -OH, -CN, CO2R 3e ,-NO2,-NH2,-N3,-SH,-O(C 1-9 alkyl), -O(C 1-8 haloalkyl), -O(C 2-6 alkenyl), -O(C 2-6 Alkynyl), -O(C 3-15 Cycloalkyl), -O(heterocyclyl), -O(C 6-10 aryl), -O(5-10 membered heteroaryl), -NH(C 1-9 Alkyl), -NH(C 1-8 haloalkyl), -NH(C 2-6 alkenyl), -NH(C 2-6 Alkynyl), -NH(C 3-15 Cycloalkyl), -NH(heterocyclyl), -NH(C 6-10 aryl), -NH(5-10 membered heteroaryl), -N(cyclo-alkyl), -N(C 1-9 Alkyl)2,-N(C 1-8 Haloalkyl)2,-N(C 2-6 Alkenyl)2,-N(C 2-6 Alkynyl)2,-N(C 3-15 Cycloalkyl)2,-N(heterocyclyl)2,-N(C 6-10 Aryl)2,-N(5-10 membered heteroaryl)2,-N(C 1-9 Alkyl)(C 1-8 haloalkyl), -N(C 1-9 Alkyl)(C 2-6 alkenyl), -N(C 1-9 Alkyl)(C 2-6 Alkynyl), -N(C 1-9 Alkyl)(C 3-15 Cycloalkyl), -N(C 1-9 alkyl)(heterocyclyl),-N(C 1-9 Alkyl)(C 6-10 Aryl), -N(C 1-9 alkyl)(5-10 membered heteroaryl), -C(O)(C 1-9 alkyl), -C(O)(C 1-8 haloalkyl), -C(O)(C 2-6 alkenyl), -C(O)(C 2-6 Alkynyl), -C(O)(C 3-15 Cycloalkyl), -C(O)(heterocyclyl), -C(O)(C 6-10 aryl), -C(O)(5-10 membered heteroaryl), -C(O)O(C 1-9 alkyl), -C(O)O(C 1-8 haloalkyl), -C(O)O(C 2-6 alkenyl), -C(O)O(C 2-6 Alkynyl), -C(O)O(C 3-15 Cycloalkyl), -C(O)O(heterocyclyl), -C(O)O(C 6-10 aryl), -C(O)O(5-10 membered heteroaryl), -C(O)NH2, -C(O)NH(C 1-9 alkyl), -C(O)NH(C 1-8 haloalkyl), -C(O)NH(C 2-6 alkenyl), -C(O)NH(C 2-6 Alkynyl), -C(O)NH(C 3-15 Cycloalkyl), -C(O)NH(heterocyclyl), -C(O)NH(C 6-10 aryl), -C(O)NH(5-10 membered heteroaryl), -C(O)N(C 1-9 Alkyl)2,-C(O)N(C 1-8 Haloalkyl)2,-C(O)N(C 2-6 alkenyl)2,-C(O)N(C 2-6 Alkynyl)2,-C(O)N(C 3-15 Cycloalkyl)2,-C(O)N(heterocyclyl)2,-C(O)N(C 6-10 Aryl)2,-C(O)N(5-10 membered heteroaryl)2,-NHC(O)(C 1-9 alkyl), -NHC(O)(C 1-8 haloalkyl), -NHC(O)(C 2-6 alkenyl), -NHC(O)(C 2-6 Alkynyl), -NHC(O)(C 3-15 Cycloalkyl), -NHC(O)(heterocyclyl), -NHC(O)(C 6-10 aryl), -NHC(O)(5-10 membered heteroaryl), -NHC(O)O(C 1-9 alkyl), -NHC(O)O(C 1-8 haloalkyl), -NHC(O)O(C 2-6 alkenyl), -NHC(O)O(C 2-6 Alkynyl), -NHC(O)O(C 3-15 Cycloalkyl), -NHC(O)O(heterocyclyl), -NHC(O)O(C 6-10 aryl), -NHC(O)O(5-10 membered heteroaryl), -NHC(O)NH(C 1-9 alkyl), -NHC(O)NH(C 1-8 haloalkyl), -NHC(O)NH(C 2-6 alkenyl), -NHC(O)NH(C 2-6 Alkynyl), -NHC(O)NH(C 3-15 Cycloalkyl), -NHC(O)NH(heterocyclyl), -NHC(O)NH(C 6-10 aryl), -NHC(O)NH(5-10 membered heteroaryl), -NHS(O)(C 1-9 Alkyl), -N(C 1-9 Alkyl)(S(O)(C 1-9 Alkyl), -S(C 1-9 Alkyl), -S(C 1-8 haloalkyl), -S(C 2-6 alkenyl), -S(C 2-6 Alkynyl), -S(C 3-15 Cycloalkyl), -S(heterocyclyl), -S(C 6-10 aryl), -S(5-10 membered heteroaryl), -S(O)N(C 1-9 Alkyl)2,-S(O)(C 1-9 alkyl), -S(O)(C 1-8 haloalkyl), -S(O)(C 2-6 alkenyl), -S(O)(C 2-6 Alkynyl), -S(O)(C 3-15 Cycloalkyl), -S(O)(heterocyclyl), -S(O)(C 6-10 aryl), -S(O)(5-10 membered heteroaryl), -S(O)2(C 1-9 Alkyl), -S(O)2(C 1-8 haloalkyl), -S(O)2(C 2-6 alkenyl), -S(O)2(C 2-6 Alkynyl), -S(O)2(C 3-15 Cycloalkyl), -S(O)2(heterocyclyl), -S(O)2(C 6-10 Aryl), -S(O)2(5-10 membered heteroaryl), -S(O)(NH)(C 1-9 alkyl), -S(O)2NH(C 1-9 alkyl), or -S(O)2N(C 1-9 wherein the alkyl, cycloalkyl, heterocyclyl, aryl or 5-10 membered heteroaryl may be substituted in each case by 1 to 3 of the following: 1-9 Alkyl, C 1-8 Haloalkyl, halogen, -OH, -NH2, CO2H, -O(C 1-9 alkyl), -O(C 1-8 haloalkyl), -O(C 3-15 cycloalkyl), -O(heterocyclyl), -O(aryl), -O(5-10 membered heteroaryl), -NH(C 1-9 Alkyl), -NH(C 1-8 haloalkyl), -NH(C 3-15 cycloalkyl), -NH(heterocyclyl), -NH(aryl), -NH(5-10 membered heteroaryl), -N(C 1-9 Alkyl)2,-N(C 3-15 Cycloalkyl)2,-NHC(O)(C 1-8 haloalkyl), -NHC(O)(C 3-15 cycloalkyl), -NHC(O)(heterocyclyl), -NHC(O)(aryl), -NHC(O)(5-10 membered heteroaryl), -NHC(O)O(C 1-9 alkyl), -NHC(O)O(C 1-8 haloalkyl), -NHC(O)O(C 2-6 Alkynyl), -NHC(O)O(C 3-15 Cycloalkyl), -NHC(O)O(heterocyclyl), -NHC(O)O(aryl), -NHC(O)O(5-10 membered heteroaryl), -NHC(O)NH(C 1-9 Alkyl), S(O)2(C 1-9 Alkyl), -S(O)2(C 1-8 haloalkyl), -S(O)2(C 3-15 Cycloalkyl), -S(O)2(heterocyclyl), -S(O)2(aryl), -S(O)2(5-10 membered heteroaryl), -S(O)(NH)(C 1-9 alkyl), -S(O)2NH(C 1-9 alkyl), or -S(O)2N(C 1-9 Alkyl)2; Each R 1b , R 1c , R 2a , R 2b , R 4a , R 4b , R 4c , R 9c , R 9d , R 12a , R 12b , and R 12c are independently H, -OH, C 1-9 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-15 Cycloalkyl, heterocyclic, C 6-10 aryl, or 5-10 membered heteroaryl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or 5-10 membered heteroaryl can be substituted by 1 to 4 Z 1b Replacement; and Each R 3e Independently H, C 1-6 Alkyl, C 1-6 Haloalkyl, -C 1-4 Alkyl-N(R 9a )(R 9b ), -C 1-4 Alkyl-C(O)N(R 9a )(R 9b ), -C 1-4 Alkyl-OC(O)-OC 1-4 Alkyl, -C 1-4 Alkyl-OC(O)-C 1-4 Alkyl-N(R 9a )(R 9b ), -C 1-4 Alkyl-C 3-8 Cycloalkyl, -C 1-4 Alkyl-heterocyclyl, C 3-10 Cycloalkyl, heterocyclic, C 6-10 Aryl, 5-10 membered heteroaryl, -P(O)(OR 9c )2,-CH2P(O)(OR 9c )2,-OCH2P(O)(OR 9c )2,-C(O)OCH2P(O)(OR 9c )2,-P(O)(R 9c )(OR 9d ), -OP(O)(R 9c )(OR 9d ), -CH2P(O)(R 9c )(OR 9d ), -C(O)OCH2P(O)(R 9c )(OR 9d ), -P(O)(N(R 9c )2)2,-CH2P(O)(N(R 9c )2)2,-C(O)OCH2P(O)(N(R 9c )2)2,-P(O)(N(R 9c )2)(OR 9d ), -CH2P(O)(N(R 9c )2)(OR 9d ), -C(O)OCH2P(O)(N(R 9c )2)(OR 9d ), -P(O)(R 9c )(N(R 9d )2), -CH2P(O)(R 9c )(N(R 9d )2), or -C(O)OCH2P(O)(R 9c )(N(R 9d )2), wherein the alkyl, alkenyl, cycloalkyl, heterocyclyl, aryl or 5-10 membered heteroaryl are each optionally substituted by 1 to 4 Z 1b substituted; wherein each 5-10 membered heteroaryl has a 5- to 12-membered structure and has 1 to 4 heteroatoms that are each independently N, O or S; and wherein each heterocyclyl has a 3- to 12-membered structure and has 1 to 4 heteroatoms that are each independently N, O or S.

2. The compound according to claim 1, wherein the compound is a compound having the general formula IA-2 or the general formula IA-3 or a pharmaceutically acceptable salt thereof, in, Ring C is C 3-10 Cycloalkyl, heterocyclic, C 6-10 aryl or 5-10 membered heteroaryl, each of which may be substituted by 1-4 Z 1 replace; Y1-V is N-CH2, N-CH(CH3), N-CF2, CH-CH2, CH-CF2, CH-NH, NS(O), NS(O)2, NC(O), CH-C(O) or cyclopropyl; Y2 is C, CH or N; R 2 Yes H, C 1-6 Alkyl, C 1-6 Alkyl-alkoxy, C 1-6 Alkyl-cycloalkoxy, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Cycloalkyl, heterocyclic, C 6-10 Aryl, 5-10 membered heteroaryl, -CN, -OR 2a , -SR 2a , -S(O)R 2a , -S(O)(NH)R 2a , -S(O)2R 2a ,-S(O)2N(R 2a )(R 2b ), or -S(O)(NR 2a )R 2b , wherein the alkyl, alkoxy, cycloalkyloxy, haloalkyl, cycloalkyl, heterocyclic, aryl or 5-10 membered heteroaryl groups can each be substituted by 1 to 4 Z 1 Replace and any two Z 1 can combine with the atoms to which they are attached to form C 3-10 Cycloalkyl or heterocyclic or C 6-10 Aryl or 5-10 membered heteroaryl; X is independently -N=, -C(H)=, or -C(R 8 )=; Each R 3 and R 3’ Independently H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen, C 3-10 Cycloalkyl, heterocyclic, C 6-10 Aryl, 5-10 membered heteroaryl, -CN, -NO2, -OR 3a , -C(O)R 3a ,-CH2C(O)OR 3a , -C(O)OR 3a ,-C(O)N(R 3a )(R 3b ), -N(R 3a )C(O)R 3b , -N(R 3a )C(O)OR 3b , -N(R 3a )C(O)N(R 3b )2,-C(O)NHS(O)2R 3a , -C(O)NR 3a S(O)2R 3b , -C(O)NR 3a S(O)2NR 3b R 3c , -C(O)NR 3a -S(O)(=NR 3b )R 3c , -S(O)2R 3a , -S(O)2OR 3a ,-S(O)2N(R 3a )(R 3b ), -N(R 3a )S(O)2R 3b ,-S(O)2NHC(O)R 3a , -S(O)(=NR 3a )R 3b , -S(O)(=NR 3a )NR 3b ,-S(=NR 3a )(=NR 3b )R 3c , -P(O)(OR 3a )(R 3b ), -P(O)(OR 3a )(OR 3b ), -B(OR 3a )(OR 3b ), or -OC 1-6 Alkyl-C(O)OR 3a , wherein the alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or 5-10 membered heteroaryl groups can each be substituted by 1 to 4 R 3d replace; Each R 3a , R 3b and R 3c Independently H, C 1-6 Alkyl, C 6-10 Aryl, 5-10 membered heteroaryl, C 1-6 Haloalkyl, C 2-8 Alkoxyalkyl, -C 1-4 Alkyl-N(R 9a )(R 9b ), -C 1-4 Alkyl-N(R 9a )C(O)-OC 1-4 Alkyl-OP(O)(OR 9c )2, -C 1-4 Alkyl-C(O)N(R 9a )(R 9b ), -C 1-4 Alkyl-OC(O)-OC 1-4 Alkyl, -C 1-4 Alkyl-OC(O)-C 1-4 Alkyl-N(R 9a )(R 9b ), -C 1-4 Alkyl-OC(O)-C 1-4 Alkyl-OP(O)(OR 9c )2, -C 1-4 Alkyl-C 3-8 Cycloalkyl, -C 1-4 Alkyl-heterocyclyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Cycloalkyl, heterocyclyl, -CH2CH(N(R 9a )2)C(O)OR 9b , C 1-6 Alkyl-heterocyclyl, C 1-6 Alkyl-aryl or C 1-6 Alkyl-(5-10 membered) heteroaryl, wherein the alkyl, alkenyl, cycloalkyl, heterocyclyl, aryl or 5-10 membered heteroaryl can be substituted by 1 to 4 Z 1b replace; Each R 5a and R 5b Independently H, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 2-6 Alkoxyalkyl, halogen, C 3-10 Cycloalkyl, heterocyclyl, -C 1-6 Alkyl-N(R 9a )(R 9b ), -CN, -OR 5a1 , or -N(R 5a1 )(R 5a2 ); or, R 5a and R 5b Combine with the atoms to which they are attached to form C 3-10 Cycloalkyl or heterocyclic group, each of which may be replaced by 1 to 4 R 5a3 Replacement Each R 5a1 and R 5a2 Independently H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Cycloalkyl, heterocyclic, C 6-10 Aryl or 5-10 membered heteroaryl, wherein the cycloalkyl, heterocyclyl, aryl or 5-10 membered heteroaryl may be substituted by 1 to 4 halogens; Each R 3d and R 5a3 Independently H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkoxyalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen, C 3-10 Cycloalkyl, heterocyclic, C 6-10 Aryl, 5-10 membered heteroaryl, oxo, -OH, -CN, -CO2R 3e , -NO2, or -C(O)N(R 2a )(R 2b ), wherein the heterocyclic group or the 5-10 membered heteroaryl group may be C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 Haloalkoxy substitution; Each R 8 Independently C 1-9 Alkyl, C 1-8 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen, oxo, -OH, -CN, CO2R 3e ,-NO2,-NH2,-N3,-SH,-O(C 1-9 alkyl), -O(C 1-8 haloalkyl), -NH(C 1-9 Alkyl), -NH(C 1-8 haloalkyl), -N(C 1-9 Alkyl)2,-N(C 1-8 Haloalkyl)2; Each R 9a and R 9b Independently H, C 1-9 Alkyl, C 1-8 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkoxyalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen, C 3-15 Cycloalkyl, heterocyclic, C 6-10 Aryl, 5-10 membered heteroaryl, oxo, -NO2, -CN, -N3, -OR 12a , -C(O)R 12a , -C(O)OR 12a ,-C(O)N(R 12a )(R 12b ), -N(R 12a )(R 12b ), -N(R 12a )2(R 12b ) + , -N(R 12a )-C(O)R 12b , -N(R 12a )C(O)O(R 12b ), -N(R 12a )C(O)N(R 12b )(R 12c ), -N(R 12a )S(O)2(R 12b ), -N(R 12a )S(O)2-N(R 12b )(R 12c ), -N(R 12a )S(O)2O(R 12b ), -OC(O)R 12a , -OC(O)OR 12a ,-OC(O)-N(R 12a )(R 12b ), -SR 12a , -S(O)R 12a , -S(O)(NH)R 12a , -S(O)2R 12a ,-S(O)2N(R 12a )(R 12b ), -S(O)(NR 12a )R 12b , or -Si(R 12a )3; or R 9a and R 9b Fusion forms a 3-10 membered heterocyclic group which may be substituted by: C 1-9 Alkyl, C 1-8 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkoxyalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen, C 3-15 Cycloalkyl, heterocyclic, C 6-10 Aryl, heteroaryl, oxo, -NO2, -CN, -N3, -OR 12a , -C(O)R 12a , -C(O)OR 12a ,-C(O)N(R 12a )(R 12b ), -N(R 12a )(R 12b ), -N(R 12a )2(R 12b ) + , -N(R 12a )-C(O)R 12b , -N(R 12a )C(O)O(R 12b ), -N(R 12a )C(O)N(R 12b )(R 12c ), -N(R 12a )S(O)2(R 12b ), -N(R 12a )S(O)2-N(R 12b )(R 12c ), -N(R 12a )S(O)2O(R 12b ), -OC(O)R 12a , -OC(O)OR 12a ,-OC(O)-N(R 12a )(R 12b ), -SR 12a , -S(O)R 12a , -S(O)(NH)R 12a , -S(O)2R 12a ,-S(O)2N(R 12a )(R 12b ), -S(O)(NR 12a )R 12b , or -Si(R 12a )3; Each Z 1 Independently C 1-9 Alkyl, C 1-8 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkoxyalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen, C 3-15 Cycloalkyl, heterocyclic, C 6-10 Aryl, 5-10 membered heteroaryl, oxo, -NO2, -N3, -CN, -OR 12a , wherein the alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or 5-10 membered heteroaryl groups can each be substituted by 1 to 4 Z 1a replace; Each Z 1a Independently H, C 1-9 Alkyl, C 1-8 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkoxyalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen, C 3-15 Cycloalkyl, heterocyclic, C 6-10 Aryl, 5-10 membered heteroaryl, oxo, -NO2, -CN, -N3, -OR 12a , -C(O)R 12a , -C(O)OR 12a ,-C(O)N(R 12a )(R 12b ), -N(R 12a )(R 12b ), -N(R 12a )2(R 12b ) + , -N(R 12a )-C(O)R 12b , -N(R 12a )C(O)O(R 12b ), -N(R 12a )C(O)N(R 12b )(R 12c ), -N(R 12a )S(O)2(R 12b ), -N(R 12a )S(O)2-N(R 12b )(R 12c ), -N(R 12a )S(O)2O(R 12b ), -OC(O)R 12a , -OC(O)OR 12a ,-OC(O)-N(R 12a )(R 12b ), -SR 12a , -S(O)R 12a , -S(O)(NH)R 12a , -S(O)2R 12a ,-S(O)2N(R 12a )(R 12b ), -S(O)(NR 12a )R 12b , or -Si(R 12a )3; wherein the alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl or 5-10 membered heteroaryl groups can each be substituted by 1 to 4 Z 1b replace; Each Z 1b Independently H, C 1-9 Alkyl, C 1-8 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen, C 3-15 Cycloalkyl, heterocyclic, C 6-10 Aryl, 5-10 membered heteroaryl, oxo, -OH, -CN, CO2R 3e ,-NO2,-NH2,-N3,-SH,-O(C 1-9 alkyl), -O(C 1-8 haloalkyl), -O(C 2-6 alkenyl), -O(C 2-6 Alkynyl), -O(C 3-15 Cycloalkyl), -O(heterocyclyl), -O(C 6-10 aryl), -O(5-10 membered heteroaryl), -NH(C 1-9 Alkyl), -NH(C 1-8 haloalkyl), -NH(C 2-6 alkenyl), -NH(C 2-6 Alkynyl), -NH(C 3-15 Cycloalkyl), -NH(heterocyclyl), -NH(C 6-10 aryl), -NH(5-10 membered heteroaryl), -N(cyclo-alkyl), -N(C 1-9 Alkyl)2,-N(C 1-8 Haloalkyl)2,-N(C 2-6 Alkenyl)2,-N(C 2-6 Alkynyl)2,-N(C 3-15 Cycloalkyl)2,-N(heterocyclyl)2,-N(C 6-10 Aryl)2,-N(5-10 membered heteroaryl)2,-N(C 1-9 Alkyl)(C 1-8 haloalkyl), -N(C 1-9 Alkyl)(C 2-6 alkenyl), -N(C 1-9 Alkyl)(C 2-6 Alkynyl), -N(C 1-9 Alkyl)(C 3-15 Cycloalkyl), -N(C 1-9 alkyl)(heterocyclyl),-N(C 1-9 Alkyl)(C 6-10 Aryl), -N(C 1-9 alkyl)(5-10 membered heteroaryl), -C(O)(C 1-9 alkyl), -C(O)(C 1-8 haloalkyl), -C(O)(C 2-6 alkenyl), -C(O)(C 2-6 Alkynyl), -C(O)(C 3-15 Cycloalkyl), -C(O)(heterocyclyl), -C(O)(C 6-10 aryl), -C(O)(5-10 membered heteroaryl), -C(O)O(C 1-9 alkyl), -C(O)O(C 1-8 haloalkyl), -C(O)O(C 2-6 alkenyl), -C(O)O(C 2-6 Alkynyl), -C(O)O(C 3-15 Cycloalkyl), -C(O)O(heterocyclyl), -C(O)O(C 6-10 aryl), -C(O)O(5-10 membered heteroaryl), -C(O)NH2, -C(O)NH(C 1-9 alkyl), -C(O)NH(C 1-8 haloalkyl), -C(O)NH(C 2-6 alkenyl), -C(O)NH(C 2-6 Alkynyl), -C(O)NH(C 3-15 Cycloalkyl), -C(O)NH(heterocyclyl), -C(O)NH(C 6-10 aryl), -C(O)NH(5-10 membered heteroaryl), -C(O)N(C 1-9 Alkyl)2,-C(O)N(C 1-8 Haloalkyl)2,-C(O)N(C 2-6 alkenyl)2,-C(O)N(C 2-6 Alkynyl)2,-C(O)N(C 3-15 Cycloalkyl)2,-C(O)N(heterocyclyl)2,-C(O)N(C 6-10 Aryl)2,-C(O)N(5-10 membered heteroaryl)2,-NHC(O)(C 1-9 alkyl), -NHC(O)(C 1-8 haloalkyl), -NHC(O)(C 2-6 alkenyl), -NHC(O)(C 2-6 Alkynyl), -NHC(O)(C 3-15 Cycloalkyl), -NHC(O)(heterocyclyl), -NHC(O)(C 6-10 aryl), -NHC(O)(5-10 membered heteroaryl), -NHC(O)O(C 1-9 alkyl), -NHC(O)O(C 1-8 haloalkyl), -NHC(O)O(C 2-6 alkenyl), -NHC(O)O(C 2-6 Alkynyl), -NHC(O)O(C 3-15 Cycloalkyl), -NHC(O)O(heterocyclyl), -NHC(O)O(C 6-10 aryl), -NHC(O)O(5-10 membered heteroaryl), -NHC(O)NH(C 1-9 alkyl), -NHC(O)NH(C 1-8 haloalkyl), -NHC(O)NH(C 2-6 alkenyl), -NHC(O)NH(C 2-6 Alkynyl), -NHC(O)NH(C 3-15 Cycloalkyl), -NHC(O)NH(heterocyclyl), -NHC(O)NH(C 6-10 wherein the alkyl, cycloalkyl, heterocyclyl, aryl or 5-10 membered heteroaryl may be substituted by 1 to 3 of the following: 1-9 Alkyl, C 1-8 Haloalkyl, halogen, -OH, -NH2, CO2H, -O(C 1-9 alkyl), -O(C 1-8 haloalkyl), -O(C 3-15 cycloalkyl), -O(heterocyclyl), -O(aryl), -O(5-10 membered heteroaryl), -NH(C 1-9 Alkyl), -NH(C 1-8 haloalkyl), -NH(C 3-15 cycloalkyl), -NH(heterocyclyl), -NH(aryl), -NH(5-10 membered heteroaryl), -N(C 1-9 Alkyl)2,-N(C 3-15 Cycloalkyl)2,-NHC(O)(C 1-8 haloalkyl), -NHC(O)(C 3-15 cycloalkyl), -NHC(O)(heterocyclyl), -NHC(O)(aryl), -NHC(O)(5-10 membered heteroaryl), -NHC(O)O(C 1-9 alkyl), -NHC(O)O(C 1-8 haloalkyl), -NHC(O)O(C 2-6 Alkynyl), -NHC(O)O(C 3-15 cycloalkyl), -NHC(O)O(heterocyclyl), -NHC(O)O(aryl), -NHC(O)O(5-10 membered heteroaryl), or -NHC(O)NH(C 1-9 alkyl); Each R 1b , R 1c , R 2a , R 2b , R 4c , R 9c , R 12a , R 12b and R 12c are independently H, -OH, C 1-9 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-15 Cycloalkyl, heterocyclic, C 6-10 aryl, or 5-10 membered heteroaryl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or 5-10 membered heteroaryl can be substituted by 1 to 4 Z 1b replace; and Each R 3e Independently H, C 1-6 Alkyl, C 1-6 Haloalkyl, -C 1-4 Alkyl-N(R 9a )(R 9b ), -C 1-4 Alkyl-C(O)N(R 9a )(R 9b ), -C 1-4 Alkyl-OC(O)-OC 1-4 Alkyl, -C 1-4 Alkyl-OC(O)-C 1-4 Alkyl-N(R 9a )(R 9b ), -C 1-4 Alkyl-C 3-8 Cycloalkyl, -C 1-4 Alkyl-heterocyclyl, C 3-10 Cycloalkyl, heterocyclic, C 6-10 aryl, or 5-10 membered heteroaryl; wherein the alkyl, alkenyl, cycloalkyl, heterocyclyl, aryl or 5-10 membered heteroaryl can be each substituted by 1 to 4 Z 1b substituted; wherein each 5-10 membered heteroaryl has a 5- to 12-membered ring structure and has 1 to 4 heteroatoms which are each independently N, O or S; and wherein each heterocyclyl has a 3- to 12-membered ring structure and has 1 to 4 heteroatoms which are each independently N, O or S.

3. The compound according to claim 1, wherein the compound is a compound having the general formula IA-4 or the general formula IA-5 or a pharmaceutically acceptable salt thereof, Wherein ring C is C 3-10 Cycloalkyl, heterocyclic, C 6-10 Aryl and 5-10 membered heteroaryl, each of which may be replaced by 1 to 4 Z 1 replace; Y1-V is N-CH2, N-CH(CH3), N-CF2, CH-CH2, CH-CF2, CH-NH, NS(O), NS(O)2, NC(O), CH-C(O) or cyclopropyl; Y2 is C, CH or N; R 2 Yes H, C 1-6 Alkyl, C 1-6 Alkyl-alkoxy, C 1-6 Alkyl-cycloalkoxy, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Cycloalkyl, heterocyclic, C 6-10 Aryl, 5-10 membered heteroaryl, -CN, -OR 2a , -SR 2a , -S(O)R 2a , -S(O)(NH)R 2a , -S(O)2R 2a ,-S(O)2N(R 2a )(R 2b ), or -S(O)(NR 2a )R 2b ,in, The alkyl, alkoxy, cycloalkyloxy, haloalkyl, cycloalkyl, heterocyclic, aryl or 5-10 membered heteroaryl groups may each be substituted with 1 to 4 Z 1 Replace and any two Z 1 can combine with the atoms to which they are attached to form C 3-10 Cycloalkyl or heterocyclic or C 6-10 Aryl or 5-10 membered heteroaryl; X is independently -N=, -C(H)=, or -C(R 8 )=; Each R 3 and R 3’ Independently H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen, C 3-10 Cycloalkyl, heterocyclic, C 6-10 Aryl, 5-10 membered heteroaryl, -CN, -NO2, -OR 3a , -C(O)R 3a ,-CH2C(O)OR 3a , -C(O)OR 3a ,-C(O)N(R 3a )(R 3b ), -N(R 3a )C(O)R 3b , -N(R 3a )C(O)OR 3b , -N(R 3a )C(O)N(R 3b )2,-C(O)NHS(O)2R 3a , -C(O)NR 3a S(O)2R 3b , -C(O)NR 3a S(O)2NR 3b R 3c , -C(O)NR 3a -S(O)(=NR 3b )R 3c , -S(O)2R 3a , -S(O)2OR 3a ,-S(O)2N(R 3a )(R 3b ), -N(R 3a )S(O)2R 3b ,-S(O)2NHC(O)R 3a , -S(O)(=NR 3a )R 3b , -S(O)(=NR 3a )NR 3b ,-S(=NR 3a )(=NR 3b )R 3c , -P(O)(OR 3a )(R 3b ), -P(O)(OR 3a )(OR 3b ), -B(OR 3a )(OR 3b ), or -OC 1-6 Alkyl-C(O)OR 3a , wherein the alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or 5-10 membered heteroaryl groups can each be substituted by 1 to 4 R 3d replace; Each R 3a , R 3b and R 3c Independently H, C 1-6 Alkyl, C 6-10 Aryl, 5-10 membered heteroaryl, C 1-6 Haloalkyl, C 2-8 Alkoxyalkyl, -C 1-4 Alkyl-N(R 9a )(R 9b ), -C 1-4 Alkyl-N(R 9a )C(O)-OC 1-4 Alkyl-OP(O)(OR 9c )2, -C 1-4 Alkyl-C(O)N(R 9a )(R 9b ), -C 1-4 Alkyl-OC(O)-OC 1-4 Alkyl, -C 1-4 Alkyl-OC(O)-C 1-4 Alkyl-N(R 9a )(R 9b ), -C 1-4 Alkyl-OC(O)-C 1-4 Alkyl-OP(O)(OR 9c )2, -C 1-4 Alkyl-C 3-8 Cycloalkyl, -C 1-4 Alkyl-heterocyclyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Cycloalkyl, heterocyclyl, -CH2CH(N(R 9a )2)C(O)OR 9b , C 1-6 Alkyl-heterocyclyl, C 1-6 Alkyl-aryl or C 1-6 Alkyl-(5-10 membered) heteroaryl, wherein the alkyl, alkenyl, cycloalkyl, heterocyclyl, aryl or 5-10 membered heteroaryl can be substituted by 1 to 4 Z 1b replace, Each R 5a Independently H, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 2-6 Alkoxyalkyl, halogen, C 3-10 Cycloalkyl, heterocyclyl, -C 1-6 Alkyl-N(R 9a )(R 9b ), -CN, -OR 5a1 , or -N(R 5a1 )(R 5a2 ); Each R 5a1 and R 5a2 Independently H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Cycloalkyl, heterocyclic, C 6-10 Aryl or 5-10 membered heteroaryl, wherein the cycloalkyl, heterocyclyl, aryl or 5-10 membered heteroaryl may be substituted by 1 to 4 halogens; Each R 3d Independently H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkoxyalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen, C 3-10 Cycloalkyl, heterocyclic, C 6-10 Aryl, 5-10 membered heteroaryl, oxo, -OH, -CN, CO2R 3c , -NO2, or -C(O)N(R 2a )(R 2b ), wherein the heterocyclic group or the 5-10 membered heteroaryl group may be C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 Haloalkoxy substitution; Each R 8 Independently C 1-9 Alkyl, C 1-8 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen, oxo, -OH, -CN, CO2R 3e ,-NO2,-NH2,-N3,-SH,-O(C 1-9 alkyl), -O(C 1-8 haloalkyl), -NH(C 1-9 Alkyl), -NH(C 1-8 haloalkyl), -N(C 1-9 Alkyl)2,-N(C 1-8 Haloalkyl)2; Each R 9a and R 9b Independently H, C 1-9 Alkyl, C 1-8 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkoxyalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen, C 3-15 Cycloalkyl, heterocyclic, C 6-10 Aryl, 5-10 membered heteroaryl, oxo, -NO2, -CN, -N3, -OR 12a , -C(O)R 12a , -C(O)OR 12a ,-C(O)N(R 12a )(R 12b ), -N(R 12a )(R 12b ), -N(R 12a )2(R 12b ) + , -N(R 12a )-C(O)R 12b , -N(R 12a )C(O)O(R 12b ), -N(R 12a )C(O)N(R 12b )(R 12c ), -N(R 12a )S(O)2(R 12b ), -N(R 12a )S(O)2-N(R 12b )(R 12c ), -N(R 12a )S(O)2O(R 12b ), -OC(O)R 12a , -OC(O)OR 12a ,-OC(O)-N(R 12a )(R 12b ), -SR 12a , -S(O)R 12a , -S(O)(NH)R 12a , -S(O)2R 12a ,-S(O)2N(R 12a )(R 12b ), -S(O)(NR 12a )R 12b , or -Si(R 12a )3; or R 9a and R 9b Fusion forms a 3-10 membered heterocyclic group which may be substituted by: C 1-9 Alkyl, C 1-8 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkoxyalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen, C 3-15 Cycloalkyl, heterocyclic, C 6-10 Aryl, heteroaryl, oxo, -NO2, -CN, -N3, -OR 12a , -C(O)R 12a , -C(O)OR 12a ,-C(O)N(R 12a )(R 12b ), -N(R 12a )(R 12b ), -N(R 12a )2(R 12b ) + , -N(R 12a )-C(O)R 12b , -N(R 12a )C(O)O(R 12b ), -N(R 12a )C(O)N(R 12b )(R 12c ), -N(R 12a )S(O)2(R 12b ), -N(R 12a )S(O)2-N(R 12b )(R 12c ), -N(R 12a )S(O)2O(R 12b ), -OC(O)R 12a , -OC(O)OR 12a ,-OC(O)-N(R 12a )(R 12b ), -SR 12a , -S(O)R 12a , -S(O)(NH)R 12a , -S(O)2R 12a ,-S(O)2N(R 12a )(R 12b ), -S(O)(NR 12a )R 12b , or -Si(R 12a )3; Each Z 1 Independently C 1-9 Alkyl, C 1-8 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkoxyalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen, C 3-15 Cycloalkyl, heterocyclic, C 6-10 Aryl, 5-10 membered heteroaryl, oxo, -NO2, -CN, -N3, or -OR 12a , wherein the alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or 5-10 membered heteroaryl groups can each be substituted by 1 to 4 Z 1a replace; Each Z 1a Independently H, C 1-9 Alkyl, C 1-8 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkoxyalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen, C 3-15 Cycloalkyl, heterocyclic, C 6-10 Aryl, 5-10 membered heteroaryl, oxo, -NO2, -CN, -N3, -OR 12a , -C(O)R 12a , -C(O)OR 12a ,-C(O)N(R 12a )(R 12b ), -N(R 12a )(R 12b ), -N(R 12a )2(R 12b ) + , -N(R 12a )-C(O)R 12b , -N(R 12a )C(O)O(R 12b ), -N(R 12a )C(O)N(R 12b )(R 12c ), -N(R 12a )S(O)2(R 12b ), -N(R 12a )S(O)2-N(R 12b )(R 12c ), -N(R 12a )S(O)2O(R 12b ), -OC(O)R 12a , -OC(O)OR 12a ,-OC(O)-N(R 12a )(R 12b ), -SR 12a , -S(O)R 12a , -S(O)(NH)R 12a , -S(O)2R 12a ,-S(O)2N(R 12a )(R 12b ), -S(O)(NR 12a )R 12b , or -Si(R 12a )3, wherein the alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or 5-10 membered heteroaryl can be each substituted by 1 to 4 Z 1b replace; Each Z 1b Independently H, C 1-9 Alkyl, C 1-8 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen, C 3-15 Cycloalkyl, heterocyclic, C 6-10 Aryl, 5-10 membered heteroaryl, oxo, -OH, -CN, CO2R 3e ,-NO2,-NH2,-N3,-SH,-O(C 1-9 alkyl), -O(C 1-8 haloalkyl), -O(C 2-6 alkenyl), -O(C 2-6 Alkynyl), -O(C 3-15 Cycloalkyl), -O(heterocyclyl), -O(C 6-10 aryl), -O(5-10 membered heteroaryl), -NH(C 1-9 Alkyl), -NH(C 1-8 haloalkyl), -NH(C 2-6 alkenyl), -NH(C 2-6 Alkynyl), -NH(C 3-15 Cycloalkyl), -NH(heterocyclyl), -NH(C 6-10 aryl), -NH(5-10 membered heteroaryl), -N(cyclo-alkyl), -N(C 1-9 Alkyl)2,-N(C 1-8 Haloalkyl)2,-N(C 2-6 Alkenyl)2,-N(C 2-6 Alkynyl)2,-N(C 3-15 Cycloalkyl)2,-N(heterocyclyl)2,-N(C 6-10 Aryl)2,-N(5-10 membered heteroaryl)2,-N(C 1-9 Alkyl)(C 1-8 haloalkyl), -N(C 1-9 Alkyl)(C 2-6 alkenyl), -N(C 1-9 Alkyl)(C 2-6 Alkynyl), -N(C 1-9 Alkyl)(C 3-15 Cycloalkyl), -N(C 1-9 alkyl)(heterocyclyl),-N(C 1-9 Alkyl)(C 6-10 Aryl), -N(C 1-9 alkyl)(5-10 membered heteroaryl), -C(O)(C 1-9 alkyl), -C(O)(C 1-8 haloalkyl), -C(O)(C 2-6 alkenyl), -C(O)(C 2-6 Alkynyl), -C(O)(C 3-15 Cycloalkyl), -C(O)(heterocyclyl), -C(O)(C 6-10 aryl), -C(O)(5-10 membered heteroaryl), -C(O)O(C 1-9 alkyl), -C(O)O(C 1-8 haloalkyl), -C(O)O(C 2-6 alkenyl), -C(O)O(C 2-6 Alkynyl), -C(O)O(C 3-15 Cycloalkyl), -C(O)O(heterocyclyl), -C(O)O(C 6-10 aryl), -C(O)O(5-10 membered heteroaryl), -C(O)NH2, -C(O)NH(C 1-9 alkyl), -C(O)NH(C 1-8 haloalkyl), -C(O)NH(C 2-6 alkenyl), -C(O)NH(C 2-6 Alkynyl), -C(O)NH(C 3-15 Cycloalkyl), -C(O)NH(heterocyclyl), -C(O)NH(C 6-10 aryl), -C(O)NH(5-10 membered heteroaryl), -C(O)N(C 1-9 Alkyl)2,-C(O)N(C 1-8 Haloalkyl)2,-C(O)N(C 2-6 alkenyl)2,-C(O)N(C 2-6 Alkynyl)2,-C(O)N(C 3-15 Cycloalkyl)2,-C(O)N(heterocyclyl)2,-C(O)N(C 6-10 Aryl)2,-C(O)N(5-10 membered heteroaryl)2,-NHC(O)(C 1-9 alkyl), -NHC(O)(C 1-8 haloalkyl), -NHC(O)(C 2-6 alkenyl), -NHC(O)(C 2-6 Alkynyl), -NHC(O)(C 3-15 Cycloalkyl), -NHC(O)(heterocyclyl), -NHC(O)(C 6-10 aryl), -NHC(O)(5-10 membered heteroaryl), -NHC(O)O(C 1-9 alkyl), -NHC(O)O(C 1-8 haloalkyl), -NHC(O)O(C 2-6 alkenyl), -NHC(O)O(C 2-6 Alkynyl), -NHC(O)O(C 3-15 Cycloalkyl), -NHC(O)O(heterocyclyl), -NHC(O)O(C 6-10 aryl), -NHC(O)O(5-10 membered heteroaryl), -NHC(O)NH(C 1-9 alkyl), -NHC(O)NH(C 1-8 haloalkyl), -NHC(O)NH(C 2-6 alkenyl), -NHC(O)NH(C 2-6 Alkynyl), -NHC(O)NH(C 3-15 Cycloalkyl), -NHC(O)NH(heterocyclyl), -NHC(O)NH(C 6-10 wherein the alkyl, cycloalkyl, heterocyclyl, aryl or 5-10 membered heteroaryl may be substituted by 1 to 3 of the following: 1-9 Alkyl, C 1-8 Haloalkyl, halogen, -OH, -NH2, CO2H, -O(C 1-9 alkyl), -O(C 1-8 haloalkyl), -O(C 3-15 cycloalkyl), -O(heterocyclyl), -O(aryl), -O(5-10 membered heteroaryl), -NH(C 1-9 Alkyl), -NH(C 1-8 haloalkyl), -NH(C 3-15 cycloalkyl), -NH(heterocyclyl), -NH(aryl), -NH(5-10 membered heteroaryl), -N(C 1-9 Alkyl)2,-N(C 3-15 Cycloalkyl)2,-NHC(O)(C 1-8 haloalkyl), -NHC(O)(C 3-15 cycloalkyl), -NHC(O)(heterocyclyl), -NHC(O)(aryl), -NHC(O)(5-10 membered heteroaryl), -NHC(O)O(C 1-9 alkyl), -NHC(O)O(C 1-8 haloalkyl), -NHC(O)O(C 2-6 Alkynyl), -NHC(O)O(C 3-15 cycloalkyl), -NHC(O)O(heterocyclyl), -NHC(O)O(aryl), -NHC(O)O(5-10 membered heteroaryl), or -NHC(O)NH(C 1-9 alkyl); Each R 1b , R 1c , R 2a , R 2b , R 4c , R 9c , R 12a , R 12b , and R 12c are independently H, -OH, C 1-9 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-15 Cycloalkyl, heterocyclic, C 6-10 aryl, or 5-10 membered heteroaryl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or 5-10 membered heteroaryl can be substituted by 1 to 4 Z 1b Replacement; and Each R 3e Independently H, C 1-6 Alkyl, C 1-6 Haloalkyl, -C 1-4 Alkyl-N(R 9a )(R 9b ), -C 1-4 Alkyl-C(O)N(R 9a )(R 9b ), -C 1-4 Alkyl-OC(O)-OC 1-4 Alkyl, -C 1-4 Alkyl-OC(O)-C 1-4 Alkyl-N(R 9a )(R 9b ), -C 1-4 Alkyl-C 3-8 Cycloalkyl, -C 1-4 Alkyl-heterocyclyl, C 3-10 Cycloalkyl, heterocyclic, C 6-10 aryl, or 5-10 membered heteroaryl, wherein the alkyl, alkenyl, cycloalkyl, heterocyclyl, aryl or 5-10 membered heteroaryl can be substituted by 1 to 4 Z 1b substituted; wherein each 5-10 membered heteroaryl has a 5- to 12-membered ring structure and has 1 to 4 heteroatoms which are each independently N, O or S; and wherein each heterocyclyl has a 3- to 12-membered ring structure and has 1 to 4 heteroatoms which are each independently N, O or S.

4. The compound according to claim 1, wherein the compound is a compound having the general formula IA-6 or the general formula IA-7 or a pharmaceutically acceptable salt thereof, Wherein ring C is C 3-10 Cycloalkyl, heterocyclic, C 6-10 Aryl and 5-10 membered heteroaryl, each of which may be replaced by 1 to 4 Z 1 replace; V is CH2, CH(CH3), NH, C(O), S(O), S(O)2; n is 0, 1, 2, 3, or 4; R 2 Yes H, C 1-6 Alkyl, -C 1-6 Alkyl-alkoxy, -C 1-6 Alkyl-cycloalkoxy, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Cycloalkyl, heterocyclic, C 6-10 Aryl, 5-10 membered heteroaryl, -CN, -OR 2a , -SR 2a , -S(O)R 2a , -S(O)(NH)R 2a , -S(O)2R 2a ,-S(O)2N(R 2a )(R 2b ), or -S(O)(NR 2a )R 2b ,in, The alkyl, alkoxy, cycloalkyloxy, haloalkyl, cycloalkyl, heterocyclic, aryl or 5-10 membered heteroaryl groups may each be substituted with 1 to 4 Z 1 Replace and any two Z 1 can combine with the atoms to which they are attached to form C 3-10 Cycloalkyl or heterocyclic or C 6-10 Aryl or 5-10 membered heteroaryl; X is independently -N=, -C(H)=, or -C(R 8 )=; Each R 3 and R 3’ Each independently is H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen, C 3-10 Cycloalkyl, heterocyclic, C 6-10 Aryl, 5-10 membered heteroaryl, -CN, -NO2, -OR 3a , -C(O)R 3a ,-CH2C(O)OR 3a , -C(O)OR 3a ,-C(O)N(R 3a )(R 3b ), -N(R 3a )C(O)R 3b , -N(R 3a )C(O)OR 3b , -N(R 3a )C(O)N(R 3b )2,-C(O)NHS(O)2R 3a , -C(O)NR 3a S(O)2R 3b , -C(O)NR 3a S(O)2NR 3b R 3c , -C(O)NR 3a -S(O)(=NR 3b )R 3c , -S(O)2R 3a , -S(O)2OR 3a ,-S(O)2N(R 3a )(R 3b ), -N(R 3a )S(O)2R 3b ,-S(O)2NHC(O)R 3a , -S(O)(=NR 3a )R 3b , -S(O)(=NR 3a )NR 3b ,-S(=NR 3a )(=NR 3b )R 3c , -P(O)(OR 3a )(R 3b ), -P(O)(OR 3a )(OR 3b ), -B(OR 3a )(OR 3b ), or -OC 1-6 Alkyl-C(O)OR 3a , wherein the alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or 5-10 membered heteroaryl groups can each be substituted by 1 to 4 R 3d replace; Each R 3a , R 3b , and R 3c Independently H, C 1-6 Alkyl, C 6-10 Aryl, 5-10 membered heteroaryl, C 1-6 Haloalkyl, C 2-8 Alkoxyalkyl, -C 1-4 Alkyl-N(R 9a )(R 9b ), -C 1-4 Alkyl-N(R 9a )C(O)-OC 1-4 Alkyl-OP(O)(OR 9c )2, -C 1-4 Alkyl-C(O)N(R 9a )(R 9b ), -C 1-4 Alkyl-OC(O)-OC 1-4 Alkyl, -C 1-4 Alkyl-OC(O)-C 1-4 Alkyl-N(R 9a )(R 9b ), -C 1-4 Alkyl-OC(O)-C 1-4 Alkyl-OP(O)(OR 9c )2, -C 1-4 Alkyl-C 3-8 Cycloalkyl, -C 1-4 Alkyl-heterocyclyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Cycloalkyl, heterocyclyl, -CH2CH(N(R 9a )2)C(O)OR 9b , C 1-6 Alkyl-heterocyclyl, C 1-6 Alkyl-aryl or C 1-6 Alkyl-(5-10 membered) heteroaryl, wherein the alkyl, alkenyl, cycloalkyl, heterocyclyl, aryl or 5-10 membered heteroaryl can be substituted by 1 to 4 Z 1b replace; Each R 4 are independently H, -OH, CH2OH, C 1-9 Alkyl, C 1-8 Haloalkyl, C 1-6 Haloalkoxy, C 2-6 Alkoxyalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen, C 3-15 Cycloalkyl, heterocyclic, C 6-10 Aryl, 5-10 membered heteroaryl, oxo, -NO2, -CN, -N3, -OR 4a , -C(O)R 4a , -C(O)OR 4a ,-C(O)N(R 4a )(R 4b ), -N(R 4a )(R 4b ), -N(R 4a )2(R 4b ) + , -N(R 4a )-C(O)R 4b , -N(R 4a )C(O)O(R 4b ), -N(R 4a )C(O)N(R 4b )(R 4c ), -N(R 4a )S(O)2(R 4b ), -N(R 4a )S(O)2-N(R 4b )(R 4c ), -N(R 4a )S(O)2O(R 4b ), -OC(O)R 4a , -OC(O)OR 4a ,-OC(O)-N(R 4a )(R 4b ), -SR 4a , -S(O)R 4a , -S(O)(NH)R 4a , -S(O)2R 4a ,-S(O)2N(R 4a )(R 4b ), -S(O)(NR 4a )R 4b , or -Si(R 4a )3, wherein the alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or 5-10 membered heteroaryl can be each substituted by 1 to 4 Z 1b or, two R attached to adjacent ring atoms 4 The groups combine with the atoms to which they are attached to form C 5-10 Cycloalkyl or heterocyclic group, each of which may be replaced by 1 to 4 Z 1b replace; Each R 5a and R 5b Independently H, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 2-6 Alkoxyalkyl, halogen, C 3-10 Cycloalkyl, heterocyclyl, -C 1-6 Alkyl-N(R 9a )(R 9b ), -CN, -OR 5a1 , or -N(R 5a1 )(R 5a2 ); or, R 5a and R 5b Combine with the atoms to which they are attached to form C 3-10 Cycloalkyl or heterocyclic group, each of which may be replaced by 1 to 4 R 5a3 replace; Each R 5a1 and R 5a2 Independently H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Cycloalkyl, heterocyclic, C 6-10 Aryl or 5-10 membered heteroaryl, wherein the cycloalkyl, heterocyclyl, aryl or 5-10 membered heteroaryl may be substituted by 1 to 4 halogens; Each R 3d and R 5a3 Independently H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkoxyalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen, C 3-10 Cycloalkyl, heterocyclic, C 6-10 Aryl, 5-10 membered heteroaryl, oxo, -OH, -CN, CO2R 3e , -NO2, or -C(O)N(R 2a )(R 2b ), wherein the heterocyclic group or the 5-10 membered heteroaryl group may be C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 Haloalkoxy substitution; Each R 8 Independently C 1-9 Alkyl, C 1-8 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen, oxo, -OH, -CN, CO2R 3e ,-NO2,-NH2,-N3,-SH,-O(C 1-9 alkyl), -O(C 1-8 haloalkyl), -NH(C 1-9 Alkyl), -NH(C 1-8 haloalkyl), -N(C 1-9 Alkyl)2,-N(C 1-8 Haloalkyl)2; Each R 9a and R 9b Independently H, C 1-9 Alkyl, C 1-8 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkoxyalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen, C 3-15 Cycloalkyl, heterocyclic, C 6-10 Aryl, 5-10 membered heteroaryl, oxo, -NO2, -CN, -N3, -OR 12a , -C(O)R 12a , -C(O)OR 12a ,-C(O)N(R 12a )(R 12b ), -N(R 12a )(R 12b ), -N(R 12a )2(R 12b ) + , -N(R 12a )-C(O)R 12b , -N(R 12a )C(O)O(R 12b ), -N(R 12a )C(O)N(R 12b )(R 12c ), -N(R 12a )S(O)2(R 12b ), -N(R 12a )S(O)2-N(R 12b )(R 12c ), -N(R 12a )S(O)2O(R 12b ), -OC(O)R 12a , -OC(O)OR 12a ,-OC(O)-N(R 12a )(R 12b ), -SR 12a , -S(O)R 12a , -S(O)(NH)R 12a , -S(O)2R 12a ,-S(O)2N(R 12a )(R 12b ), -S(O)(NR 12a )R 12b , or -Si(R 12a )3; or R 9a and R 9b Fusion forms a 3-10 membered heterocyclic group which may be substituted by: C 1-9 Alkyl, C 1-8 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkoxyalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen, C 3-15 Cycloalkyl, heterocyclic, C 6-10 Aryl, 5-10 membered heteroaryl, oxo, -NO2, -CN, -N3, -OR 12a , -C(O)R 12a , -C(O)OR 12a ,-C(O)N(R 12a )(R 12b ), -N(R 12a )(R 12b ), -N(R 12a )2(R 12b ) + , -N(R 12a )-C(O)R 12b , -N(R 12a )C(O)O(R 12b ), -N(R 12a )C(O)N(R 12b )(R 12c ), -N(R 12a )S(O)2(R 12b ), -N(R 12a )S(O)2-N(R 12b )(R 12c ), -N(R 12a )S(O)2O(R 12b ), -OC(O)R 12a , -OC(O)OR 12a ,-OC(O)-N(R 12a )(R 12b ), -SR 12a , -S(O)R 12a , -S(O)(NH)R 12a , -S(O)2R 12a ,-S(O)2N(R 12a )(R 12b ), -S(O)(NR 12a )R 12b , or -Si(R 12a )3; Each Z 1 Independently C 1-9 Alkyl, C 1-8 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkoxyalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen, C 3-15 Cycloalkyl, heterocyclic, C 6-10 Aryl, 5-10 membered heteroaryl, oxo, -NO2, -CN, -N3, or -OR 12a wherein the alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl or 5-10 membered heteroaryl groups may be each substituted by 1 to 4 Z 1a replace; Each Z 1a Independently H, C 1-9 Alkyl, C 1-8 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkoxyalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen, C 3-15 Cycloalkyl, heterocyclic, C 6-10 Aryl, 5-10 membered heteroaryl, oxo, -NO2, -CN, -N3, -OR 12a , -C(O)R 12a , -C(O)OR 12a ,-C(O)N(R 12a )(R 12b ), -N(R 12a )(R 12b ), -N(R 12a )2(R 12b ) + , -N(R 12a )-C(O)R 12b , -N(R 12a )C(O)O(R 12b ), -N(R 12a )C(O)N(R 12b )(R 12c ), -N(R 12a )S(O)2(R 12b ), -N(R 12a )S(O)2-N(R 12b )(R 12c ), -N(R 12a )S(O)2O(R 12b ), -OC(O)R 12a , -OC(O)OR 12a ,-OC(O)-N(R 12a )(R 12b ), -SR 12a , -S(O)R 12a , -S(O)(NH)R 12a , -S(O)2R 12a ,-S(O)2N(R 12a )(R 12b ), -S(O)(NR 12a )R 12b , or -Si(R 12a )3, wherein the alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or 5-10 membered heteroaryl can be each substituted by 1 to 4 Z 1b replace; Each Z 1b Independently H, C 1-9 Alkyl, C 1-8 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen, C 3-15 Cycloalkyl, heterocyclic, C 6-10 Aryl, 5-10 membered heteroaryl, oxo, -OH, -CN, CO2R 3e ,-NO2,-NH2,-N3,-SH,-O(C 1-9 alkyl), -O(C 1-8 haloalkyl), -O(C 2-6 alkenyl), -O(C 2-6 Alkynyl), -O(C 3-15 Cycloalkyl), -O(heterocyclyl), -O(C 6-10 aryl), -O(5-10 membered heteroaryl), -NH(C 1-9 Alkyl), -NH(C 1-8 haloalkyl), -NH(C 2-6 alkenyl), -NH(C 2-6 Alkynyl), -NH(C 3-15 Cycloalkyl), -NH(heterocyclyl), -NH(C 6-10 aryl), -NH(5-10 membered heteroaryl), -N(cyclo-alkyl), -N(C 1-9 Alkyl)2,-N(C 1-8 Haloalkyl)2,-N(C 2-6 Alkenyl)2,-N(C 2-6 Alkynyl)2,-N(C 3-15 Cycloalkyl)2,-N(heterocyclyl)2,-N(C 6-10 Aryl)2,-N(5-10 membered heteroaryl)2,-N(C 1-9 Alkyl)(C 1-8 haloalkyl), -N(C 1-9 Alkyl)(C 2-6 alkenyl), -N(C 1-9 Alkyl)(C 2-6 Alkynyl), -N(C 1-9 Alkyl)(C 3-15 Cycloalkyl), -N(C 1-9 alkyl)(heterocyclyl),-N(C 1-9 Alkyl)(C 6-10 Aryl), -N(C 1-9 alkyl)(5-10 membered heteroaryl), -C(O)(C 1-9 alkyl), -C(O)(C 1-8 haloalkyl), -C(O)(C 2-6 alkenyl), -C(O)(C 2-6 Alkynyl), -C(O)(C 3-15 Cycloalkyl), -C(O)(heterocyclyl), -C(O)(C 6-10 aryl), -C(O)(5-10 membered heteroaryl), -C(O)O(C 1-9 alkyl), -C(O)O(C 1-8 haloalkyl), -C(O)O(C 2-6 alkenyl), -C(O)O(C 2-6 Alkynyl), -C(O)O(C 3-15 Cycloalkyl), -C(O)O(heterocyclyl), -C(O)O(C 6-10 aryl), -C(O)O(5-10 membered heteroaryl), -C(O)NH2, -C(O)NH(C 1-9 alkyl), -C(O)NH(C 1-8 haloalkyl), -C(O)NH(C 2-6 alkenyl), -C(O)NH(C 2-6 Alkynyl), -C(O)NH(C 3-15 Cycloalkyl), -C(O)NH(heterocyclyl), -C(O)NH(C 6-10 aryl), -C(O)NH(5-10 membered heteroaryl), -C(O)N(C 1-9 Alkyl)2,-C(O)N(C 1-8 Haloalkyl)2,-C(O)N(C 2-6 alkenyl)2,-C(O)N(C 2-6 Alkynyl)2,-C(O)N(C 3-15 Cycloalkyl)2,-C(O)N(heterocyclyl)2,-C(O)N(C 6-10 Aryl)2,-C(O)N(5-10 membered heteroaryl)2,-NHC(O)(C 1-9 alkyl), -NHC(O)(C 1-8 haloalkyl), -NHC(O)(C 2-6 alkenyl), -NHC(O)(C 2-6 Alkynyl), -NHC(O)(C 3-15 Cycloalkyl), -NHC(O)(heterocyclyl), -NHC(O)(C 6-10 aryl), -NHC(O)(5-10 membered heteroaryl), -NHC(O)O(C 1-9 alkyl), -NHC(O)O(C 1-8 haloalkyl), -NHC(O)O(C 2-6 alkenyl), -NHC(O)O(C 2-6 Alkynyl), -NHC(O)O(C 3-15 Cycloalkyl), -NHC(O)O(heterocyclyl), -NHC(O)O(C 6-10 aryl), -NHC(O)O(5-10 membered heteroaryl), -NHC(O)NH(C 1-9 alkyl), -NHC(O)NH(C 1-8 haloalkyl), -NHC(O)NH(C 2-6 alkenyl), -NHC(O)NH(C 2-6 Alkynyl), -NHC(O)NH(C 3-15 Cycloalkyl), -NHC(O)NH(heterocyclyl), -NHC(O)NH(C 6-10 aryl), or -NHC(O)NH(5-10 membered heteroaryl), wherein the alkyl, cycloalkyl, heterocyclyl, aryl or 5-10 membered heteroaryl may be substituted by 1 to 3 of the following: 1-9 Alkyl, C 1-8 Haloalkyl, halogen, -OH, -NH2, CO2H, -O(C 1-9 alkyl), -O(C 1-8 haloalkyl), -O(C 3-15 cycloalkyl), -O(heterocyclyl), -O(aryl), -O(5-10 membered heteroaryl), -NH(C 1-9 Alkyl), -NH(C 1-8 haloalkyl), -NH(C 3-15 cycloalkyl), -NH(heterocyclyl), -NH(aryl), -NH(5-10 membered heteroaryl), -N(C 1-9 Alkyl)2,-N(C 3-15 Cycloalkyl)2,-NHC(O)(C 1-8 haloalkyl), -NHC(O)(C 3-15 cycloalkyl), -NHC(O)(heterocyclyl), -NHC(O)(aryl), -NHC(O)(5-10 membered heteroaryl), -NHC(O)O(C 1-9 alkyl), -NHC(O)O(C 1-8 haloalkyl), -NHC(O)O(C 2-6 Alkynyl), -NHC(O)O(C 3-15 cycloalkyl), -NHC(O)O(heterocyclyl), -NHC(O)O(aryl), -NHC(O)O(5-10 membered heteroaryl), or -NHC(O)NH(C 1-9 alkyl); Each R 1b , R 1c , R 2a , R 2b , R 4a , R 4b , R 4c , R 9c , R 12a , R 12b , and R 12c are independently H, -OH, C 1-9 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-15 Cycloalkyl, heterocyclic, C 6-10 aryl, or 5-10 membered heteroaryl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or 5-10 membered heteroaryl can be substituted by 1 to 4 Z 1b replace; and Each R 3e Independently H, C 1-6 Alkyl, C 1-6 Haloalkyl, -C 1-4 Alkyl-N(R 9a )(R 9b ), -C 1-4 Alkyl-C(O)N(R 9a )(R 9b ), -C 1-4 Alkyl-OC(O)-C 1-4 Alkyl, -C 1-4 Alkyl-OC(O)-C 1-4 Alkyl-N(R 9a )(R 9b ), -C 1-4 Alkyl-C 3-8 Cycloalkyl, -C 1-4 Alkyl-heterocyclyl, C 3-10 Cycloalkyl, heterocyclic, C 6-10 Aryl, 5-10 membered heteroaryl, wherein the alkyl, alkenyl, cycloalkyl, heterocyclyl, aryl or 5-10 membered heteroaryl can be substituted by 1 to 4 Z 1b replace; wherein each 5-10 membered heteroaryl has a 5- to 12-membered ring structure and has 1 to 4 heteroatoms each independently being N, O or S; and wherein each heterocyclyl has a 3- to 12-membered ring structure and has 1 to 4 heteroatoms each independently being N, O or S.

5. The compound according to any one of claims 2 to 4 or a pharmaceutically acceptable salt thereof, wherein each R 5a and R 5b , if present, are independently H, C 1-9 Alkyl, C 2-6 Alkoxyalkyl and wherein the C 1-9 Alkyl or C 2-6 The alkoxyalkyl groups may each be substituted by one or more halogens.

6. The compound according to any one of claims 2 to 4 or a pharmaceutically acceptable salt thereof, wherein ring C is C 6-10 Aryl or 5-10 membered heteroaryl selected from the group consisting of: Each of them may be substituted with 1 to 4 substituents, each of which is independently selected from the group consisting of H, OH, oxo, halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 2-6 Alkoxyalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Cycloalkyl, heterocyclic, -NO2, -N3, -CN, -OC 1-6 Alkyl, -C(O)-C 1-6 Alkyl, -C(O)-N(C 0-6 Alkyl)(C 0-6 Alkyl) and -N(C 0-6 Alkyl)(C 0-6 alkyl), in, The 1 to 4 substituents may each be substituted with one or more halogens.

7. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein Ring A is selected from the group consisting of: Each of them can be 1 to 4 Z 1a replace.

8. The compound according to claim 7, wherein the 1 to 4 Z 1a Each of which is independently selected from H, halogen, C 1-9 Alkyl, C 1-6 Alkoxy, C 2-6 Alkoxyalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-15 Cycloalkyl or heterocyclyl, each of which may be substituted by one or more halogens.

9. The compound according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, wherein R 2 C 1-6 Alkyl, C 1-6 Alkyl-alkoxy, C 1-6 Alkyl-cycloalkoxy, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Cycloalkyl, heterocyclic, C 6-10 aryl, or 5-10 membered heteroaryl, each of which may be substituted by 1 to 4 Z 1 replace.

10. The compound according to claim 9, or a pharmaceutically acceptable salt thereof, wherein R 2 Selected from the group consisting of: Each of them can be 1 to 4 Z 1 replace.

11. The compound according to claim 10, or a pharmaceutically acceptable salt thereof, wherein R 2’ For H, C 1-6 Alkyl, C 1-6 Haloalkyl, or -C 1-6 Alkyl-cycloalkoxy groups, each of which may be substituted by one or more halogens.

12. The compound according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, wherein R 3 and R 3’ Each independently is H, C 6-10 Aryl, 5-10 membered heteroaryl, -C(O)R 3a ,-CH2C(O)OR 3a ,-C(O)N(R 3a )(R 3b ), -N(R 3a )C(O)R 3b , -N(R 3a )C(O)OR 3b , -N(R 3a )C(O)N(R 3b )2,-C(O)NHS(O)2R 3a , -C(O)NR 3a S(O)2R 3b , -C(O)NR 3a S(O)2NR 3b R 3c , -C(O)NR 3a -S(O)(=NR 3b )R 3c ,-S(O)2N(R 3a )(R 3b ), -N(R 3a )S(O)2R 3b ,-S(O)2NHC(O)R 3a , or -OC 1-6 Alkyl-C(O)OR 3a , each of which can be 1 to 4 R 3d replace.

13. The compound according to claim 12, or a pharmaceutically acceptable salt thereof, wherein R 3 and R 3’ Each independently represents H, C(O)NR 3a (CH2) m R 3b , C(O)NR 3a (CH2) m C(O)R 3b , NR 3a C(O)(CH2) m R 3b , NR 3a (CH2) m R 3b , NR 3a (CH2) m C(O)R 3b , C(O)NR 3a R 3b , or NR 3a C(O)R 3b , each of which can be 1 to 4 R 3d Substitution, wherein m=0, 1, 2, or 3.

14. The compound according to claim 13, or a pharmaceutically acceptable salt thereof, wherein R 3 and R 3’ Each independently represents H, C(O)NHR 3b , or NHC(O)R 3b .

15. The compound according to claim 14, or a pharmaceutically acceptable salt thereof, wherein R 3b Each independently is H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-8 Alkoxyalkyl, -C 1-4 Alkyl-N(R 9a )(R 9b ), -C 1-4 Alkyl-C(O)N(R 9a )(R 9b ), -C 1-4 Alkyl-OC(O)-OC 1-4 Alkyl, -C 1-4 Alkyl-OC(O)-C 1-4 Alkyl-N(R 9a )(R 9b ), -C 1-4 Alkyl-C 3-8 Cycloalkyl, -C 1-4 Alkyl-heterocyclyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Cycloalkyl, heterocyclic, C 6-10 Aryl, 5-10 membered heteroaryl, -CH2CH(N(R 9a )2)C(O)OR 9b , C 1-6 Alkyl-heterocyclyl, C 1-6 Alkyl-aryl or C 1-6 Alkyl-(5-10 membered) heteroaryl, wherein the alkyl, alkenyl, cycloalkyl, heterocyclyl, aryl or 5-10 membered heteroaryl can be substituted by 1 to 4 Z 1b replace.

16. The compound according to claim 15, or a pharmaceutically acceptable salt thereof, wherein R 3b Each independently is C 6-10 aryl or 5-10 membered heteroaryl, each of which may be replaced by 1 to 5 R 3f Substitution, where R 3f H, OH, oxo, NH2, halogen, -NO2, -N3, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 2-6 Alkoxyalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Cycloalkyl, heterocyclic, -OC 1-6 Alkyl, -C(O)-C 1-6 Alkyl, -C(O)-N(R 12a )(R 12b )、-N(R 12a )(R 12b ), C 6-10 Aryl, or 5-10 membered heteroaryl, wherein R 3f Each may be substituted by one or more of the following: halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, or C 1-6 Halogenated alkoxy.

17. The compound according to claim 16, or a pharmaceutically acceptable salt thereof, wherein R 3b The aryl or 5-10 membered heteroaryl in is selected from the group consisting of: , Each of them can be 1 to 5R 3f replace.

18. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R 4 are independently H, -OH, -CH2OH, C 1-9 Alkyl, C 1-8 Haloalkyl, C 1-6 Haloalkoxy, C 2-6 Alkoxyalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen, C 3-15 Cycloalkyl, heterocyclic, C 6-10 Aryl, 5-10 membered heteroaryl, oxo, -NO2, -CN, -N3, -OC 1-9 Alkyl, or -C(O)C 1-9 Alkyl, each of which may be replaced by 1 to 4 Z 1b replace; in, Two R attached to adjacent ring atoms 4 The group can combine with the atom to which it is attached to form a C 5-10 Cycloalkyl or heterocyclic group, each of which may be replaced by 1 to 4 Z 1b replace.

19. The compound according to claim 18, or a pharmaceutically acceptable salt thereof, wherein R 4 are independently H, halogen, -CH2OH, C 1-9 Alkyl, C 1-8 Haloalkyl, C 1-6 Haloalkoxy, C 2-6 Alkoxyalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, or C 3-15 Cycloalkyl.

20. The compound according to any one of claims 1 to 19, or a pharmaceutically acceptable salt thereof, wherein Z 1 Each is independently C 1-9 Alkyl, C 1-8 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkoxyalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen, C 3-15 Cycloalkyl, heterocyclic, C 6-10 Aryl, 5-10 membered heteroaryl, oxo, -NO2, -N3, -CN, -OR 12a , -C(O)-R 12a , -C(O)OR 12a ,-C(O)-N(R 12a )(R 12b ), or -N(R 12a )(R 12b ).

21. A compound according to any one of claims 1 to 20, or a pharmaceutically acceptable salt thereof, wherein Z 1a are independently H, -OH, C 1-9 Alkyl, C 1-8 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkoxyalkyl, or halogen.

22. A compound according to any one of claims 1 to 21, or a pharmaceutically acceptable salt thereof, wherein Z 1b Each independently is H, C 1-9 Alkyl, C 1-8 Haloalkyl, halogen, oxo, -OH, or -CN.

23. A compound according to any one of claims 1 to 22, or a pharmaceutically acceptable salt thereof, wherein R 8 are independently H, oxo, OH, C 1-9 Alkyl, C 1-8 Haloalkyl, halogen, -O(C 1-3 alkyl), or -O(C 1-3 haloalkyl).

24. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, having a structure selected from the group consisting of:

25. A pharmaceutical composition comprising the compound according to any one of claims 1 to 24, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

26. A method for treating a GLP-IR-mediated disease or disorder comprising the following steps: A therapeutically effective amount of a compound according to any one of claims 1 to 25, or a pharmaceutically acceptable salt thereof, is administered to a subject in need of such treatment, wherein the GLP-IR-mediated related disease or condition is selected from the group consisting of: T1D, T2DM, prediabetes, idiopathic T1D, LADA, EOD, YOAD, MODY, malnutrition-related diabetes, gestational diabetes, hyperglycemia, insulin resistance, hepatic insulin resistance, impaired glucose tolerance, diabetic neuropathy, diabetic nephropathy, nephropathy, diabetic retinopathy, adipocyte dysfunction, visceral fat deposition, sleep apnea, obesity, eating disorders, weight gain caused by the use of other drugs, excessive sugar addiction, dyslipidemia, hyperinsulinemia, NAFLD, NASH, fibrosis, cirrhosis, hepatocellular carcinoma, cardiovascular disease, atherosclerosis, coronary artery disease, peripheral vascular disease, hypertension, endothelial dysfunction, impaired vascular compliance, congestive heart failure, myocardial infarction, stroke, hemorrhagic stroke, ischemic stroke, traumatic brain injury, pulmonary hypertension, restenosis after angioplasty, intermittent claudication, postprandial lipemia, metabolic acidosis, ketosis, arthritis, osteoporosis, Parkinson's disease, left ventricular hypertrophy, peripheral arterial disease, macular degeneration, cataracts, glomerulosclerosis, chronic renal failure, metabolic syndrome, syndrome X, premenstrual syndrome, angina pectoris, thrombosis, atherosclerosis, transient ischemic attack, vascular restenosis, impaired glucose metabolism, impaired fasting glucose, hyperuricemia, gout, erectile dysfunction, skin and connective tissue diseases, psoriasis, foot ulcers, ulcerative colitis, hyperlipoprotein B lipoproteinemia, Alzheimer's disease, schizophrenia, cognitive impairment, inflammatory bowel disease, short bowel syndrome, Crohn's disease, colitis, irritable bowel syndrome, polycystic ovary syndrome, and substance addiction.